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Chapter 1 Computational techniques at every level of biochemical 
                    discovery 
 
1.1 Introduction 
 As modern biochemistry, computational chemistry, and computing power advance, there 
are ever expanding opportunities for computational methods to be developed and applied to the 
process of discovery. The rapid development of technology has changed our lives in 
unprecedented ways. More computing power is available in the average cell phone than was 
used to put a man on the moon in 1969 (2). We are able to store and search the whole human 
genome on an iPod (3). When combined with bright and creative minds, the ability to perform 
complex calculations has been truly transformative for science. In biochemical discovery 
computational theory is being applied everywhere. Quantum chemistry tools can accurately 
model the electronic structure of a ligand molecule, and bioinformaticians can compare 
hundreds of complete human genomes to look for the roots of genetic disease. In terms of 
molecular biology, the applications range from target identification and initial druggability testing, 
to final structural modifications on potential small molecule drugs and fundamental studies on 
the nature of biomolecules. The concept of a "rationally designed drug", one that has been 
created through a deep understanding of both the receptor structure and the salient small 
molecule interactions was an entirely new concept when it was suggested in 1986 (4). In 2012 
alone there were more than 40 publications on successful rational drug design.  
 Historically the development of pharmaceuticals was based on "whatever works", rather 
than understanding how a bioactive substance acts. In the long years since herbal remedies 
were simply put into pill form, we have gained the ability to capably understand the "why" 
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associated with effective treatments. As a scientific community are now at the stage where we 
can look at a biological system as a whole, from genome to phenotype. This has led to a much 
broader perspective for examining a biological system.  
 The scope of our biological understanding has expanded, and so has the associated 
data. The rapid expansion of "omics" fields threatened to drown researchers under a deluge of 
"big data". It seemed initially that our ability to generate data had outpaced our ability to extract 
meaningful information from it. This situation drove the development of a whole range of 
computational and statistical analytics that up until recently, would have been unnecessary. Not 
only has the creative application of statistical modeling and data deconvolution necessary, it's 
illuminating. For the first time, we are able to not only think about, but model whole interaction 
networks and observe how they react when perturbed. The exponentially growing field of 
systems biology is a testament to the value of combining traditional molecular biology with 
methods originally developed for computer science.  
 Within the context of probing a disease for either cause or cure, computational chemistry 
has become invaluable at each stage of discovery. Genomic and bioinformatic investigations 
can assist in finding causal genes or potential drug targets. Applications of systems biology can 
determine how those genes or drug targets are interacting within a broader system. Network 
analysis is shifting the way we think about drug design. Should we hit one target hard? Or hit 
many associated targets weakly? Will off target hits render this a dead end for treatment? 
Structural biology literally allows us to look at the proteins we are working with. Rather than a 
line on a gel, we can hold up a three-dimensional structure and get a good look at what makes it 
tick. Once we know how it ticks, rational drug design techniques can allow us to build a 
molecule that stops the clock. 
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  From start to finish, computational chemistry has changed the way we function as 
scientists and will continue to do so in the future. This work will focus on current applications of 
computational chemistry to biochemical discovery. The techniques discussed will include novel 
bioinformatics applied to both human and bacterial genomes, structural and dynamic analyses 
applied to both fundamental understanding of biomolecules and drug discovery, and small 
molecule development methods. The following chapters will illustrate productive application of 
these techniques to the design of inhibitors for Clostridium difficile toxin, and the development of 
bioinformatic software for both human and bacterial genomic data. 
 
Figure 0-1 Opportunities to apply computational methods to biochemical discovery 
The workflow here describes one possible pathway to biochemical investigation or drug design. Initially, a 
gene or protein of interest is identified as a target for further study. Biochemical interaction pathways are 
then pursued, traditionally by methods of molecular biology. Structural characterization is carried out where 
possible to deepen the understanding of the system, followed by small molecule design either for the 
purposes of drug development, or for developing biochemical tools to interrogate the system. At each step, 
computational intervention can assist the process and provide otherwise intractable information. 
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1.2 Target identification 
 
 Traditional methods of identifying targets for biochemical investigation involve direct 
biochemical methods, where a gene, RNA or protein is identified, purified, characterized and 
then further studies are performed based on the goal of the project. These methods often 
require a heroic amount of work, along with sophisticated technologies and years of training for 
skilled scientists in the field. With the advancement of high-throughput methods such as DNA 
microarrays and RNA sequencing  data collection has greatly accelerated generating an 
overwhelming  mountain of data. It's been well documented that the rate at which publically 
available sequence data has been expanding has far outpaced our ability to handle that data 
manually(5, 6). Making sense out of a massive dataset has required complex computational 
analysis techniques, as significance cannot be assessed by simple examination. Bioinformatics 
has exploded as a field, and its popularity is well warranted. By combining mathematical and 
statistical analysis with big "omics" data, not only are significant associations detected, but 
patterns of associations, and the patterns are where it gets interesting. The following sections 
will discuss applications of bioinformatics to genomic level data.  
1.2.1 Genome-wide association studies 
 Following the completion of the Human Genome Project, the technologies for whole 
genome sequencing developed extremely rapidly. This has led to the practice of investigating 
diseases thought to have a genetic link with Genome Wide Association Studies (GWAS). In 
these experiments, large numbers of individuals with a specific disease are subjected to whole-
genome genotyping, and the results are deposited in massive databases. While this work has 
led to a number of striking discoveries, most well known of which is the BRCA1 and BRCA2 
breast cancer genes(7-9), many scientists have been disappointed in the low productivity of the 
project(10). The reigning paradigm at the time was that introduction of GWAS studies would 
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result in the deconvolution of many genetic diseases: one gene, one mutation, one disease-
termed the "common-variant hypothesis". Simple statistical methods were employed to 
determine strongly predictive mutations in diseased individuals in the hope that this would result 
in a causal relationship between mutation and disease(11). Unfortunately, this paradigm 
became the exception rather than the rule. Rather than revealing simple links between genome 
and disease, frequently a huge number of associations were detected between diseases and 
genomes, or weak clinical correlation between strong statistical predictors and disease 
phenotypes(12). Manolio et al. in 2009 was among the first to openly discuss GWAS studies as 
not meeting the expectations of the scientists involved and suggest that the "disease-common 
variant" hypothesis was incorrect. The interplay between numerous mutations may be more 
biologically relevant, something that would not be detected by trying to apply extremely stringent 
statistical methods to find a single direct connection. Others suggested that the worth of GWAS 
studies lies in the detection of rare variants (13), that statistical analysis of GWAS are 
confounded by rare variants (14), or that the combination of several alleles into a haplotype may 
be a more accurate predictor (15, 16).  
 While many people were disheartened at the failure of the common-variant hypothesis, 
this development did spur investigations into pathway associations and combinations of low-
significance mutations. The association of multiple loci with disease phenotypes has resulted in 
a reimagining of the function of GWAS studies, that rather than seeking a single mutation, 
GWAS experiments have the capability to expose novel biological pathways. Notably, the 
linkage between Crohn's disease and both the autophagy and interleukin-23 related pathways 
was completely unexpected (17). The illumination of unexpected biological pathways relevant to 
disease has resulted in an explosion in the realm of "big data analysis" applied to GWAS data. 
While the deposition of data still proceeds at a much faster rate than the growth of processing 
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power, novel analysis and data storage methods are making an attempt to keep pace with this 
ever expanding wealth of data(5).  
 The complexity of genetically linked diseases has spurred creativity in the computational 
algorithms used for analysis, far surpassing the simple statistical methods that were initially 
applied to the GWAS data. To date, over 35 major software suites have been developed 
specifically for the handling and analysis of GWAS data (5), ranging from methods for genome 
assembly (18-24), to "big data" storage and query methods(25-27), to novel data mining 
techniques(28-34). Furthermore, there has been some considerable success in identifying 
potentially "druggable" targets within the human genome using bioinformatics techniques (35-
40). With the development of novel computational techniques, and the continued re-examining 
of GWAS data(41-45), there is much more potential for a deep understanding of genetically 
linked diseases as well as a future in genome-to-pharmacy drug design.  
1.2.2 Data mining in single genome studies 
 While the term "bioinformatics" has been around since the 1970's(46), a turning point 
came in 1984 when a technique had only previously been applied to mathematical data, was 
turned on a biological system. A method was developed to align sequences from the Dayhoff 
Atlas of Protein Sequence and Structure, and very rapidly thereafter bioinformatics became 
associated with genetic and proteomic data(47). Largely, modern computational techniques in 
data mining are applied to organisms for which whole genome sequence data is available. 
Rather than analyzing a cohort of genomes for variation, these techniques focus on pattern 
determination and deep understanding of the function and interaction of the genome of a single 
organism. Frequently programs are designed to find patterns or comparisons in the genomes 
that would be undetectable without assistance. Bioinformatic software at this level ranges from 
the well established sequence alignment tools available such as ClustalX, BLAST, and TCoffee 
(48-50), to highly complex pattern and motif searching tools like PairMotif and DISCOVER (51-
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55). A comprehensive overview of the breadth of methods available is beyond the scope of this 
document, but the categories of genomic analysis to which computational methods have been 
critical will be discussed.  
 While the utility of these kinds of bioinformatics tools varies widely, we will focus on 
application of two general categories of "small data" investigation to antimicrobials. Finding 
genes that code for bacterial pathogens or that may be exploitable with new antibiotics 
comprises a non-human form of "Target Identification".  
 Target identification within bacterial genomes can generally be divided into two fields: 
sequence-based, or composition-based. Sequence based methods rely on comparison of 
multiple bacterial sequences(56-59), while composition-based methods require only a single 
genome sequence (60-65). Recent application of genomic interrogation techniques has been 
quite successful in the study of antimicrobials. 
 One such success story describes the identification of 214 unique enzymes in 
Pseudomonas aeruginosa. By using comparative genomics based on information from the 
Kyoto encyclopedia of Genes and Genomes (KEGG) Perumal et al. were able to identify 
essential genes unique to Pseudomonas aeruginosa. A case study was pursued using a 
homology model of one of the identified proteins, targeted with in silico docking of several 
inhibitors. Results indicated that this protein would be a suitable target for antibiotic 
development and further in vitro studies.  
 Study of genomic islands has become quite popular in trying to understand the 
underlying mechanisms of antibiotic resistance and pathogenicity transfer. Genomic islands are 
clusters of genes, acquired by horizontal gene transfer, which frequently confer some 
evolutionary advantage and are frequently associated with pathogenesis or antibiotic resistance. 
While many of the studies focus on determining druggable targets in pathogenic organisms(66, 
8 
 
67), some focus on organisms with inherent antimicrobial activities. (68-74). Originally these 
mobile genetic elements were analyzed using gene cloning techniques(75), but with the 
availability of genomic data on many organisms several computational techniques have 
expedited the process(65, 76, 77). The goal of many of these studies is to identify genomic 
islands associated with pathogenicity, in hopes of identifying possible targets for future anti-
microbial work.  
 A comparative analysis of three strains of antibiotic resistant Acinetobacter baumanii is 
one such application. Once fully sequenced, the genomes were examined using comparative 
genomics analysis and individual genomic island detection with IslandViewer (56, 57). Work by 
Zhu et al (78)revealed that while the three strains shared drug-resistant genomic elements, the 
context in which these elements were present was quite different. In the most genetically 
divergent strain, antibiotic resistance was conferred by a large resistance island, containing 
multiple drug-resistance genes and several transposons. The analysis indicated that one 
challenge that will be encountered by researchers targeting Acinetobacter baumanii, is the 
genomic flexibility of this organism. 
 Motif searching is also a broadly applied term in both bacterial genomics and 
proteomics. The ability to quickly identify genetic regions characteristic for protein-binding(79, 
80), sRNA-controlled regulation(80), subcellular localization(81), determination of sequence 
families(82, 83) as well as many other genome-based inquiries has a wide range of applications 
(83-89). However, computational identification of motifs remains challenging and recent surveys 
of the field indicate that there is no "best" method (90, 91). Whether informed by experiment or 
built on probabilistic modeling and neural networks, there has been no clear success in the field. 
Perhaps the best example of fully utilizing the various methods of motif recognition is the work 
done by Hu and Rajasekaran (92, 93) in developing a consensus ensemble algorithm. This 
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method combines the results from multiple external motif searches, and results in a 6-45% 
improvement in accurate motif identification.  
 As completing a full genome for an organism has become increasingly fast and cost-
effective, the tools facilitating thorough exploration have proliferated. In addition to the 
bioinformatic methods discussed above, there is a wide range of bioinformatic techniques that 
can be applied to the transcriptome and proteome. In brief, the development of computational 
tools for single-genome analysis has been both expansive and creative, facilitating the 
discovery of numerous genomic features that can be exploited for either fundamental learning, 
or antimicrobial development.   
1.3 Pathway and Network analysis 
 
 As was discussed in section 1.2.1, the richness of GWAS studies lies not in directly 
connecting a single gene mutation to a disease, but with illuminating networks of interactions 
whose cumulative effect may be more salient. Recent work in graph theory and "big data" 
analysis has led to the growth in the field of network theory, a subset of graph theory, which 
seeks to represent complex sets of interactions in tractable ways. Following the construction of 
a network of various components, data mining and mathematical sub-analysis can be applied. 
While it's easy to think of networks in terms of genes or protein-regulation, network theory is 
being applied far more broadly in computational chemistry. Network theory has been applied to 
cheminformatics, drug design, repurposing of drugs, and target identification.  
 In order to mentally parse and bring coherent understanding to the sweeping datasets 
capable of being generated by both next-generation lab techniques and those generated 
computationally, a human-readable expression of the data is necessary. While visualization 
packages are rapidly developing, it still requires human intuition and interpretation to recognize 
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some of the more biologically relevant patterns. In combination with a researchers deep 
fundamental understanding of their research focus, network analysis can provide a fascinating 
way of stepping outside the system and looking at a biological problem in a broader context. 
1.3.1 Network theory in visualization 
 Just as novel approaches have  changed the way we approach the data that we're 
aggregating, so to do new or innovative visualization methods change the way we literally view 
the data. Representing biological pathways as complicated networks in textbooks has very 
nearly reached trope status. Complex, difficult-to-interpret diagrams of cellular interaction 
pathways are in nearly all biochemical textbooks. While this is technically an application of a 
network representation, there is distinct room for improvement. Visually, there are huge strides 
being made towards visual deconvolution of networks. Uninformative hairballs have been the 
norm for genetic network interpretation, which rather than aiding in interpretation, can convolute 
it.  
 
Figure 0-2 Yeast interaction network hairball 
A visually uninformative,  but typical interaction hairball reproduced from www.visualcomplexity.com 
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 A thorough survey of modern network analysis algorithms has been published by 
Csermely et al.(94, 95) which includes an overview of available visualization and analysis 
programs as well as suggested methods for use. Appropriate use of network analysis must 
necessarily take into account the viewer, and the viewers paradigm for data interpretation. 
Effective application of network analysis can both accommodate and add to pre-existing 
paradigms for biological representation. We are familiar with the "alphabet soup" interaction 
diagrams in biochemistry textbooks. Chromosomes and sets of genes are represented as neatly 
organized straight lines. Plasmids are perfect circles with cleanly annotated features. Well 
heeled scientists have these visual organizational structures deeply embedded in how we think 
about our science and how we communicate effectively with others. The addition of network 
analysis on top of those pre-existing templates can help us clearly understand the complex 
system of connections and interactions that can be layered on top of that fundamental 
understanding. As the field of systems biology develops, we will likely become open to novel 
visual organizational structures, but as the "hairball" above illustrates, focus on understanding is 
key.  
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Figure 0-3 Various forms of network visualization 
Example plots of each of several types of network visualization. A simple force directed graph is shown in 
(A), these are most similar to biological network schemes. An arc plot, useful for depicting relationships on 
gene regions or chromosomes is shown in (B). An adjacency matrix plot combined with an arc plot is shown 
in (C), these are frequently useful for connecting data that is spatially or temporally distant. Panel D shows a 
radial/circular plot commonly used in depicting bacterial genome interactions. A network representation of 
data interpreted by an attribute driven heatmapping method is shown in E. This method is excellent for 
decomposing complex sets of unrelated interactions. Panel F shows the relatively new "hive plots", where 
nodes are organized by characteristic leading to a dramatic deconvolution of hairy networks. Data 
reproduced from references  78-94.  
  Numerous algorithms have been developed to assist in the visual reinterpretation of 
networks, and they can be decomposed into several categories: Force-directed(96-98), arc-
type(99-102), adjacency matrix (also known as correlation plots)(103-107), circular layouts(108-
111), attribute driven and hive plots(95, 112). While each of these methods has applications in 
many fields, all of them can be useful in the analysis of biological data. Figure Figure 0-3 depicts 
some of the more common types of network layouts 
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 In thinking about how to best represent data, it is critical to place emphasis what the 
viewer should take away. For example, with a network of interacting proteins, understanding 
which sets interact closely, and which are only peripherally involved in a processes can help us 
understand what role each protein plays. For this application, a force directed graph would be 
useful. Force directed graphs use mathematically applied attraction and repulsion to distribute 
nodes in a network. This visually recreates many of the standard characteristics of a biological 
interaction scheme and can illustrate which nodes are highly connected and integral to the 
system.  
 Chromosomes and gene loci are commonly represented as linear. Information on 
regulation or common protein-binding locations could be layered onto linear plots using an arc 
method without occluding the original data. By literally connecting the dots, it becomes visually 
tractable to determine if there are "hot spots" of activity on a given chromosome, or if a DNA 
binding protein is interacting with a specific family of proteins. Circular networks perform 
similarly for plasmid information, but have other applications as well. Circos (113, 114) released 
in 2009, has gained popularity as a way to visualize relationships in genomic data. Adjacency 
matrices are used to describe relationships between spatially or temporally distant data, in 
molecular dynamics these are used as "correlation plots". Representing data as a matrix has a 
range of advantages, including quick visual assessment of symmetry. One recent paper in 
Nature applied both circular and adjacency matrix plotting to yeast genomic inter-chromosomal 
interactions(115). By reducing the visual complexity of the interactions to colored diagrams, it 
becomes simple to quickly find the "take away" of the data.  
 There are times when the density of a dataset becomes intractable, even using 
appropriate network visualization techniques. With the generation of both ever larger, and 
higher dimensionality data sets on gene expression, regulation, and various other properties, it 
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becomes necessary to step away from traditional visualizations and move towards methods that 
may be able to handle such complex data.  
 Newer methods of attribute driven binning can reduce the complexity of a network to a 
heatplot, representing a single network characteristic. The recently available GraphPrism (116) 
software decomposes networks into sub-plots relevant to a single node or characteristic. This 
deconvolutes extremely dense data into visually interpretable pieces. Each heatmap is a 
statistical summary of the interactions of a node or metric. As this technique is extremely new, 
there are no published scientific articles that have effectively used this technique, though one 
could imagine its utility when applied to variable expression data, or large scale regulatory 
networks.  
 Hive plots are gaining traction for numerous applications, as these allow the grouping of 
nodes into axes by user-defined properties (112). Developed by Martin Krzwinski specifically for 
the interpretation of systems biology information, this allows the creator of the plot to decide 
which groupings of data points are most relevant when viewed together and reduces the visual 
clutter of networks. Typically color is required to bring out the salient characteristics of these 
plots, but they are ideal for displaying relationships between families of related nodes.  
 Regardless of which type of visualization algorithm is applied, appropriate use facilitates 
the recognition of patterns and connections in the data that would otherwise be hidden. As the 
size and scale of biological data grows, so too does our understanding of the interconnected 
nature of it all. Unfortunately, the working memory of the human mind is not linearly increasing 
as well. Effective graphical representations are necessary to assist in the comprehension and 
communication of the salient information an author wishes to express. 
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1.3.2 Network theory applied to genomics 
 
 Network analysis is frequently applied to large-scale genomic data to avoid deferring to 
reductionist tactics. The proposal of genome-wide regulatory networks as an alternative to the 
"disease-common variant" interpretation of GWAS data relies heavily on the treatment of 
genome level data with network theory and an analysis (117). Interrogation of regulatory 
networks rather than single genes has been illuminating in several fields, as discussed by 
Arujaho et al. (118). He suggested that as our ability to collect broad information on cellular 
function and subcellular interaction increases, we should increasingly implement that knowledge 
in our biochemical investigations. For example, high throughput methods allow us to identify 
genes that are overexpressed in tumors. Targeting those genes without considering the greater 
context of the genomic system may lead researchers down a dead end path. The detected 
associations may be peripheral, reactionary, or have a compensatory backup system in the cell. 
When using large-scale data for target identification, it is absolutely essential to consider the 
complexity of the system; network analysis is ideal as a solution.  
 In the application of network modeling to the human genome project, it has been 
suggested that the inclusion of genomic analysis methods may increase the amount of potential 
human drug targets by up to fourfold (119-121) depending on the method of estimation. While 
no new druggable protein families have been detected, bioinformatics methods have been 
applied to search for new members of those families. It should be made clear however that 
identifying a druggable protein does not necessarily result in a drug target, as many proteins, 
which can bind small molecules are not currently disease associated(122, 123).  
 Statistical analysis of genomic data is useful, however, novel insights have been 
obtained using network visualization. The concept of "bottleneck, hub and peripheral" nodes is 
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one entirely resultant from the interrogation of interaction networks of both genes and proteins, 
and provides an interesting perspective (124, 125). Hub nodes have numerous connections to 
other nodes, and typically manifest as a "starburst" when graphed. Peripheral nodes have a low 
number of connections, and may be only secondarily connected to a hub. Bottleneck nodes 
connect hub nodes, and usually have no redundant connections, i.e. information that needs to 
travel from one hub to another may pass through a bottleneck node if there are no other routes 
of communication available. Analysis of several known drug-target inclusive networks indicate 
that hub nodes are generally not targetable as they contribute significantly to the stability of the 
overall network(125). Many drug targets have turned out to be peripheral nodes, as removal of 
these nodes is less likely to destabilize the entire network system.  Similarly to hub nodes, 
bottleneck nodes are unlikely to be good drug targets, and frequently knockouts of these genes 
are lethal as the removal of a bottleneck node destabilizes the overall network(124).  
 As network analysis increases our understanding of genomic and protein interactions, 
this opens the door to reimagining drug design. Excellent work by Agoston et al. indicated that 
weak perturbation of several nodes in a transcriptional regulatory network was more efficacious 
in altering the system than singling out a particular node (126). The transcriptional regulatory 
networks of E. coli and S. cerevisiae were modeled as weighted networks, and then subjected 
to a series of perturbations. Each node was "attacked" in several ways; complete knockout, 
partial removal of interactions, or all interactions were attenuated by decreasing the weight of 
the interaction. These "attacks" mirror the biological phenomena of strong inhibitors, weak 
inhibitors and broad-spectrum inhibitors. Combinatorial simulation of the networks was carried 
out to determine what combination of effects maximally perturbed the system. Surprisingly, 
weakly targeting multiple nodes in the network was more able to shut down the system than the 
complete removal of a node. This fundamental work on a simulated model system echoes failed 
"common-variant" hypothesis from GWAS work. The general consensus of the GWAS literature 
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indicates that multiple mutations or factors are more likely to be causal than a single mutation. 
Looking forward, Agoston's work suggests that with respect to pharmacology, the design of 
multiple ligands may be more efficacious than striving towards ever more potent inhibitors. The 
concept of polypharmacology has caught like wildfire and has caused a push towards designing 
multiple ligands capable of weakly interacting with many target structures.   
1.3.3 Network theory applied to drug development  
 While no completely novel drug families have been found using network analysis, 
statistical network modeling has made some surprising discoveries. Frequently the overarching 
concept in drug design is to find one target, and bind that target as tightly as possible. Many 
branches of medicinal chemistry are devoted to substrate optimization and understanding ligand 
binding affinity. However, following the initial work by Agoston et al. mathematical modeling of 
perturbed interaction networks has repeatedly stated that there may be significant benefit in 
approaching multi-target drugs (127-129). Modest interference in an interaction network at 
several points has been shown to result in a more significant overall downstream effect(128, 
130). So far this method has been successfully applied to the discovery of ligand-gated ion 
channels as potential drug targets(131), as well as novel methods of targeting kinases in anti-
cancer treatments(132). This has led to the application of network theory to the field of drug 
development.  
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Figure 0-4 Example network illustrating standard and multiple ligand pharmacology 
Both panels show the same randomly generated interaction network. We see two typical small regulatory 
networks connected by a bottleneck. Panel A illustrates the one drug, one target paradigm. Panel B 
illustrates the concept of multiple ligands.  
 These early successes in polypharmacology led to the pursuit of "designed multiple 
ligands"(133-135). Figure 0-4 describes the concepts behind both traditional drug design and 
polypharmacology. Both panels show the same randomly generated interaction network. We 
see two typical small sub-regulatory networks connected by a bottleneck. Panel A illustrates the 
one drug, one target paradigm, with several targets highlighted for inhibition. Shown in red are 
hub nodes, which would destabilize separate sections of the network. In blue is a bottleneck 
node, inhibition of which would decouple the two, but not alter their independent behavior. In 
green are peripheral nodes, which would affect their respective small networks without 
completely shutting them down. Panel B illustrates the concept of multiple ligands. If a substrate 
weakly targets numerous nodes in a regulatory network this may provide more complete 
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inhibition than strongly targeting a single node. Small molecules that affect multiple cellular 
targets within a single cellular interaction network have shown some promise in a range of 
diseases including cancer, HIV, neurodegenerative disorders and obesity (136-139). Many 
drugs whose mechanism of action was not known during their discovery and trial phases have 
been determined to exploit multiple targets within a system(140).  
1.3.3 Integration of genomics, network analysis and pharmacology  
 In the discovery workflow described in Figure 0-1, network analysis is shown as being 
connected to pathway determination of known targets. While this is indeed a valid application for 
network analysis, it also provides an excellent bridge between the genomic data involved in 
target validation and the downstream steps involved in small-molecule design. Integration of 
genomic level data with interaction networks and current ligand databases have been used to 
"repurpose" a number of small molecule drugs. Several successes have been published 
connecting genome level data to disease treatment through network analysis(141, 142). 
Perhaps one of the most thorough is Sanseau et al. applying GWAS level information to drug 
repositioning. In this study, disease-associated SNPs were analyzed and through several 
iterations of database mining were linked to various disease therapies. This resulted in several 
small molecules being suggested for alternative usage in diseases such as Crohn's  and 
smoking cessation(143).  
 Regardless of the application, integrating genome level data, network analysis, and 
pharmacology is promising for future work from target identification to pathway analysis. Once 
potential targets have been found and the systems they participate in elucidated, further studies 
are warranted. Whether the goal is novel small molecule design, or fundamental understanding, 
structural information is an irreplaceable contributor. 
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1.4 Structural analysis 
 Computational chemistry has long been applied to the structural analysis of 
biomolecules. The initial techniques of X-ray crystallography were applied to large biomolecules 
in the early 1950's, and have steadily progressed since then. Use of 3D structural information 
can greatly assist in the interpretation of in vitro experimental results, and frequently obtaining a 
structure quickly becomes a goal when an interesting target or system is discovered.  
 Static structures themselves can be informative, as much information can be gleaned 
from thorough examination of active sites and known substrate binding regions. However, 
queries into the nature of the biomolecular surface and the dynamic properties of the molecule 
are also quite valuable. Wet-lab technologies are making great strides towards more real-world 
structural data, with the development of single molecule techniques(144-147), atomic force 
microscopy(148-151), and the combination of individual-particle electron tomography and 
focused electron tomography reconstruction (152) in addition to traditional NMR and X-ray 
techniques. Structural information is a fantastic resource, but observing biomolecules in a 
cellular setting is still far beyond our current capabilities. Until those experiments are possible, 
computational techniques can attempt to fill the gap.  
 Given a static structure, surface characteristics and electrostatic analyses provide 
context for some of the behaviors of the molecules, both alone and in contact with protein 
partners and can be used to guide both protein and ligand design. Where available, multiple 
crystal structures can provide snapshots of the motions of a protein, but dynamic calculations 
such as normal mode, molecular dynamics, and advanced sampling techniques are required to 
turn the stills into movies, so to speak. The following sections will address some of the 
computational techniques that assist in structural investigation of a biomolecule once it has 
been assessed as a potential target for study. 
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1.4.1 Static analyses 
 The importance of static structural characteristics in structural analysis should not be 
understated. Innumerable mutagenesis studies have shown that altering just a single residue in 
an active site can abolish activity. Similarly substitution on the surface of a protein can 
dramatically alter protein-protein interaction. When the alteration is not dramatic enough to 
perturb the structural dynamics of the protein, the effects of substitution can be attributed to 
either catalytic relevance, or surface effects. Electrostatics are critical to binding events between 
proteins(153), as well as with substrates(154). Polarizability and electron movement have a 
distinct role in the behavior of proteins at the catalytic level, but assessment of all quantum 
computational techniques applied to biomolecules is outside the scope of this document. With 
respect to the workflow discussed in Figure 0-1, the interjection of computational chemistry to 
the analysis of biomolecular structures can aid in fundamental understanding, engineering of 
proteins, and ligand design. The surface property most commonly discussed is largely 
electrostatics(154-164), while hydrophobicity(165-168), ligand binding pocket analysis(169-171), 
and protein-protein interaction hotspot detection(172-177) are all also popular.  
 Electrostatic calculations applied to proteins suffer from a few assumptions that must be 
made in order to facilitate the calculations. As always, computational cost and accuracy are 
inversely related. The more accurate your calculations are, the more computationally 
demanding they become. There have been attempts to use combined QM/MM and full quantum 
mechanical calculations to obtain highly accurate electrostatic potentials of small proteins, 
however this is not the norm. By and large, most electrostatic calculations are done under 
continuum rather than explicit solvent, as solvation greatly increases the computational cost of 
the calculations.  Some excellent comparisons have been made by Tan, Lee and Godschalk 
with respect to the differences in explicit and implicit electrostatic calculations (178-180) and will 
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not be discussed here, rather we will focus on the information that can be discerned from 
application of electrostatic calculations in implicit solvent.  
 Within the context of continuum electrostatics, there are two primary techniques: solution 
of the Poisson-Boltzmann equation for the system, or application of the generalized Born 
approach. A broad array of programs exists to facilitate these calculations, and several 
overviews are available in the recent literature (162, 181-183) . Two of the most common are 
DelPhi and APBS, the adaptive Poisson-Boltzmann solver(184, 185). While the ability to obtain 
an electrostatic representation of a protein is in itself a valuable thing, electrostatic surfaces can 
be used in a multitude of ways to aid in the analysis and prediction of structural properties. 
Electrostatic surface calculations can be applied to the detection of protein-protein binding(153, 
157, 158), ligand interactions(154), or the predictions of ligand binding pockets, among many 
others.  
 Experimentalists are able to find protein-protein binding partners through various 
techniques such as pull down assays, but frequently investigating the protein-protein binding 
interface is difficult without extensive mutagenesis studies. Electrostatic calculations have been 
used to guide protein-protein docking(158, 186-189), protein-protein interface detection(177, 
190-192), and have been determined to be strongly involved in protein-localization(193, 194). 
With respect to fundamental studies, analysis of protein-protein interfaces and docked 
conformations can assist in directing mutagenesis studies(195, 196) and has made great 
contributions in the field of designed proteins(156, 197).  
1.4.2 Dynamic properties from Normal mode to molecular dynamics 
 When interrogating a static structure, we are excluding all the dynamic properties of a 
protein in a warm solvated system. It is not yet possible to observe biomolecules in their natural 
environment, but by simply incorporating information on the motion of a molecule, we can 
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greatly expand our understanding. Simple estimations of predicted motion such as Normal 
mode or hinge region decomposition provide computationally cheap methods for study of 
motion. Normal mode calculations applied to proteins give an estimate of the low energy 
vibrational modes by grouping sets of amino acids into dummy groups and then treating them 
like an oscillating system. Normal-mode theory involves a harmonic approximation of the 
potential energy around a global minimum, in most cases the crystal structure is used at a 
starting point and is assumed to be near an energetic minimum. This allows the solution of the 
equations of motion by diagonalization of the Hessian matrix. The eigenvectors of this matrix 
provide the normal modes and the eigenvalues are the square of the frequencies of the 
oscillations. Every atomic displacement vector is a linear superposition of normal modes 
weighted by each of its eigenvector coordinates for the atomic mass, an amplitude, phase, and 
frequency. This technique has been in use since the early 1980's and have proved highly 
reliable for predicting overall structural movement. Recent estimations suggest that in many 
cases where there are known changes in tertiary structure, normal mode calculations correctly 
represent them roughly 50% of the time(198), and given an EM map, application of normal 
mode analysis can aid in interpretation of the diffuse density observed in experiment up to 
20Å(199). Furthermore, frequently representative motions are contained within one of the three 
lowest energy normal modes (200-202). While domain level movement is particularly interesting 
in enzymes with open-closed conformational transitions such as polymerases (203), certain 
hydrolases (204, 205) and immunoglobulins (206), these types of calculations are less effective 
when the goal of a project is to interrogate a catalytic site.  
 Methods that move beyond domain level include coarse grain, all atom molecular 
dynamics, and accelerated sampling techniques, where the equations of motion are 
approximated for a system. The objective of these methods is to simulate real world phenomena 
as accurately as our technological limits will allow. In these types of simulations, classical 
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physics is applied to a three dimensional system. Molecular dynamics propagates Newton's 
equations of motion using a force field to evaluate the potential energy. The most commonly 
used force fields describe bonded and non-bonded terms and are parameterized to reproduce 
experimental data. Bonds and angles are represented as springs, dihedrals are represented 
using a sine function. This reproduces the energy cost of rotating a group through an eclipsed 
position. Van der Waals and electrostatics are included as non-bonded terms and are typically 
modeled using a Lennard-Jones potential and Coulumb's law respectively. A range of methods 
are being developed to improve on the standard force fields, in hopes of better reproducing 
physical phenomena. The development of a force field including polarizability is expected to 
improve the accuracy of simulation, and these are being pursued by various methods including 
electronic structure theory, induced dipoles, point charges, distributed multipoles and density 
fitting.  
 While there are certainly concessions to the method, all-atom molecular dynamics has 
been broadly accepted as the gold standard for exploring macromolecular motion on a per-
residue scale. As we cannot yet observe the sub-domain motions in a protein barring collecting 
crystallographic snapshots, dynamic methods give insight into systems that are beyond the 
reach of experiment and are likely to remain that way for some time.  
 Coarse grained methods involve representing clusters of atoms as larger "dummy 
atoms", assigned various properties such as size, weight, and charge based on various metrics. 
This reduction in complexity is particularly useful for simulating large or complex systems where 
discrete residue-based information isn't required, but where sub-domain detail is needed. 
Successful applications to membrane bending (207-211), lipid layer perturbation (212-216) and 
motor proteins (217, 218) have been among some of the most interesting in the literature. 
Frequently, coarse-grained simulations are capable of reproducing some gross characteristics 
of an experimentally measured system. For example, membrane tubule diameter was 
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successfully reproduced by coarse grained simulation of membrane-bending by BAR domain 
proteins (208, 209). While excellent in conjunction with biophysical experimental methods, 
coarse graining does not allow for analysis at the atomic level.  
 All-atom molecular dynamics (MD) are capable of illustrating the behavior of 
biomolecules on an atomistic scale, and can describe very fine networks of interactions when 
properly constructed. The capability in dynamics simulation has exploded in recent years, with 
studies surpassing the millisecond long milemarker in 2009 (219). While extremely long 
timescale dynamics are now within reach, frequently the resources to facilitate those studies are 
not. This has led to the development of accelerated dynamics techniques, designed to sample 
the conformational space present in an extremely long timescale simulation without explicit 
performance of those dynamics. Accelerated MD(220, 221), replica exchange MD(222-224), 
temperature accelerated dynamics(225-229) and other forms of enhanced sampling (230-237) 
are all methods that seek to decrease the computational cost associated with traditional 
molecular dynamics. Most traditional studies limit themselves to the nanosecond range and a 
plethora of analysis tools have been developed to facilitate the extraction of data from these 
simulations. Detection of correlated motions(238), solvent effects(239), per-residue 
rearrangement to facilitate salt bridges and hydrogen bonds are all common analysis 
techniques.  
 Detailed understanding of the motions of a biomolecular system are incredibly 
informative, but until recently, the computational cost, resources, and skill needed to perform 
robust dynamics simulations were prohibitive. As the methods develop to thoroughly and 
efficiently investigate biomolecular structures in a semi-native environment, the breadth of 
systems and downstream applications for which molecular dynamics has been used has greatly 
expanded. In terms of the workflow discussed in Figure 0-1, biomedical research has recently 
seen a huge push towards incorporating the data from dynamic techniques into drug design.  
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1.4.3 Molecular dynamics applied to drug design 
  As our ability to perform molecular dynamics has increased, there has been a continual 
press to increase the usage of these types of studies in drug design. There is a considerable 
body of evidence suggesting that drug design can be enhanced by studying the interactions of 
ligands with an array of protein conformations (240-244). The concept of a rigid receptor and 
rigid small molecule has lost favor over the years, as our understanding of protein 
conformational dynamics has evolved. Conformational selection and conformational capture are 
gaining favor as more realistic interpretations of protein-ligand interaction (245-251). To design 
drugs around a cadre of protein conformations, one must first have access to that 
conformational space. Molecular dynamics, as well as Markov state modeling and enhanced 
sampling have been applied recently to the generation of protein structures, which can then be 
used for ligand design. 
 Following the profound success in drug design on HIV-1 integrase leading to the now 
FDA-approved drug raltegravir, application of MD to drug design gained a considerable amount 
of notoriety(252, 253). A cryptic binding site on the surface of HIV-1 integrase was detected 
following molecular dynamics studies. Further work with molecular modeling and optimization 
was used to develop a set of small molecules which were then tested in vitro and found to have 
significant inhibition constants. This substrate optimization was directly based on the detection 
of a novel trench detected in the molecular dynamics work.  
 There have been a few other notable success stories, though none have been as 
popular in the news. Histone deacetylases have been long known to be valuable, but 
challenging drug targets. Work by Estiu et al. on the numerous crystal structures of HDAC 8 led 
to the differentiation of several critical interactions governing isoform selectivity in small 
molecules(254, 255). Molecular dynamics simulations indicated that the HDAC8 structure was 
highly mobile, with a few critical contacts in the interior of the protein. It was determined that the 
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alterations in HDAC8 conformation when bound to small molecules were essential for inhibitor 
function and isoform selectivity. This information was exploited to design isoform specific 
HDAC8 inhibitors (256-258). Further studies extended this hypothesis on isoform selectivity to 
HDAC10 and 11, where it was determined that small molecules which tightly bind HDAC8 have 
weaker contacts with the other two structures (256-259).  
 Inhibitor design targeting influenza A virus M2 (IA/M2) used molecular dynamics to 
investigate the binding dynamics of amantadine, the well known anti-viral. In this case, the 
dynamics studies were used to dissect the interactions in the active site and determine which 
contacts were stable. Reoptimization of the initial ligand structure resulted in a set of 
amantadine analogues that perform similarly in simulation and which are now being investigated 
as potential drugs(260, 261).  
 In application to protein-protein interface disruptors, molecular dynamics was used to 
detect the critical contacts in tubulin polymerization, which were then built into antimitotic 
peptides(262). Simulations of tubulin dimers allowed access to the conformational and energetic 
characteristics of the interaction. Simulation following computational alanine scanning was used 
to discern which components of the interface were most critical. Based on the essential 
sequences, a series of peptides were designed to mimic those tight interactions. Tubulin-
peptide simulations were performed and in several cases the peptides remained tightly 
associated with the tubulin monomer. In vitro assays indicated that the peptides had a strong 
inhibitory effect on tubule formation. A control peptide that dissociated in silico was found to 
have no inhibitory properties in vivo suggesting that the efficacy of the design was not random.  
 While there has been some considerable success, the popular opinion is that there 
needs to be far more inclusion of computational methods in drug design. Historically most 
dynamics studies went after structures with interesting physical properties, or those that were 
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interesting to the fundamentals of biochemistry. The few attempts at combining MD and drug 
design have been quite productive, but as the concept of combining these techniques is still 
quite new it is difficult to ascertain extent of that productivity . A text-mining and citation tracking 
foray reveals that of 35 studies performing molecular dynamics on potential drug targets since 
2001 (252, 253, 263-296), 21 of these resulted in the synthesis of an active inhibitory molecule 
(131, 263, 287, 291, 294, 297-312). That is not to say that studies without verified synthetic 
molecules have been unsuccessful; many computational investigators lack the facilities to 
synthesize and test potential drug-like molecules. When facilities or collaborations exist, it still 
may take time to translate computational results into wet-lab successes. All told, a 60% success 
rate in the last dozen years is still nothing to sneeze at.  
 The response from key figures in the drug design field has been unanimous, whatever 
can possibly be done to increase the amount of dynamic data related to drug design should be 
done. High-throughput GPU powered MD facilities, black box servers for the generation of 
Markov model structures, integration of data resources, and improvement in protein and small 
molecule forcefields have all been suggested as ways to facilitate the incorporation of dynamic 
information into drug design (313-319). Computational methods that give additional structural 
information about receptors are already becoming invaluable to the process.  
1.5 Small molecule development 
 
 With a thorough understanding of the target, the pathway, and the structure in hand, the 
final step towards drug design or investigation is to determine the ligand possibilities available. 
When receptor structure is unknown, or where there are multiple substrates with binding data 
available, there are a range of methods possible to assist in the development of small 
molecules. The broad field of quantitative structure-activity relationships (QSAR), bootstrapping, 
bioisostere and rescaffolding methods are just a few(320-323). When a receptor structure is 
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available however, computational tools can provide a considerable advantage over either high-
throughput screening or "spaghetti-to-wall" synthesis. It is generally agreed that the return on 
investment for chemical high-throughput screens is lower than expected, and they are limited by 
the contents of the screening library. Similarly, purely virtual compound screens suffer from a 
staggering number of algorithmic options, as well as a lack of consensus in scoring methods for 
potential drugs (319). An alternative to high-throughput screening that has performed well is 
chemical fragment screening. In these experiments low molecular weight molecules are 
screened for binding affinity against a target. Once small fragments are identified, these results 
are typically combined with crystallography and computational methods to develop a more drug-
like compound. A review by Murray et al  presents a list of the numerous successes in both 
industry and academic literature (324). Fragment-based drug design is an excellent example of 
how the combination of experimental and computational techniques can be more productive 
than either technique alone.  
  As structure building and conformational optimization for small molecules have become 
commonplace, these methods will not be discussed. In the last stage of the workflow discussed 
in Figure 0-1, design of small molecules for either clinical inhibition or fundamental inquiry is a 
common pursuit when studying a biomolecular system. Molecular modeling and docking, as well 
as novel structure reoptimization methods can considerably improve the pace at which a new 
molecule can be brought to bench. Additionally, this is the part of the workflow where 
computational chemistry has been most frequently applied. The following chapter sub-sections 
will focus on techniques relevant to the previous discussions, and new advancements in the 
field.  
 It is important to note that with respect to small molecule development, there are a 
spectrum of goals that can be worked towards. Small molecule design can include optimization 
of physiological transport properties, tuning of binding, increasing stability in vivo, and selecting 
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for various protein isoforms or multiple targets. As discussed in section 1.3.3, tight binding is not 
always the goal of a drug design project. Tuning a small molecule to target a range of proteins is 
becoming increasingly popular as polypharmacology catches on. Furthermore, the behavior of a 
small molecule inside a body needs to be considered. Many drug leads that perform 
spectacularly in vitro have little or no in vivo activity, alternatively off-target effects can result in 
considerable toxicity. Pharmacokinetics must be considered as well. The suite of biological 
processes known as ADME (absorption, distribution, metabolism and excretion) all affect the 
pharmacokinetic efficacy of a drug and there are numerous computational methods directed at 
tuning these properties, the well known "Rule of five" is the result of one such study.  
1.5.1 Small molecule docking 
 In assessing the interaction between a ligand and receptor, a conformation for the ligand 
is required. Numerous algorithms have been developed since the 1980's to perform this task, 
and it has been largely established that docking is a good way to generate a putative ligand 
binding conformation. While the number of docking programs has proliferated over the years, 
the fundamental protocol remains the same. Generate a set of starting structure guesses, and 
score them to assess binding or interaction affinity.  
 Generating the docked structures can be done in a number of ways. Docking a rigid 
ligand to a rigid receptor has long since been abandoned as inefficient and ineffective for small 
molecules, so these historical techniques will not be discussed. The dominant paradigm places 
flexible ligands into protein active sites of variable flexibility. Many programs still use a rigid 
receptor, while some include side chain "softness", while some accommodate docking to a 
group of related structures. Of the techniques commonly in use today, programs can be sorted 
by algorithm: Monte-Carlo methods, grid-based methods, genetic algorithm methods, fragment-
based methods, and "soft-docking".  
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 Monte Carlo methods rely on the statistical theory of Metropolis et al. (325). In its 
simplest form, this method can be thought of as a repeated series of three steps. A ligand is 
moved in cartesian space, the new position is evaluated by some heuristic, and then the move 
is accepted if the new position is more energetically favorable, or rejected if it is above an 
energetic threshold and statistical probability based on a Boltzmann distribution. In the program 
AutoDock, the AMBER force field is used for energetic scoring(326). Frequently Monte Carlo 
steps are used as a cheap form of minimization, such as in ProDock(327). The stochastic 
nature of the search means that compared to many other docking algorithms, MC methods can 
be slow. There are some structural shortcuts that decrease the computational cost, such as 
representing the protein receptor as a grid rather than an explicit 3D structure. A particularly 
interesting new stochastic method is swarm optimization, where the search is conducted using a 
model of swarm intelligence. The method of particle swarm optimization was originally 
developed to model flocking behavior, but was observed to be a mathematically efficient method 
for optimization. SODOCK(328) and PSO@AUTODOCK(329, 330), are just two examples.  
 Systemic search methods use an algorithmic approach to explore all possible 
conformational space available to a ligand, within a designated interaction space. GLIDE(331, 
332) performs an exhaustive brute-force search, as does FRED(333). Another way of 
performing a systemic search is to apply a  genetic algorithm. In the programs GOLD(334) and 
AutoDock(335), ligand docking is treated like an evolving system. A population of ligand 
conformations are generated, moved, and ranked. Poorly scoring conformers are removed from 
the pool and the process is repeated with the newly culled ligand pool.  
 Fragment based methods explore the protein binding site by decomposition of the ligand 
into small pieces which are placed in the active site, providing seeds for reconstruction of the 
ligand. While there are a range of methods for fragmentation of the ligand and placement of the 
initial fragments from which building will proceed, nearly all of them use an interaction based 
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assessment. Fragment division is typically performed in a manner that will leave major 
functional groups intact. For example, FlexX severs the ligand at all acyclic single bonds. This 
would leave protein backbone fragments and Murcko cyclical drug fragments intact (336-340). 
The advantage of the fragment based methods is their relative speed. Pre-assessment of the 
protein binding site, and the incremental construction of the ligand minimizes the amount of of 
calculations performed per docking solution(340, 341).  
 While there are many methods used to generate the set of ligand conformation, 
evaluation of the conformations is also required. A plethora of scoring algorithms is available, 
and a thorough review of recent developments is available in Ramsland et al. (342). 
Comparative studies of docking and scoring algorithms for the past few years have universally 
reached the same conclusion. While current docking methods all are capable of generating 
excellent docking conformations, the scoring algorithms are insufficient and generally are 
difficult to assess. Inclusion of solvation estimates, entropy, knowledge-based scoring based on 
database information, and even machine learning has only moderately improved the situation, 
and in no system has one scoring method proven unequivocally superior. In most cases human 
assessment of the docking conformation is still required. Regardless, the ability to generate 
structures that are reliable, even when a human eye is required for the final assessment, is a 
significant achievement.  
 
1.5.2 Lead optimization 
 It frequently happens that a small molecule is found to bind a target protein, just not with 
a particularly good dissociation constant. When a structure of the protein is available, and the 
ligand has been modeled, computational lead optimization can be performed. Before the 
development of explicit algorithms for optimization, much of the restructuring of the ligand was 
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done by eye. Newer methods however have increased our ability to explore the chemical space 
available for synthesis and more accurately assess active site interactions.  
 One popular computational technique for retooling small molecules is one that was 
borne out of the combinatorial docking studies. The generation of ligand libraries facilitated the 
generation of ligand fragment libraries. CAVEAT was the first program designed to mine 
fragment libraries in the hopes of retooling lead compounds(343). Fragment-space searching 
seeks to replace unfavorable pieces of bound ligands with small molecule fragments in the 
hopes of improving the binding. Various protocols incorporate shape complementarity, 
electrostatics, desolvation, and more recently explicit water binding (344-348). Upon obtaining a 
docked conformation, a researcher inspects the binding pose and either by eye or using a 
scoring method assesses which contacts or contact regions are negatively impacting binding. A 
region of ligand is selected to be replaced, or extended, and then a global search of the 
fragment library is used to do the substitution. Fragments are pre-screened before docking by 
assessing the region of the receptor in which they'll be binding and if possible a pharmacophore 
can be designated as a desired point of interaction. A library of derivatives is generated in this 
manner and they can be docked, scored and compared to the original ligand. There are several 
drawbacks to this method, one of which is that only fragments currently in the fragment library 
can be assessed. Second, it is highly dependent on the initial selection of regions for 
replacement and iterative investigation can be time consuming. However, the recent 
implementation of the fragment search software ReCore (349-352) has shown some promise in 
the literature (353).  
 Other methods of lead optimization are based on free energy perturbation theory (FEP), 
and thermodynamic integration (TI). While some computational groups have applied these 
methods to drug design, in very productive ways, there are no "easy" ways to perform these 
calculations. Application of these methods has been successful in the design of fructose 1,6-
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bisphosphatase inhibitors (354-359), COX1-COX2 inhibitors(360-363) and fatty acid amide 
hydrolase inhibitors(364-367). Cheaper and easier methods based on molecular 
mechanics/generalized born solvent approximation (MM/GBSA) have not proved accurate 
enough for functional lead optimization(368).  
 
1.6 Conclusions  
 As computational techniques advance and become both more sophisticated and less 
expensive, there is no denying that there is benefit to inclusion at every step on the path to 
biochemical understanding. From target identification and systems biology to structure 
interrogation and ligand design, computational chemistry can play an important role.  
 Application of bioinformatic and statistical techniques to genome level data has the 
ability to deconvolute the massive amount of data generated. High throughput sequencing is 
capable of generating a staggering amount of data very quickly, and it's only recently that 
computational techniques have been catching up to the pace. Working in conjunction with 
geneticists and clinicians, bioinformaticians have the unique ability to find novel targets and 
biomarkers hidden in the data. When data mining is applied to non-human genomes it opens 
the door to finding novel antimicrobial targets. Beyond that, the foundation of human genetics 
was laid by studying regulation in model organisms. We now have the ability to more deeply 
understand the underlying patterns of gene expression and regulation in simple organisms, 
which may in time lead to a greater understanding of human genetics.  
 With that in mind, the extrapolation of graph and network theory to biological data has 
unprecedented potential to change the way we think about biosystems. Not only does this type 
of modeling lead to a clearer understanding of the interactions in a system through 
deconvolution, mathematical modeling has revealed entirely new paradigms for drug design. 
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The prospect of generating as complete a network model as possible, and then probing the 
effects of perturbations on the system holds a lot of promise. The validation of the work of 
Csermely and Nussinov on network perturbation applied to multi-target drugs has opened the 
door for a completely new method of drug design. Multiple protein-binding ligands and network 
based repurposing of known molecules may help remedy the well-known dearth of novel drugs 
being released. Application of network analysis to both gene and transcript level data allows the 
formation of meaningful connections and novel perspectives in drug design. 
 At the level of atomic structure of biomolecules is where computational chemistry really 
shines. When you get down to the level of a 3D atomic structure, computational chemists are 
able to give insights on structure and function that are just out of the reach of experimentalists. It 
is at this point that the in vitro data from experiment can be at least partially interpreted by 
computational results at the atomic level. Static assessment of protein, RNA or DNA structures 
can help us understand the physical characteristics that are observed in experiment. 
Electrostatic and surface properties govern the subcellular interactions of biomolecules; 
computational investigation can help give context to those interactions. Protein-protein binding 
is one of the major areas where electrostatic and surface properties can assist experimentalists. 
Though determination of the protein-binding interface can be examined by mutagenesis, 
computational methods can help guide those studies and vice versa. With respect to dynamic 
information, such as normal mode or molecular dynamics studies, the level of understanding 
increases exponentially. As we begin to think about proteins as more than just rigid bodies with 
a catalytic function, dynamic structural information becomes a necessity. Molecular dynamics 
studies in particular are both highly valued, and rarely applied. There is incontrovertible 
evidence that MD investigations are highly productive when applied to drug design, but both 
computational cost and skill required are hurdles that need to be overcome.  
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 Small molecule studies are the oldest application of computational chemistry, and also 
some of the most well developed. Algorithms for in vacuo structure and energy optimization 
became the gold standard long ago and we can only hope that much of the rest of 
computational chemistry goes that way as technology advances. Modeling of protein-ligand 
complexes has reached the point where the question is no longer "Did we find a  binding 
orientation?" but is rather "Which one of these is best?". Scoring and binding energy 
assessment accuracy still lag behind the generation of docked conformations, but not for lack of 
effort. In this area, computational chemists and skilled modellers still require the input and "eye" 
of skilled wet-lab chemists. However, with respect to reoptimization of binding conformations, 
fragment space searching is a great assist in the generation of derivatives. A thorough fragment 
space search capably assesses the result of performing literally millions of substitutions on a 
molecule. While there is no software that will hand over a "magic molecule", these types of 
studies can provide inspiration, and are an excellent starting point for conversations between 
computational chemists and synthesists.  
 Computational chemistry can make critical contributions at all stages in the biochemical 
discovery workflow. From identifying targets and facilitating genome level analysis, to the 
development of systems and network biology, to structural assessment, drug design, and small 
molecule optimization, integration of computational techniques is becoming essential. The ability 
of computational methods to handle extremely large datasets, be it genomic or dynamic puts a 
wealth of information within reach. Whether for fundamental or goal-oriented studies, the 
combination of computational and experimental work is extremely powerful.   
 Looking forward, across all facets of biochemical discovery, communication and 
collaboration is key in solving the challenges we face. While presented as four separate steps in 
a process, target identification, network analysis, structural investigation and small molecule 
development each have the potential to affect other parts of the discovery pathway. 
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Collaborations between experimentalists and computational chemists are highly valued,  but 
beyond that, to really make the most of the new developments in computational chemistry, we 
need to expand our reach.  
 The rapidly expanding amount of "omics" data available is presenting a huge challenge 
in data storage, analysis and interpretation. To help us develop creative and innovative ways to 
meet the challenges we face we need to "think outside our field". Network and graph theory 
have permanently changed the way we think about genomic data and small molecule inhibition, 
though the initial studies had nothing to do with biochemistry. Bioinformatics is assisting in 
building a bridge between computer science and biochemistry, but the application of purely 
statistical techniques to biology has not been entirely helpful.  
 The initial results from genome wide association studies were considered a let-down, but 
we as scientists should know better than to approach a disproven hypothesis as a failure. The 
common-variant hypothesis failed. Genome wide association experiments did not. In fact, they 
are changing our perception of human genetics is linked to disease. Now that we have access 
to large scale genomic data, we should move past reductionist techniques and attempt to 
understand the complex interactions underlying our complex diseases.  
 When we cannot communicate our experiments, results, or interpretation, science 
suffers. As we layer network theory on top of dense systems biology information to find 
understanding in a broader context, a major challenge will be finding a way to effectively present 
our findings. While current network visualization techniques can build off of pre-established 
ideas, we need to develop a visual language that can effectively communicate the depth of 
information in pathways networks and systems. In the future perhaps we can look to cognitive 
psychologists or graphic designers to help us find new methods to express our research in a 
way that doesn't overload our brain-processing power.  
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 Novel drug targets and disease associated proteins are being identified regularly and in 
order to really get to the root of how these proteins tie into their network, we need to understand 
them. Our ability to quickly and accurately determine molecular structure has grown immensely, 
providing a wealth of information for modelers. Over 30% of the structures in the RCSB protein 
data bank have been deposited in just the last three years. As our ability to investigate structure 
grows, we need to propagate that information both backwards and forwards in our discovery 
process. Surface analysis methods have not dramatically changed in recent years, but novel 
applications of those methods should be something to strive towards particularly as inhibition at 
the protein-protein interface becomes popular.  
 There is a resounding chorus calling for more molecular dynamics in drug design, and 
one would hope that in the future, the dynamic properties of a potential drug target would be 
commonly investigated. Rationally designing a clinically valid therapy from a single crystal 
structure is similar to trying to figure out the ending of a movie from a still frame. You may be 
able to figure out some bits and pieces and make a good guess, but you're still missing the big 
picture.  
 While we should constantly strive for higher accuracy and better sampling methods, 
current methods allow for a basic investigation even into relatively large biomolecules. As both 
the methods and computational power improve, there is no doubt that in the future molecular 
dynamics should become a much more widely applied technique.  
 Challenges in the future of small molecule design seem to be largely human. Both the 
experimental and computational technologies are well advanced with respect to building new 
drugs, but a quick survey of the literature indicates a disconnect. In the future small molecule 
development needs to be enthusiastically interactive. The plethora of tools designed for small 
molecule building, docking, ranking, optimization, and physiochemical property determination 
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are staggering, and this proliferation of techniques and publications can be unwieldy to process. 
Similarly the work involved in synthesis, purification, assay development and testing can be 
gargantuan.  
 Purely computational methods lack the persuasiveness of in vitro experiments as the 
results are semiquantitative at best due to the approximations that are involved. Frequently 
organic chemists balk at synthesizing molecules from a pure computational screen. This is 
appropriate; frequently structural biologists and computational chemists are less familiar with the 
practical aspects of organic synthesis and lack the ability to quickly weed out structures that a 
specialist in pharmacokinetics or drug metabolism would easily spot as problematic. Synthesists 
overlook the capabilities of computational chemists when it comes to suggesting ore 
reoptimizing a structure. It is far faster to determine whether a substituent location will enhance 
or interfere with ligand binding computationally than it is to synthesize and test. Also, the ability 
to search millions of subtituent fragments may inject creativity into the drug design process.  
 Try as we might, no individual will ever be capable of working effectively on all facets of 
biochemical research. Rather than attempt to create polymaths of us all, collaboration and 
communication should necessarily connect experimentalists and theorists at all levels of 
biochemical discovery. Hopefully in the future our ability to generate and manage large datasets 
should go hand in hand with generating and managing profound discoveries.  
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Chapter 2 Conformational analysis of Clostridium difficile Toxin B and 
                 its implications for substrate recognition1 
2.1 Background 
One of the most common and serious hospital-acquired infections is Clostridium difficile 
(C. difficile), responsible for a suite of diseases collectively known as Clostridium difficile 
associated diseases (CDAD) (369, 370). C. difficile typically affects patients undergoing 
antibiotic treatment for other infections, as it leaves the GI tract susceptible to colonization by 
this highly virulent pathogen due to the reduced protection by the normal gut microbiota (371, 
372). Currently, U.S. health care costs associated with treating CDAD are estimated to be 
between $750 million and $3.2 billion (372-376). With the emergence of an epidemic strain that 
is both hypervirulent and more resistant to current therapies (377-379), costs will surely 
continue to rise, so new approaches to treating CDAD are needed. 
 C. difficile is a spore forming bacillus, and thus is difficult to effectively sanitize against, 
as the spores are easily spread 
from person to person and can 
survive most normal sanitization 
methods (380). Figure 0-1 shows 
an electron micrograph of both a 
vegetative bacillus and a spore, 
red and blue respectively (381). 
 Although two thirds of 
patients infected with C. difficile are asymptomatic, those that are symptomatic can experience 
severe complications such as fulminative colitis which is potentially fatal (372). A recent upswing 
                                                          
1
 Sections of Chapter 2 have been previously published (449)  
Figure 0-1: Electron micrograph of C. difficile spore (blue) and bacillus (red).   
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in symptomatic infection rates has spurred numerous hospital facilities to track and report 
outbreaks as they occur. In one instance, it was observed that that patients who acquired a C. 
difficile infection averaged a hospital stay of 3.6 days longer than unaffected patients, and 
increased their average hospital cost by $3669(375). C. difficile is also a rapidly changing 
bacterium that has acquired progressively more antibiotic resistance. Though this resistance 
varies by strain and geographic location, strains can be found that exhibit resistance towards 
most antibiotics.(377, 382-384) It also has been implied that the increase in C. difficile infection 
is due to the emergence of such widespread antibiotic resistance (382). As the C. difficile is an 
opportunistic pathogen, taking over when healthy intestinal flora are suppressed by broad-
spectrum antibiotics, antibiotic resistance is prerequisite to infection. Currently the main form of 
treatment for this antibiotic-initiated disease, are stronger antibiotics. Treating a naturally 
antibiotic-resistant bacterium with ever-stronger doses of antibiotics makes no sense. It simply 
makes C. difficile harder to treat. 
The complement of diseases known as CDAD is the result of cellular damage in the 
intestines due to exogenous virulence factors produced by the bacillus(385, 386). C.difficile 
produces two large cytotoxins known as Toxin A and Toxin B, referred to as TcdA and TcdB. 
These toxins are members of the type A glucosyltransferase family, and cause cellular damage 
by targeting small G-proteins such as RhoA, Rac and Cdc42 (387). Utilizing their UDP-Glucose 
as a substrate, the toxins glucosylate a conserved threonine residue on their target G-protein, 
inactivating it permanently and ultimately leading to cell death (387, 388). The toxins themselves 
are large, and consist of four domains. Both contain C-terminal repetitive oligopeptides referred 
to as the CROP domain, which acts as a receptor binding region, a translocation domain and 
the N-terminal catalytic domain responsible for glucosylation (387, 389-391). 
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2.2 C. difficile toxins A and B 
C. difficile damages the intestines primarily through the action of TcdA and TcdB as 
described above (371). These are members of the lethal subclass of large clostridial toxins 
(392). The holotoxins are ~300 KD and are comprised of four domains, each having a specific 
function related to cellular uptake and toxicity (393). The CROP domain (Clostridial Repetitive 
Oligopeptide) helps to identify and bind to appropriate target cells by recognizing cell surface 
glycoproteins and inducing endocytosis (394-397). The translocation domain is responsible for 
forming a transmembrane pore capable of passing the two remaining domains from the 
endosome to the cytoplasm (397-400). A cysteine protease domain, activated by inositol 
hexakisphosphate in the cytoplasm, intramolecularly cleaves the cytotoxic glucosyltransferase 
(GT) domain from the holotoxin (401-403). This last step is critical since at this point the GT 
domain is released into the cytosol where it can act on the RhoA, glucosylating residue T37 in 
the switch I region (or its equivalent S/T residue in the case of other Rho family members) (388). 
Glucosylation of RhoA permanently inactivates it, causing defects in the cell-signal pathways 
that lead to cell rounding and ultimately apoptosis (388). 
While one could develop new antibiotics to better target C. difficile, resistance is likely to 
be a major concern with any new agents. A potentially complementary approach to antibiotic 
therapy is to develop methods that target and neutralize the GT domain of the toxin (404).  
Several steps in the etiology pathway could be targeted for inhibition, however this work focuses 
solely on the glucosyltransferase domain. 
Several approaches are currently being used to target TcdA and TcdB. Clinical studies 
are under way with humanized monoclonal antibodies that recognize and sequester the toxins, 
but this approach has some issues and will not be suitable for all patients (378, 405, 406). 
Peptides and small molecules that recognize and inhibit toxin function are also being studied 
43 
 
 
(407). By better understanding the domain structures of the holotoxin, it will be easier to design 
or select molecules that disrupt their activity. 
2.3 Glucosyltransferase domain of TcdB 
The GT domain from TcdB (PDBID: 2BVL) was crystallographically characterized 
several years ago (408). This domain was found to be a 543 amino acid domain that adopts a 
characteristic GT-A glucosyltransferase fold, and binds a catalytically-important Mn(II) ion. 
Previous studies comparing the C. difficile toxins to other glucosyltransferases, as well as 
extensive mutagenesis analysis on the toxins themselves, have identified a number of amino 
acid side chains critical for activity (409-411). Figure 0-2 illustrates some of the important 
structural elements of TcdB that will be discussed later in this chapter. A four helix amphipathic 
bundle comprising residues 1-87 (shown in blue) has been implicated in membrane association 
(412); we will show that it is a key component in the large scale molecular motions exhibited by 
TcdB. Residues 510-522, shown in yellow, are part of a mobile loop which supports the catalytic 
manganese and includes a standard DXD motif. The two regions shown in cyan will be referred 
to as "upper promontories". The function of these structural motifs is not yet understood, 
although they participate in a scissoring motion that will be described below. The beta hairpin 
shown in purple (residues 374-387) will be referred to as the active site flap and may have 
implications in catalysis and substrate recognition. The green region (residues 436-456) has 
been shown to be involved in recognition of RhoA by TcdB (413). Finally, the red region 
(residues 483-497) shows motions that are highly correlated to those of the recognition site 
(residues 436-456) in our analyses (411, 414, 415). Shown in transparent orange is RhoA, 
following docking. 
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Figure 0-2: Structure of TcdB Glucosyltransferase domain 
Relevant regions for discussion: The four helix bundle is shown in blue, the mobile loop containing the DXD 
motif is in yellow, the catalytic manganese is shown in black. Regions shown in green and red are involved 
in RhoA recognition. The B-hairpin shown in purple will be referred to as the active site flap. The upper 
regions in cyan are two flexible promontories unique to TcdB. RhoA is shown in transparent orange. 
 
2.4 Experimental design and rationale 
 A comprehensive understanding of the conformational space that TcdB can occupy will 
better guide design of potential inhibitors. TcdB must pass through a pore to gain entry into the 
cell, therefore it is expected to have a flexible form to facilitate transient unfolding and refolding 
during translocation. Hinge region (416, 417) and normal mode analysis (418) were applied to 
determine the location and extent of the primary flexions. Both of these techniques have 
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previously proven useful in determining the major motions attributed to well-studied systems, 
and give a fundamental impression of the overall motions one should expect to see in a flexible 
protein. 
 Long timescale unbiased molecular dynamics (MD) simulations may give insight about 
the conformational space a protein occupies, as well as the mechanism of transition between 
those conformations. Additionally, the atomic scale detail in these simulations allows us to take 
a look at how large scale motions can have consequences in small regions, such as within an 
active site. 
Understanding in a broad sense how TcdB moves and flexes both on its own and in 
contact with RhoA is expected to lead to better understanding of catalysis, substrate recognition 
and most importantly, drug design. The GT domain of TcdB has not yet been crystallized bound 
to substrates other than UDP-Glucose, and thus, nothing is known about the range of 
conformational space it can occupy, or what consequences binding to the RhoA protein might 
have. Recent evidence suggests that RhoA employs a conformational selection mechanism 
(419), rather than induced fit or lock and key. Thus, it is expected that a toxin targeting such a 
protein might have similar properties. Here we report normal mode and hinge region analysis, 
as well as long timescale molecular dynamics of TcdB. Additionally, macromolecular docking 
and long timescale simulation of the TcdB/RhoA complex was performed. Principle component 
analysis (PCA) and Generalized Masked Delaunay (GMD) analysis of the resulting 
conformations were used to help understand the conformational space TcdB occupies both 
alone and in complex with RhoA as well as the nature of the transitions between these 
conformational spaces. 
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2.5 Flexibility studies on TcdB 
 To quickly assess TcdB’s flexibility range, initially two computationally inexpensive 
methods were employed. A hinge region analysis was performed to determine simply if there 
were regions that would be amenable to macroscopic motions. Following this analysis, normal 
mode calculations were carried out. 
2.5.1 Hinge region analysis 
 
 Hinge regions are determined by finding the consensus between two methods, 
StoneHingeP and StoneHingeD. StonehingeP incorporates ProFlex, which decomposes the 
structure into rotatable and non-rotatable bonds. These are then used to analyze flexibility 
based on bond rotation constraints. StoneHingeD incorporates DomDecomp, which uses 
gaussian normal mode analysis. StoneHingeP identifies the two largest rigid domains in the 
protein, and designates hinge regions as residues between these domains. StoneHingeD 
identifies hinge residues as those that are between domains or at domain boundaries, following 
normal mode analysis. StoneHinge (420) determined three major hinge regions on TdcB. The 
total search returns any StoneHingeD residue within five residues of a StoneHingeP residue. 
The results for TcdB are shown in Figure 0-3. These hinge regions involve the residues 
connecting the four-helix bundle to the body of the protein, as well as the region on the 
underside of the active site, and between the two upper promontories to either side of the active 
site. 
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2.5.2 Normal Mode analysis 
 Once it was determined that hinge regions were present that would allow for 
macroscopic conformational changes, a Normal Mode analysis was carried out. elNemo (421) 
was used to find the low energy modes of TcdB. Normal-mode theory involves a harmonic 
approximation of the potential energy around a global minimum, in this case the crystal structure 
is assumed to be near a minimum. This allows the solution of the equations of motion by 
diagonalization of the Hessian matrix. The eigenvectors of this matrix provide the normal modes 
and the eigenvalues are the square of the frequencies of the oscillations. Every atomic 
displacement vector is a linear superposition of normal modes weighted by each of its 
Figure 0-3: Hinge regions identified by StoneHinge shown in green.  
 Backbone is shown as a chain trace, hinge residues are represented as green 
spheres. Hinge regions are observed to occur between regions of flexibility in 
the normal mode analysis 
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eigenvector coordinates for the atomic mass, an amplitude, phase, and frequency. The normal 
modes were represented by a moving gif. Several of the modes appeared to have significant 
effect on the conformation of the active site, and this information was used to assist in 
generation of a putative RhoA-TcdB complex. The primary motions were a wagging of the four 
helix bundle, and scissoring of the upper promontories described in Figure 0-2. The intersection 
of these modes results in an opening and closing motion in the active site center.   
2.6 Macromolecular docking 
 Currently no crystal structure of TcdB bound to RhoA exists, though individual crystal 
structures of both TcdB and RhoA are available. Studies performed by the Aktories group 
determined the conformation of RhoA preferred during attack by TcdB (388). It’s also known 
that TcdB functions by glycosylating a key Threonine residue on RhoA (388, 422). The 
combination of these pieces of information was then used to begin study of the protein-protein 
interface during the glycosylation of RhoA. 
 The first step in understanding the protein-protein interface was macromolecular docking 
to determine whether or not the structures were compatible in their near crystallographic forms. 
To this end, a multi-step protocol was developed. Rough dockings using Hex 4.5 (423, 
424)were performed, followed by a more refined search using RosettaDock (425). 
2.6.1 Hex 4.5 docking 
 Hex 4.5 models rigid protein bodies using three dimensional expansions of real 
orthogonal spherical polar basis functions for both shape and electrostatics. By using the vector 
coefficients of these basis functions along with a surface representing the shape of the protein, 
it’s possible to evaluate a docked conformation through the overlap of pairs of these functions. 
The docked conformations being evaluated are generated through a Monte Carlo search 
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allowing for translational and rotational steps. This relatively simple and fast search was used to 
find initial conformations that place Threonine 37 of RhoA near the active site of TcdB. 
2.6.2 RosettaDock docking 
 To further refine the docking poses, RosettaDock was employed. Rosettadock allows for 
additional steps of minimization and side chain refinement. Beginning with a coarse grained 
Monte Carlo search, rigid body docking is carried out, following 500 Monte Carlo steps, explicit 
side chains are added using a backbone-dependent rotamer packing algorithm, and are 
optimized using a simulated annealing Monte Carlo search. A Davidson-Fletcher-Powell quasi-
Newtonian minimization technique (425) is employed to find a local minimum of the structure 
with the newly added sidechains. This process of repacking and optimization is repeated 
through fifty cycles. Initially, side-chains are repacked in a sequential manner, but once every 
eight cycles, the side chains are repacked combinatorially. Following side chain repacking, the 
structure is randomly perturbed by rigid body translation and rotation, and the process is 
repeated.  
 
Figure 0-4: Flowchart of RosettaDock algorithm  
Reproduced from Gray et al(1) Rosetta dock uses a series of low cost conformational searches followed by 
high resolution refinement steps to generate docked conformations 
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 Docking results for the initial trials did not result in a “Docking Funnel” following cluster 
analysis indicating that no preferred low energy conformation was reached. Failure to find a 
binding conformation using RosettaDock is typically due to conformational flexibility in one or 
more of the binding partners. It is known that RhoA has a region of high flexibility, however 
these studies were performed with the TcdB crystal structure. To incorporate the information 
from the flexibility studies discussed in Section 2.5 Flexibility studies on TcdB, we repeated 
these experiments with the most open of the normal mode conformations. 
Figure 0-5: Structure Energy plots generated following RosettaDock  
Panel A shows RhoA docking to the crystal structure of TcdB, and it can be observed that all energies are 
relatively high, and no cluster of low energy structures is observed. Panel B shows RhoA docked to the 
normal mode relaxed structure of TcdB. A reduction in docking energy is observed, and a few low energy 
regions are apparent. Of note is the improvement in docking when the normal mode structure of TcdB is 
utilized, indicating that flexibility in the face presented for docking may be a feature in TcdB’s target 
recognition process. 
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2.6.3 Normal Mode dockings 
 Following the failure of crystal-crystal conformation docking, The steps described in 
sections 2.6.1 Hex 4.5 docking and 2.6.2 RosettaDock docking were repeated using the crystal 
structure of RhoA and the most open normal mode conformation of TcdB. 
The normal mode docked conformations showed improvement in binding over the 
crystal-crystal docked structures in proximity of the glucosylation site to the catalytic 
manganese. In the original docking, threonine 37 had a closest approach of 18 Å to the catalytic 
manganese. Subsequent docking to normal mode structures yielded a closest approach of 
12.38 Å. A fully docked conformation might be expected to have a contact distance of between 
7.1Å and 7.7Å based on comparison to several glycosyltransferases crystallographically 
characterized in the presence of UDP and an appropriate acceptor (426, 427). Additionally, 
improvements were noted in the structure/energy plots. Overall complex energy was lower, and 
docked solutions are more tightly clustered. However, while the use of a normal mode structure 
improved the docking, none of the structures that were obtained were catalytically valid. It was 
concluded from these results that while the normal mode calculation represented some 
measure of the flexibility of the toxin, it was insufficient to model a conformation capable of 
glucosyltransferase activity--particularly with respect to the regions in and around the active site. 
2.7 Molecular dynamics and associated analyses 
To fully elucidate the interaction between these partners, all atom molecular dynamics 
simulations were performed. Apo-TcdB and the structure of the normal mode conformation 
docked to RhoA (NM-RhoA) were simulated for a minimum of 150ns. Our purpose in performing 
a full all-atom simulation was to determine what conformational changes occur in the 
TcdB/RhoA pair to allow binding when compared to TcdB in the absence of substrate. 
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 All simulations were performed using a parallel build of NAMD(428) employing the 
CHARMM (429) force field on the WSU grid. The simulations were run on eight nodes, of eight 
processors each.  Structures were solvated, and appropriate counterions were added to reach 
0.5mM NaCl. A timestep of one femtosecond was used, along with a 1-4 scaling factor of 0.4, 
recommended for protein simulations, to prevent additional contribution of bonded atoms to the 
calculated Van der Waals forces as this energetic contribution is partially included in the 
torsional terms of the force field. As in any molecular motion, there is energy associated with 
folding or unfolding of a protein. In a natural system, this energy is typically dissipated into or 
taken from the surrounding environment, however in a molecular dynamics simulation; the 
extensive surroundings that typically accommodate this thermodynamic process are absent. In 
order to maintain the simulation temperature in the form of a Boltzmann distribution around 
300K, the velocities and trajectory of the atoms is regularly rescaled using a method based on 
the Langevin equations of fluid motion. In the context of a simulation, the technique of Langevin 
Dynamics (430) provides apparent viscosity and an element of randomness while maintaining 
the Boltzmann distribution around the selected temperature. As the simulations were run 
piecewise, they were joined, and all water and counterions were removed using CatDCD (431) 
to facilitate statistical analysis. 
2.7.1 Principal Component Analysis 
In order to more effectively compare the conformational space occupied by TcdB 
through the MD trajectories, PCA was applied. PCA is useful in that it decomposes the complex 
motions of the simulation into the major types of movements that are observed across the entire 
trajectory. These can be observed as series of conformations varying in a single dimension. 
Analysis of the long MD simulations by PCA indicates that the principal component 
motions of the simulations echo the normal mode conformations as seen in Figure 0-6. Figure 
0-6A shows a superposition of snapshots from the Apo molecular dynamics simulation. Figure 
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0-6B shows the results of the fundamental normal mode analysis. Figure 0-6C shows the first 
principal component extracted from the simulation of Apo-TcdB. Figure 0-6D displays the first 
principal component of the simulation of NM-RhoA. In normal mode analysis, MD, and PCA, the 
wagging motion of the four-helix bundle dominates, while the scissoring motions of the 
promontories is secondary. In each case, movement of these three regions affects the 
conformation of the highly flexible active site. The coupling of the motions of large peripheral 
structural elements of TcdB with highly specific rearrangements in the active site appears to be 
relevant to the process of substrate accommodation. Because normal mode analysis accurately 
predicts global protein movements in approximately 70% of cases (421, 432), agreement 
between these methods can be used as a measure of validation for the molecular dynamics 
simulations.  In addition, it is apparent that in the NM-RhoA, the extent of flexibility is highly 
restricted (see Figure 0-6C and Figure 0-6D). Qualitatively the motions remain quite similar, with 
the exception of movement in regions near the active site which will be discussed below. 
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Figure 0-6: Comparison of general motile features of TcdB analyses and simulations 
All structures are colored by rainbow per residue to allow better comparison between structures. A) 
Superposed frames representing various conformations in the Apo simulation,  transparency indicates 
progression through the simulation. B) normal mode structures of TcdB in the apo form. C) First principal 
component of the Apo simulation. Degree and direction of displacement is shown by broadened ribbons. D) 
First principal component of NM-RhoA simulation. 
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Upon visual inspection the primary normal mode shows considerable similarity to the 
principal component motion of both the Apo-TcdB and NM-RhoA simulations throughout both 
trajectories, as can be observed by comparing panels B, C and D from Figure 0-6. It should be 
noted that the degree of motion is less pronounced when the protein is in contact with RhoA. 
This result is expected since there is a physical object impeding flexibility. Also, the second 
principal component, represented by the wagging of the upper promontories comprises a larger 
fraction of the variance in the Cartesian motions of both simulation 
Figure 0-7: Crossplots and Breakdown of Variance for Apo-TcdB and NM-RhoA simulations 
Panels A and B are the crossplots of the first and second principal components of the simulations. Each data point 
represents a single conformation from the MD simulations, and can be used to interpret the occupancy of the 
conformational space of a simulation. Panels C and D plots of the proportion of variance to Eigenvalue rank. These 
indicate relative contributions of the lower order principal components.  
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 It is apparent in panel A that Apo-TcdB has a broad range of conformations available. 
Panel B shows three clusters of conformations observed during the NM-RhoA simulation, one of 
which is heavily populated. Plots of the proportion of variance to Eigenvalue rank indicate 
relative contributions of the lower order principal components. In the NM-RhoA simulation a 
slightly higher contribution from the primary normal mode is observed relative to the Apo 
structure. The slight decrease in the contribution from the second principal component in the 
NM-RhoA PCA analysis indicates that the scissoring motion of the upper promontories is less 
prevalent. 
The primary difference between the Apo-TcdB simulation and the NM-RhoA simulation 
occurs upon approach of RhoA to the catalytic center of TcdB. In the Apo-TcdB simulation, the 
active site flap (Figure 0-2 shown in purple) performs a repetitive back and forth motion, never 
completely obstructing the active site. During the course of the NM-RhoA simulation, the active 
site flap folds down directly over the TcdB active site, completely precluding access to the 
catalytic manganese. We interpret this behavior as indicative of the order of binding required for 
catalysis. In the absence of UDP glucose, the TcdB conformation required for successful RhoA 
is not accessible, and folding of the active site flap precludes close association. In the presence 
of UDP-glucose, this folding would not be possible, as the sidechains of the active site flap 
would run into the bound UDP-glucose. However, the similarities between the simulations 
indicate that the majority of the large-scale motion of TcdB has been captured, and this may be 
of interest to those designing RhoA mimics. 
2.7.2 Quantitation of RhoA-TcdB contacts 
To assess improvements in the protein-protein interface following molecular dynamics, 
three structures were analyzed. One structure was selected as a representative frame from the 
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most populated cluster throughout the simulation. The structure of the closest approach 
between Threonine 37 of RhoA and the catalytic manganese of TcdB was selected, as was the 
original normal mode docked structure; NM-RhoA. Table 0-1: Quantitation of RhoA-TcdB 
contacts, lists the total number of interactions, number of hydrogen bonds, hydrophobic, ionic, 
aromatic-aromatic interactions, and cation-pi interactions. Hydrogen bonds are divided into main 
chain-main chain, side chain-main chain, and side chain-side chain interactions. The structures 
of both closest approach and most populated cluster both show improvement in the total 
number of interactions relative to NM-RhoA. Between the original docking and both MD 
structures, a shift from side chain-main chain interactions to side chain-side chain interactions 
occurs. No main chain-main chain hydrogen bonds were observed in any of the structures. A 
significant increase in ionic interactions is also observed relative to the original docked 
structures. 
 
Table 0-1: Quantitation of RhoA-TcdB contacts 
 
NM-
RhoAa Closestb Clusterc 
Total 
interactions 33 45 42 
H-bonds 20 24 20 
MC-MC 0 0 0 
SC-MC 19 4 4 
SC-SC 1 20 16 
Hydrophobic 8 5 7 
Ionic 0 15 13 
Aro-Aro 1 0 0 
Cation-pi 4 1 2 
a
 Structure of RhoA docked to the most open normal mode of TcdB. 
b
 Structure of closest Thr37-Mn approach within NM-RhoA MD simulation. 
c
 Structure of representative frame from the most populated cluster of the NM-RhoA MD simulation. 
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2.7.3  Normal Mode and molecular dynamics correlation 
 In the simulation of TcdB alone, movements were observed that mimicked the normal 
mode motions we anticipated. Moreover, in the presence of RhoA, these motions were also 
observed.  To determine how well correlated the normal mode motions were to the simulation, a 
plot of backbone RMSD from the Apo-TcdB simulation to each frame of the normal mode was 
created. Periodicity across the simulation is observed, as are fluctuations indicating normal 
mode motions coming slightly in and out of phase with the simulation 
 Both a three dimensional landscape and binned heat plot were prepared to visualize the 
correlation between the normal mode and molecular dynamics trajectories. Figure 0-8 shows 
the RMSD from the normal mode structures across the dynamics trajectory. Panel A shows 
RMSD vs. Normal mode frame vs.MD frame, with coloring by RMSD. Panel B is a binned 
version of this plot where RMSD is plotted as a color scale while molecular dynamics trajectory 
frame and normal mode frame are on the y and x axes, respectively. This correlation results in a 
plot where the fluctuations in RMSD can be interpreted as the MD motions going in and out of 
phase with the normal mode conformations. For example, at roughly frames 25, 50 and 97 
within the scaled trajectory, a low RMSD relative to the most open conformation of normal mode 
(Frame 41 on the x axis) is observed. This indicates that during the course of the molecular 
dynamics trajectory, Apo-TcdB exhibited a conformer similar to that of the normal mode 
structure, rebounded from that open conformation, and returned to the same open conformation 
later in the trajectory.  
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Figure 0-8: Correlation of MD structures to Normal Mode Structures 
Normal mode frame is on the X-axis, MD frame is on the Y-axis, and RMSD is shown as gradient from blue 
(low) to red (high). This arrangement allows observation of the  correlated motions between the normal mode 
and the simulation. As the RMSD becomes low between the various normal mode structures and the MD 
simulations, occupation of the extremes of the normal mode conformations are observed. The periodicity 
seen in the plot can be interpreted as Apo-TcdB flexing through the range of normal mode conformations. 
2.7.4 Generalized Masked Delaunay analysis 
 GMD analysis shows the rate of occurrence of significant events over the course of a 
molecular dynamics simulation. To create a time-dependent contact graph sensitive to large-
scale conformational changes the GMD analysis performed utilized a Delaunay 
tetrahedralization. In this technique, a recrossing filter is applied to remove transient local 
positional changes that are the result of thermal motion. In order to separate trivial from non-
trivial motion, a protein structure is converted into a Voronoi graph in which a representative 
atom from the side chain of each residue is considered the center of the Voronoi cell.  A 
Delaunay triangulation is the dual graph of the Voronoi tessellation, but as we are in three 
dimensions, in practicality it is a tetrahedralization. The Delaunay graph, after excluding all 
faces of significant distance from the representative sidechain atoms and in combination with a 
recrossing filter, is then used to separate significant persistent motions from trivial recrossings. 
A B 
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The recrossing filter gives several angstroms leeway for atoms to thermally fluctuate across a 
plane in the Delaunay graph without that motion being considered persistent and significant. 
When a residue crosses a plane in the Delaunay graph and remains there for the duration of the 
frame window selected, that motion is considered significant and is reported as an “event” for 
further analysis. 
 A plot of events per frame is generated following analysis, where the pattern of detected 
events in the context of contact making, breaking and total activity can be observed. In our 
analysis we observed no major folding events, and used the plots for comparative analysis of 
activity patterns. 
 
Figure 0-9: GMD plots of Apo-TcdB and NM-RhoA simulations 
This analysis plots events per frame through the course of the simulation. Total activity is shown in blue, 
contact making shown in red, and contact breaking in green. The event pattern indicates that while Apo-
TcdB is flexing through its conformational space at a relatively constant pace, the NM-RhoA simulation 
undergoes a brief period of conformational rearrangement and then persists at a low level of activity through 
the rest of the simulation. 
 Figure 0-9 panels A and B are the results of a Generalized Masked Delaunay analysis 
across the molecular dynamics trajectories of Apo-TcdB and NM-RhoA respectively. Activity is 
plotted as events per frame, and is decomposed from total activity, shown in blue, to contact 
making (red) and contact breaking (green). The patterns of activity for Apo-TcdB compared with 
that of NM-RhoA are markedly different, with Apo-TcdB showing a relatively high level of activity 
throughout the simulation, while NM-RhoA very rapidly settles down and then exhibits a much 
lower level of activity throughout the simulation. This can be interpreted as a rearrangement 
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followed by reduction of the available conformational space, or alternatively, a slowing of the 
transit between available conformations. 
Throughout the Apo-TcdB simulation, the number of events per frame as shown in 
Figure 0-9 does not change dramatically, indicating a steady fluctuation between conformations 
rather than defined transitions. This can be interpreted as smooth flexion, rather than 
spontaneous and rapid conformational switches, providing support for the argument that the GT 
domain of TcdB utilizes a conformational selection mechanism to find its targets. It is likely that 
TcdB with bound substrate will have access to an alternative range of conformations that affects 
the movement of the active site flap when in contact with RhoA. While there is some overlap in 
conformational space of the Apo and bound simulations, the absence of UDP-Glucose 
precludes formation of a catalytic complex. 
2.7.5 RMSF analysis 
Over the course of the Apo simulation, major rearrangements have been observed in 
and around the active site. Both the mobile loop supporting the catalytic center, and the regions 
responsible for recognition of RhoA appear to be highly flexible. This flexibility is illustrated by 
the relative  RMSF (root mean square fluctuation) as shown in Figure 0-10, representing atomic 
freedom of motion over the time course of the simulation. It is expected that residues on a 
protein surface are quite flexible, while interior residues tend to be less mobile (433, 434). The  
RMSF of TcdB ranges between 0.7Å and 3.9Å. In our simulation both mobile loops near the 
active site reach  RMSF values of near 2Å and thus undergo quite significant motions over time. 
The flexibility of the active site is unusual but understandable for this protein. Since the toxin 
must interact with a protein target well known for its conformational switch (435), flexibility near 
the active site would increase the ability to capture and glucosylate RhoA regardless of the 
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conformation in which the switch is presented. Detailed analysis of the active site motions from 
MD simulations of TcdB in complex with UDP-Glc will be discussed at length in Chapter 3. 
.  
Figure 0-10: RMSF of Apo-TcdB simulation 
RMSF was calculated across the Apo-TcdB simulation, and mapped onto the TcdB structure. Ribbons are 
colored by average atomistic rmsf per residue, from 3.5Å (red) to 0.7Å (blue). High flexibility is observed at 
the periphery of the protein, while the core of the four helix bundle and RhoA recognition site are stable. The 
active site flap and mobile loop reach rmsf values near 2Å 
  
63 
 
 
2.8 Conclusions 
Unbiased long timescale simulations of TcdB from C. difficile both Apo and in contact 
with RhoA were performed. Analysis on these trajectories included GMD, PCA, and comparison 
to motions observed in normal mode analysis. Large-scale flexibility was observed both in the 
presence and absence of a protein binding partner without a catalytic binding event being 
observed. The dramatic rearrangement of the TcdB active site and the consequences for 
substrate binding point to the possibility that TcdB utilizes a conformational selection 
mechanism rather than lock and key, or induced fit binding. 
Application of normal mode analysis to the crystal structure of TcdB from C. difficile 
correctly captured the large-scale motions of this prototypical glucosyltransferase. The great 
degree of flexibility of TcdB is both expected and shown in evidence through normal mode 
analysis and molecular dynamics. A loose fold and considerable flexibility would be practical as 
the glucosyltransferase domain TcdB must, by necessity, thread through the membrane pore 
created by the translocation domain. The normal mode conformations bind RhoA moderately 
well while the crystal structure conformation of TcdB is completely incapable of forming a 
docked protein-protein complex. While the docking was unable to achieve a fully 
accommodated form where the toxin has Thr37 fully in the active site, this is a solid step 
towards determining the manner in which TcdB recognizes the Rho-family GTPases and 
excludes alternative G-proteins that might be structurally similar but which are not viable 
substrates. 
In simulation, the conformations sampled between the Apo-TcdB and NM-RhoA bound 
structures are similar with respect to the primary normal modes. PCA plots in Figure 5, indicate 
that the NM-RhoA and Apo simulations are separately populated, with distinct conformational 
space occupancy. Taken together, this provides evidence for a conformational selection 
mechanism, which has been perturbed by Apo-Apo binding. In light of the dramatic alterations in 
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the active site landscape through the course of the simulations. it is possible that the presence 
of substrate may shift the conformation of TcdB towards a more suitable orientation for protein-
protein binding. 
Very recently, high resolution crystal structures for C. difficile Toxin A were reported, both alone 
and in complex with UDP-Glucose (436). These proteins are highly homologous and catalyze 
the same glucosylation chemistry. Superposition of the TcdA structures shows considerable 
rearrangement of the active site in both the mobile loop, and active site flap. This has 
implications for the RhoA binding we observed. During the course of the NM-RhoA simulation, 
RhoA approach and active site flap orientation were correlated. In the absence of UDP-Glucose, 
the active site flap motions precluded close approach of RhoA to the catalytic center. In light of 
the rearrangements observed in the TcdA crystal structures, it is likely that conformational 
changes initiated by UDP-glucose binding are required before RhoA can be fully 
accommodated. 
It is logical that a protein that seeks out Rho GTP-ases would employ a conformational 
search mechanism, as Rho GTP-ases are known to employ conformational selection in their 
binding interactions both with small molecules and macromolecules 
The exploration of this non-catalytic binding event has large implications for the kinetics 
of glucosyltransferase-substrate interactions. As anticipated, flexion in the active site alters 
substrate binding, and further study will elucidate the consequences of substrate binding on the 
conformational space available to TcdB. The combination of normal mode analysis, MD and 
GMD and PCA was shown to be a very effective method for study of protein-protein 
interactions. 
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2.9 Methods 
Normal mode analysis of the toxin structures in question were performed via the El 
Nemo (418) web server and confirmed via hinge analysis using the StoneHinge (416, 417) 
hinge region prediction software. Docked conformations of the Apo-Toxin in contact with RhoA 
were generated using the RosettaDock (1) server using Hex 4.5 (424) for preliminary 
conformation generation, and systems were selected for simulation based on proximity to the 
catalytic binding site. 
MD simulations were run using the CHARMM27 (437-440) force field with the NAMD 
(428) suite of programs on the WSU rocks cluster. The canonical ensemble was maintained via 
periodic boundaries, Langevin dynamics and thermostat (430). Simulation stability was verified 
by use of the trajectory analysis tools available with the VMD software (431). Stability was 
monitored by energy and RMSD. Two systems were prepared and subjected to MD: Apo-TcdB 
and NM-RhoA. 
The Apo-TcdB simulation includes only the TcdB structure, while the NM-RhoA 
simulation contains TcdB and RhoA in a putative docked conformation following protein-protein 
docking as described above. 
The systems were solvated with TIP3P water, neutralized with counter ions and 
subjected to 1000 steps of conjugate gradient minimization and temperature ramped to 300K. 
The Apo-TcdB simulation contains 543 residues, 28,330 water molecules, and a total of 94,013 
atoms. The NM-RhoA simulation contains 719 residues, 30,780 water molecules and a total of 
102,970 atoms. 
Frames from the trajectories were written every 1 ps. Apo-TcdB was simulated for 300ns 
and NM-TcdB was simulated for 150ns post minimization. The solvation box includes a 15Å pad 
on each face of the box. Electrostatics were calculated using the particle mesh Ewald (441), and 
van der Waals were calculated with a nonbonded cutoff of 8Å and a switching function between 
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7-8Å.  Results were analyzed by use of the GMD method, via the TimeScapes (442) software 
from the D.E. Shaw research group, as well correlation analysis manually handled by the 
Mathematica software (443). For the purposes of the correlation analysis, a corkscrew 
interpolation was applied to the eleven original normal mode structures, resulting in a total of 41 
normal mode structures. MD frames were selected evenly throughout the simulation, and 
pairwise RMSDs were calculated. 
Analysis of the protein-protein interface was carried out across three structures using 
PIC (436). Following clustering, a representative frame from the most populated cluster was 
selected, designated Cluster 1. The frame representing closest approach between Threonine 37 
on RhoA and the catalytic manganese of TcdB, and the NM-RhoA structure described above. 
Hydrogen bond analysis was broken into two types, side chain-main chain interactions, and side 
chain-side chain interactions. Main chain-main chain interactions were looked for, but none 
occurred. Additionally, hydrophobic pairs, ionic, aromatic, and cation-pi interactions were 
tabulated. 
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Chapter 3 Development of peptide based inhibitors of TcdA and B2. 
 
3.1 Background  
 Clostridium difficile infection is increasingly becoming problematic to treat, due to both 
the intrinsic antibiotic resistance and the emergence of hypervirulent strains. An opportunistic 
pathogen, C. difficile primarily affects patients taking, or having recently completed, a course of 
broad-spectrum antibiotics (377). Development of anti-virulence therapies as opposed to 
antibiotics may be an effective way of mitigating the damage of an infection without inciting 
further antibiotic resistance(383, 384). Toxins A and B (TcdA and TcdB) are responsible for the 
bulk of the cellular damage that occurs upon infection, and thus are excellent targets for 
development of antitoxin therapies. While investigation into both immunotherapy (13), toxin-
binding materials (444), and probiotics (445) are making progress, none have been approved 
for clinical use. 
  It has been proposed that inhibition of the glucosyltransferase activity of toxins A and B 
may provide some protection against CDAD(407, 446, 447). Considering the etiology of the 
toxins discussed in Chapter 2, preventing the final step in cellular intoxication may preclude 
apoptosis of intestinal cells while a C. difficile infection is present. As a proposed treatment, GT 
inhibitors would be co-administered at the start of broad-spectrum antibiotics to abrogate tissue 
damage if or when C. difficile is contracted. By preventing the cellular death and consequent 
structural damage, many of the symptoms of C. difficile infection will be avoided. From a clinical 
perspective, decreasing the symptoms of C. difficile infection would decrease the amount of 
patien-to-patient transmission. Additionally, preservation of tissue integrity may provide 
                                                          
2
 Sections of Chapter 3 have been previously published (407,484) 
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protection against recurrence as C. difficile spores will be less likely to remain in the digestive 
tract.  
 Early work by S. Abdeen on anti-toxin therapies included a phage display experiment 
designed to find heptapeptides with potential anti-TcdA/TcdB activity. This experiment was 
successful and a library of peptides with inhibitory potential was discovered. Due to the way the 
experiment was performed, it was unclear if the potential lead peptides were inhibiting 
glucosyltransferase activity, or protein-protein binding. Computational experiments were 
designed to determine the binding modes of these peptides and improve on their in cellulo 
activity. This chapter describes the successful development of a potent anti-toxin molecule.  
3.2 Identification of a library of inhibitory peptides  
 
 TcdA and TcdB both target a wide range of Rho GTP-ases, and as such it is possible 
that they would recognize and bind to a broad array of peptides. To determine if any peptides 
have affinity for TcdA/B, a phage display experiment was performed. The PhD-7 phage library 
was queried with an affinity capture method.  As shown in Figure 0-1 the phage display query 
was performed in several steps. The recombinant GT domain of TcdA rTcdA540 containing a 
histidine tag was generated, to allow collection on nickel coated magnetic beads. The phage 
pool was first pre-cleared against the Ni-NTA beads to preclude selection of phage that bind 
nickel rather than rTcdA540. The pre-cleared phage were allowed to interact with rTcdA540 coated 
beads, which were then washed. Three rounds of selection were performed with different elution 
methods. Following each cycle of elution, the recovered phage were amplified in an E. coli host, 
and used as the phage pool for the next cycle of selection. The first round elution was carried 
out using EDTA. The following three rounds of elution were performed with RhoA, to select for 
phage that bind either the protein-binding face or active site of TcdA.  
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Figure 0-1 Flowchart of phage-display experiment.  
A PhD 7 phage library was pre-screened against Nickel-coated magnetic beads. The pre-cleared phage pool 
was then exposed to beads coated in recombinant TcdA. Following a wash, the bound phage were eluted, 
amplified in an E. Coli host, and the cycle was repeated several times. Following the final round of selection, 
phage were grown, isolated and sequenced.  
 Phage were then sequenced and grouped into families by S. Abdeen. This provided an 
excellent starting point for the computational assessment of peptide binding. Figure 0-2 shows 
the breakdown of phage sequences into families and subfamilies. A phage-based ELISA assay 
was performed to determine the apparent Kd for all sequences. Marks to the right of each 
sequence indicate the range of binding affinity. Red marks indicate binding affinity less than 200 
nM; blue, 200-1000 nM; and gray, >1 µM. It is of note that the affinity of TcdA for RhoA is poor, 
with a Km of over 300 µM(448). Relative to the natural substrate, several of the phage exhibited 
what would be considered "tight" binding.  
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Figure 0-2: Phage sequences from biopanning experiment.  
 Sequences were sorted into families based on sequence similarity. Bars to the right of the sequence 
indicate Kd. Red indicates a Kd <200nm, Blue have Kd between 200-1000nm, and Gray bars indicate Kd > 
1µM 
 However, as polyvalent phage were used for these assessments, chelate and avidity 
effects were a consideration. Before moving forward with peptide binding assays, computational 
modeling was used to suggest putative binding modes for the peptides. 
3.3 Computational studies of inhibitory peptides 
 
 To better understand the possibilities of the inhibitory peptides found in the study, 
several computational investigations were launched. Initial dockings of the peptides to the TcdB 
crystal structure were carried out. As TcdB is highly flexible and MD relaxed structures were 
available from the work performed in Chapter 2, we also docked the peptides to several 
snapshots from the MD. Lastly molecular dynamics studies were performed.  
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 Previous studies (449) showed that a conformational selection mechanism is likely at 
work in TcdB, and that the presence of a protein binding partner can dramatically alter the 
conformational space of the toxin. While all peptides in the scan were subjected to initial 
assessment, two were selected for more in depth analysis. A combination of computational and 
experimental evidence suggested that the peptides EGWHAHT and HQSPWHH were likely to 
have the most potential as inhibitors. These two peptides had good docking scores to both the 
crystal and MD relaxed structure, as well as good in vitro activity in RhoA glucosyltransfer 
assays. EGWHAHT was found to have the highest Kd of all inhibitory peptides in the phage 
based ELISA assay, and HQSPWHH showed up the most frequently in the sequencing of 
clones. To determine the effects of substrate binding on the conformational space of TcdB, the 
structure PDBID:2BVL was simulated in the presence of it's native substrate UDP-Glucose, and 
these two inhibitory peptides.  
3.3.1 Peptide docking with LeadIT 
 FlexX was selected as the best candidate based on its inclusion of user-definable 
coordination for metals. Investigation of the peptide binding characteristics of TdcB began 
following a proof of method docking with UDP-Glucose,. The peptides obtained from the phage 
display experiments were built using Spartan, minimized at the AM1 level and concatenated into 
a database file for use with FlexX (338). Active site designation was carried out by selecting all 
residues within 20Å of any atom in the crystallographic substrates UDP and Glucose. Water 
visible in the crystal structure within the active site area were allowed full rotation, and were 
displaceable in the event that a fragment of the docking candidate bound more favorably in a 
location occupied by water.  
 The docking results ranked the peptides by favorability of binding using an arbitrary 
ranking scheme. It was determined that TcdB contains two primary grooves where peptides are 
capable of binding. The model peptide shown in blue has the sequence SPHLHGS; peptides 
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binding in this location tend to form contacts with two glutamine residues and an asparagine, 
thus this nitrogen heavy groove has been termed the N pocket. The peptide shown in green has 
the sequence EGWHAHT, and the groove in which it binds contains several charged residues, 
including two glutamic acid residues, an aspartic acid residue, it has been termed the A pocket 
due to the acidic nature of the residues contacting the peptides that bind in this location.   
 
 EGWHAHT ranked higher than the rest of the peptides, this result is confirmed by the 
inhibition studies being performed concurrently. EGWHAHT has a Ki of approximately 105 pfu 
and is ranked first among the docked peptides. 
Figure 0-3 Depiction of two peptide binding pockets of TcdB 
Representative peptides EGWHAHT (green)  and SPHLHGS (blue) shown in their docked conformations 
to illustrate the two binding pockets of TcdB 
 
73 
 
 Peptides were ranked using a modified Boehm's scoring algorithm, which includes terms 
for hydrophobic interactions, amphiphilic residue interactions, steric clashes and number of 
rotatable bonds. includes a comparison of the docking scores with Kd and apparent binding 
pocket.  
Table 0-1: Comparison of docking scores to experimental data. Kd and Ki experiments performed with 
phage. 
Ligand  Score  Kd  Ki  (pfu) Pocket  
EGWHAHT  -57.3 100+5  10
5
 Green  
SPTHGHD  -53 900+400    Blue  
QPQYHTS  -49.5 200+40     Blue  
NPHAHLQ  -49 115+5     Blue  
SPHLHGA  -48.9 105+10     Blue  
TPHLHRD  -48.1 530+80     Blue  
ITAPHPH  -47.7 840+200     Blue  
QLSHTHI  -46.7 500+50     Blue  
SPHLHGS  -45.6 770+130     Blue  
HQSPWHH  -43.7 330+40  10
3
 Both  
KPHPHVP  -42.3 145+35     Blue  
UDP-Glucose  -40.3 N/A     N/A  
QFTSLLH  -36.6 210+10     Green  
HAIYPRH  -35 170+10     Green  
ISAHEHL  -18.1 480+60     Blue  
LQPHLHR  -6.7 100+5     neither  
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3.3.2 Peptide docking to MD relaxed TcdB 
 To incorporate information from the molecular dynamics studies discussed in Chapter 2, 
the above docking protocol was applied to the MD relaxed structure of TcdB. The peptides were 
built using the Spartan (450) modeling program, minimized at the AM1 level of theory, subjected 
to fragmentation and docked. Base placement was performed using a triangle-matching scan, 
which gives preference to base placements that pair complementary functional groups such as 
Hydrogen bond donor-acceptor pairs. Docking results were ranked using an internal scoring 
function (451-453). Results from all techniques described here and below were visualized and 
all images generated using UCSF Chimera(454).  
  
Figure 0-4 Alteration in peptide binding following MD.  
Alteration in the conformation of peptide HQSPWHH docked to both the TcdB Crystal structure in Panel A, 
and the MD relaxed structure in panel B. Active site residues are shown in green. The peptide interacts with a 
mobile loop shown in orange to a greater degree in the MD relaxed structure. 
 It was determined that the peptides dock deeper into the active site, exhibit more 
hydrogen bonding and ring stacking interactions, and their ranking scores better agree with in 
vitro inhibition data relative to the crystal structure dockings.  
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Table 0-2 Comparison of Crystal and MD docking scores to experimental data 
Ligand  Kd (nM) Ki (nM) Crystal rank Crystal Score MD rank MD Score 
EGWHAHT  100+5  500 1 -57.3 3 -23.6 
SPHLHGA  105+10     4 -48.9 2 -35.3 
NPHAHLQ  115+5     3 -49 6 -38.8 
HAIYPRH  170+10     9 -35 8 -37 
QFTSLLH  210+10     8 -36.6 7 -32.5 
HQSPWHH  330+40  300 7 -43.7 1 -41.1 
ISAHEHL  480+60     10 -18.1 4 -27.3 
SPHLHGS  770+130     6 -45.6 9 -39.4 
ITAPHPH  840+200     5 -47.7 5 -21.5 
SPTHGHD  900+400     2 -53 10 -40.1 
 
 We determined from this study that peptide binding is improved when the structural 
constraints imposed by crystallization are alleviated. Table 0-2 synthesizes the experimental 
and computational docking information. Peptides are ordered by ascending Kd. For The two 
peptides selected for lead optimization, Ki values were calculated. The relative rank and score 
for the dockings to the crystal and MD relaxed structures are also shown. It is noteworthy that 
EGWHAHT outperformed the other peptides in the crystal docking, while HQSPWHH docked 
best to the MD relaxed structure. These results suggested that the flexible nature of TcdB may 
play a role in designing molecules with inhibitory properties.  
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3.4 Determination of mechanism by Molecular Dynamics and Analysis 
 While the studies discussed in Chapter 2 and Section 3.3 showed that conformational 
flexibility in TcdB affects both protein-protein binding and small molecule binding, it was unclear 
what effects the binding of small molecule substrates would have on the conformational 
flexibility of the toxin. Interesting behavior in inhibition assays indicated that while EGWHAHT 
had a tighter Kd, HQSPWHH had a better Ki for both TcdA and TcdB.  
Table 0-3 Differential activity of two inhibitory peptides.  
Sequence Kd (nM)  
Ki (peptide) nM  
TcdA540  TcdB 
EGWHAHT 100 ± 5 500 ± 200 54 ± 20 
HQSPWHH 330 ± 40 300 ± 200 18 ± 9 
 
 This suggests that even the peptides may inhibit the toxins in different ways, possibly 
through disruption of the intrinsic motions of the protein. By applying MD followed by GMD and 
PCA, it was determined that a conformational selection mechanism is likely at work in this 
system. The specific consequences of substrate presence in the active site were determined 
with respect to the subsets of conformational space contingent on substrate binding. To 
facilitate interpretation of the results from these experiments, an overview of the structure of 
TcdA and B and relevant domains for analysis is shown in Figure 0-5 
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Figure 0-5 Domain organization of C. difficile toxins, structure of C. difficile Toxin B glucoysltransferase 
domain (TcdB).  
Panel A:Toxins A and B share a common domain organization, differing in the size of the CROP receptor 
binding region. The glucosyltransferase domain is cleaved from the translocation and CROP domains by the 
cysteine protease domain upon endocytosis. Panel B: Structure of the glucosyltransferase domain. Toxin 
specific upper promontories shown in cyan, DXD supporting mobile loop shown in yellow, active site flap 
shown in purple, Protein-protein recognition loops shown in green and red, and N-terminal four helix bundle 
shown in blue. Panel C. Inset showing orientation of UDP-glucose in the active site, relative to the mobile 
loop and active site flap. 
 A protein that employs a conformational selection mechanism occupies a large 
conformational space, which is then restricted or modified by interactions with its substrates or 
binding partners (455). To understand known substrates and develop novel binding partners 
such as inhibitors, it is necessary to recognize the malleability of the active site and thoroughly 
understand the consequences of each internal motion and interaction. One avenue to evaluate 
the available conformational space and understand how it is affected by substrate binding 
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involves using a combination of molecular dynamics, General Masked Delaunay (GMD) 
analysis and principal component analysis (PCA). Long-timescale unbiased molecular dynamics 
allows us to sample a the conformational space available to a given protein, without biasing the 
population density. Utilization of GMD analysis allows us to pinpoint significant transitions 
between conformations or clusters of conformations, without relying solely on clustering or PCA 
(442).  
3.4.1 Simulation of Apo, UDP-Glucose and peptide bound TcdB 
 Four simulations were carried out to study the inhibitory peptides EGWHAHT and 
HQSPWHH. For the purpose of the description below we will refer to EGWHAHT as peptide 1 
(P1) and to HQSPWHH as peptide 2 (P2). TcdB was also simulated in the Apo conformation, 
and bound to its native substrate UDP-Glucose (UPG). Peptide-bound conformations were 
created by docking using LeadIT, and then performing MD simulation of the docked structures 
according to the protocol described in the Methods section. All simulations were carried out for 
75 ns under unbiased conditions. Analysis was performed using PCA and GMD.  All simulations 
completed normally, and observation of root mean square deviation (RMSD) and total energy 
indicated that they were continuously stable. The docked structures are shown in Figure 2, 
where EGWHAHT is shown in panel A in red and HQSPWHH is presented in panel B in green. 
Both peptides bind in the active site, interacting with the yellow mobile loop and purple active 
site flap. The active site conformation shown in the docking is consistent the mass spectrometric 
analysis of peptides crosslinked to TcdA (407). Following completion of the dynamics a 
comparison between docking clusters and dynamics peptide conformations was carried out, to 
verify agreement between both methods.  
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3.4.2 Clustering analysis 
 A complete clustering analysis workflow is shown in Figure 0-6. The aim of this 
comparison was to determine whether or not the docked peptide conformations generated by 
LeadIT were well represented within the simulation and vice versa. Agreement between the two 
experiments indicates that the docking succesfully generated a series of low energy 
conformations, and that the molecular dynamics was run long enough to explore a range of 
peptide conformers.  
 All docking results as well as the two molecular dynamics simulations were clustered. To 
assess the presence of peptide conformations in both the docking and MD simulated structures, 
a cluster comparison was performed. All docking conformations were superposed on selected 
structures from the four most populated clusters from the molecular dynamics. In all cases, 
following superposition, RMSDs were calculated and cluster membership assessed. As shown 
in Table 0-4, the conformations represented in the molecular dynamics studies are 
overwhelmingly represented within the top four clusters of the dockings from each state. 
Backbone RMSDs for all paired structures are <1.1Å (for a visual comparison see  
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Figure 0-7). The backbone structure of representative members of the top four clusters from the 
molecular dynamics is shown as a block ribbon, while the side chains are shown as wire.  
  
Figure 0-6 Workflow of the clustering comparison.  
Following Apo MD, peptide docking was performed. The peptide bound structures were simulated, resulting structures 
were clustered, and comparison between the docking and the molecular dynamics was performed. 
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Table 0-4 Comparison between the MD and Docking clusters 
Following superposition, RMSDs were calculated, and the cluster to which each structure belonged was 
identified. There is strong agreement between the molecular dynamics structures and the docking clusters. 
 
EGWHAHT 
Crystal 60 ns 80 ns 
MD 
cluster 
Docking 
cluster 
RMSD 
(Å) 
MD 
cluster 
Docking 
cluster 
RMSD 
(Å) 
MD 
cluster 
Docking 
cluster 
RMSD 
(Å) 
1 3 0.849 1 2 0.969 1 3 0.849 
2 1 0.986 2 1 0.804 2 1 0.986 
3 2 1.028 3 2 0.902 3 1 0.969 
4 2 1.013 4 2 1.013 4 2 1.013 
 
HQSPWHH 
Crystal 60 ns 80 ns 
MD 
cluster 
Docking 
cluster 
RMSD 
(Å) 
MD 
cluster 
Docking 
cluster 
RMSD 
(Å) 
MD 
cluster 
Docking 
cluster 
RMSD 
(Å) 
1 4 0.919 1 1 0.941 1 3 0.818 
2 2 1 2 3 0.958 2 1 1.05 
3 2 1.042 3 1 0.76 3 1 1.099 
4 2 0.93 4 1 0.754 4 2 0.959 
 
Figure 0-7 Visualization of the MD clustering results.  
Representative members of the top four MD clusters from the peptide bound simulations. Clusters 1-4 are 
shown in blue, green, pink and gold respectively. Backbones are represented as block ribbon and sidechains 
as wire. In both simulations, good clustering was observed, and when compared to the docking clusters 
described in table S1 and S2, a high degree of similarity was present. We interpret this as good agreement 
between the docked conformations selected for study, and the conformational cohort described by the 
molecular dynamics 
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3.4.3 Solvent interaction analysis 
 An analysis of hydrogen bonding and salt bridges was performed to look for solvent 
interactions and other significant contributions to the stability and coordinated motions of the 
protein. All interactions present in more than 90% of the frames were subjected to further 
analysis and are listed in Table 1. While the overall number of H-bonds fluctuates from frame-to-
frame, solvation of the active site behaves differently. Hydrogen bonds related to the regions 
described above have been tabulated separated. The "active site" for the purposes of this 
analysis was defined in the same way as it was for the docking. The Apo and P1 bound 
simulations show higher numbers of H-bonds overall, while the UPG and HQ bound simulations 
show fewer interactions. In all simulations, one water molecule remains stationary, interacting 
with residue E472 on the TcdB-RhoA recognition face. In the UPG and P1 bound simulations, 
no stationary waters are observed in the active site. The Apo simulation contains one active site 
water, and the P2 bound simulation contains two. Hydrogen bonding is observed between 
solvent water and residue D286 of the DXD motif in both cases.  This indicates that P2 is not 
interacting with the active site in the same way that P1 is, and that P2 preserves the active site 
hydration observed in the Apo simulation. Salt bridge analysis echoes these results with a 
higher overall number of salt bridge interactions in the Apo and P2 simulations, and fewer in the 
UPG and P1 simulations. Again, this reiterates that P1 is mimicking the UPG bound behavior, 
while P2 is not.  
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Table 0-5 Interaction analysis of MD simulations.  
Interactions Apo UPG P1 P2 
Total solvent H-bonds 81 77 87 74 
Active site solvent H-bonds 1 0 0 2 
Protein binding interface solvent H-bonds 1 1 1 1 
Salt bridges 77 58 58 74 
 
3.4.4 Principal component analysis 
 Principal component analysis was performed to determine the effects of peptide binding 
on protein structure and flexibility. Following simulation, the principal components of each 
trajectory were extracted and plotted along with the contribution of each eigenvalue to the total 
variance as shown in Figure 3. It is apparent that the binding of the three substrates (UPG, P1 
and P2) each has an effect on the conformational space that TcdB explores. In columns 1 and 
2, principal component structures are overlaid for each simulation. A widened ribbon in these 
plots indicates motion, whereas narrow ribbons indicate residues that remain relatively 
stationary. Column 3 contains the cross-plots of principal components 1 and 2 (PC1 and PC2), 
in essence, giving a two-dimensional representation of the conformational space that the protein 
structure is occupying. Since the simulations were projected onto the same core residues for the 
PC decomposition, all plots in column three are comparable. Column four breaks down the 
variance in the simulation into contribution by each individual eigenvalue, i.e. the point with the 
highest proportion of variance is principal component one. The distribution of points along the 
plotted line indicates the relative contribution to the overall motion from each component 
eigenvalue.  
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Figure 0-8 PCA analysis of MD simulations; Apo-TcdB, UPG, P1 and P2 bound  
Simulations are organized by row, analyses by column. Principal component 1 of each simulation is shown 
in column 1, principal component 2 is shown in column 2. All structures are colored as in Figure 1 for 
comparison. Crossplots of the first two principal components are shown in column three. PC1 and PC2 are 
plotted on the X- and Y-axes respectively. Column four presents the contribution of all calculated principal 
components to the total variance as a percentage. Proportion of variance is plotted against eigenvalue rank 
to allow assessment of the relative weight of each component 
 
 The Apo simulation shows a high degree of flexibility in both mobile loops, as well as 
considerable "wagging" of the four-helix bundle at the N-terminus of the structure. The first 
principal component, PC1 largely describes this motion, while the second captures the side-to-
side scissoring of the two promontories shown in cyan (described in Figure 1). The cross-plot of 
these two principal components shows an organized set of conformations connected by smooth 
transitions. The relative contribution of these principal components shows that 36% of the 
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variance in conformation is captured by the wagging motion of the four-helix bundle, and 19% 
by the scissoring motion. All other motions are captured in lower rank eigenvalues.  
 The UPG-bound simulation shows less flexibility than the Apo simulation, which is to be 
expected upon binding of a natural substrate. PC1 is again the wagging of the N-terminal four-
helix bundle, while PC2 is a distributed motion, not specific to any single region. The cross-plot 
of principal components shows contraction of the conformational space, particularly with respect 
to the second principal component. The proportion of variance between the first and second 
eigenvalues is comparable to the Apo structure.  
 Peptide 1 binding appears to induce modifications in both the nature of the principal 
components and the distribution of variance. PC1 again is the wagging of the four-helix bundle, 
but the motion becomes exaggerated relative to both the Apo and UPG-bound simulations. PC2 
is very similar to that of the UPG bound simulations, with very little motion in the active site 
apparent in either principal component. The cross-plot of principal components shows a pattern 
that appears to be somewhat intermediate between the cross-plots of the Apo and UPG-bound 
structures described above. We interpret this result as an indication that peptide 1 is inhibiting 
TcdB by mimicking UPG to a great extent. It has previously been shown by Abdeen et al. that 
Peptide 1 is competitive with UPG and can be displaced at high concentrations of UPG (407). 
Interestingly, the proportion of variance of the first principal component is considerably higher 
than for either the UPG or Apo structures, with 52.9% of the variance in the conformational 
space due to the wagging of the four helix bundle and moderate motion around the active site.   
 The simulation of peptide 2 bound to TcdB shows considerable alteration in both the 
principal components and distribution of variance. PC1 shows motion in the upper promontories, 
as well as the RhoA recognition site, something unseen in prior simulations. PC2 indicates 
scissoring of the promontories, albeit in a different direction than observed previously. 
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 Additionally, major rearrangements of the RhoA recognition site are observed. The 
cross-plot of the first and second principal components bears little resemblance to any of the 
other simulations, and the contributions to the variance are moderately distributed. Abdeen at al. 
previously showed that peptide 2 is not competitive with UDP-glucose, thus using a distinctly 
different mechanism for inhibition. This evidence suggests that TcdB uses a conformational 
selection mechanism (449) and that deformation of the substrate binding site, rather than direct 
substrate competition is sufficient to achieve inhibition. This avenue for inhibitor may be 
effective since avoiding direct competition with a natural substrate is desirable to achieve 
maximum efficacy. The sum of these analyses leads us to believe that peptide 2 inhibits TcdB 
by perturbing the RhoA binding site, rather than by mimicking UDP-Glucose while peptide 1 
represents a relatively classical competitive binding mode of inhibition. 
 Analysis of the simulations by PCA indicates that the UPG and peptide bound 
conformers have restricted flexibility relative to the apo conformation as expected. However the 
inhibitory peptides display differing behaviors with respect to their conformational restriction. As 
was previously shown by Abdeen et al, peptides show inhibitory potential by either interfering 
with RhoA or UPG binding (407). The spatial freedom exhibited by the apo toxin indicates that it 
is likely that TcdB is subject to a conformational selection and induction mechanism similar to 
that of the small G-proteins (419). Since TcdB must recognize RhoA and it is undergoing 
significant motions in response to its own conformational selection process, it makes logical 
sense that its binding partners, TcdB in this case, might also exhibit similar conformational 
selection behavior. The dramatic perturbation of the conformational space of TcdB upon contact 
with the inhibitory peptides, may illustrate a good way to identify proteins involved in 
conformational selection and study the way they interact with their substrates and/or targets.  
3.4.5 Local RMSD analysis  
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 To quantitate these results, total as well as local backbone RMSDs of the regions 
described in Figure 1 were calculated and are shown in. The RMSD overall for the Apo 
simulation is higher in all regions with the exception of the two protein-protein interface regions, 
which are dramatically perturbed in the P2 bound simulation. This result is in agreement with the 
PCA analysis where perturbation of these regions was a major component of the motion. The 
UPG bound simulation shows a low RMSD in all regions, again in agreement with the PCA 
analysis. The P1 bound simulation shows some increased movement in the protein-protein 
interface regions, while both the mobile loop and active site flap behave similarly to the UPG 
bound simulation. The combination of the qualitative PCA with the quantitative local RMSD 
breakdown shows good agreement.   
 RMSD in angstroms was calculated for the overall trajectory, as well as for each region 
described in Figure 1. The Apo simulation shows the highest overall RMSD as well as generally 
higher local RMSDs for all regions with the exception of the two protein-protein interfaces. The 
green and red binding sites are greatly perturbed by the binding of the P2 peptide with their 
RMSD reaching over 3Å. The UPG bound simulations shows the lowest overall RMSDs with low 
activity in the mobile loop and active site flap. P1 shows similar behavior in the active site, while 
still perturbing the protein-protein binding sites to some extent 
 
 
 
Table 0-6 Overall and Local RMSDs of MD simulations 
RMSD (Å) Apo UPG P1 P2 
Overall 2.475 1.294 1.798 2.101 
Promontories 2.09 1.746 1.759 1.967 
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Mobile Loop 1.297 1.247 1.21 1.458 
Active Site Flap 2.509 0.964 0.989 1.172 
Binding Site 
Green 1.237 1.297 2.464 3.42 
Binding Site Red 1.058 1.216 2.217 3.105 
Four Helix 
Bundle 2.09 1.629 2.464 2.147 
 
3.4.6 Generalized Masked Delaunay analysis 
 Generalized Masked Delaunay analysis was used to determine the effects of substrate 
binding on the relative rate of conformational activity.  GMD assesses the "activity" of a 
simulation, by creating a masked Delaunay representation of the protein structure, and using it 
to determine how frequently side chains exhibit significant and persistent motion (16). As this is 
a "sliding window" analysis, the presented data has been truncated to remove artifacts that 
occur at the end of these plots. We examined the activity pattern across all four simulations, to 
determine what effect each substrate had on the rate and degree of activity of TcdB. Figure 0-9 
shows the results of GMD analysis on the 4 simulations. Column 1 shows plots of activity vs. 
scaled frame, all simulations were scaled to 5% of the total frame count for the finished 
simulation. Columns 2 and 3 show the decomposition of the activity into contact forming 
interactions and contact breaking interactions. 
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Figure 0-9 GMD analysis of MD simulations; Apo-TcdB, UPG, P1 and P2 bound.  
As in the PCA analysis, simulations are organized by column, analyses are organized by row. Column 1 
shows the total activity of each simulation as a function of frame. The count of significant persistent events 
are plotted on the Y- axis, against simulation progress on the X-axis. Columns 2 and 3 decompose the total 
activity into contact-forming events and contact-breaking events.  
 
 The Apo simulation shows a high level of flexibility throughout, along with a rapid event 
pattern.  The decomposition of activity shows somewhat more contact breaking than forming, as 
well as a more steady level of contact breaking. The high number of activity spikes may be 
indicative of continuous conformational transitions, with low points in activity representing 
conformations amenable to the approach of a binding partner or substrate. Visual inspection of 
the trajectory shows a repetitive breathing motion that opens the active site somewhat, possibly 
accounting for the higher level of contact breaking.  
90 
 
 The UPG bound simulation exhibits a dramatically different activity plot. Following an 
initial rearrangement, activity steadily declines, until reaching a relatively steady state roughly 
halfway through the trajectory. A few slow moderate rises in activity occur following this point, 
but the overall rate of activity remains moderate. The plot of contact forming events shows a 
steady decrease, suggesting that the bulk of the conformational change involves some degree 
of unfolding. Analysis of the conformational trajectory agrees with this interpretation. The active 
site flap moves away from the catalytic center, presenting the region near the manganese ion 
for catalysis, presumably to allow binding of a glucosylation partner such as RhoA. It has been 
previously shown that in the absence of UPG, the active site flap folds down, precluding protein-
protein binding (449). The level of contact breaking throughout the UPG simulation shows an 
initial increase, likely associated with the initial rearrangements due to UPG binding.  
 Analysis of the P1 simulation shows the same initial rearrangements observed in both 
the UPG and Apo simulations, with an event pattern intermediate to both. A decrease in activity 
is observed, similar to the bound form with UPG, but remains at a higher level overall, roughly 
1.5-1.75 events per frame. The number and frequency of activity spikes are also intermediate to 
the Apo and UPG-bound simulations. Interestingly the shape of the contact forming and contact 
breaking plots is similar to the Apo simulation, but with an increase in the number and frequency 
of activity spikes, similar to the Apo simulation. This seems to indicate that P1 is in some way 
acting as a UPG mimic; upon P1 binding, TcdB takes on activity characteristics of the UPG 
bound toxin.  
 The P2 simulation has an activity pattern disparate from all other simulations. The 
overall level of activity is higher, with smooth transitions between regions of high and low 
activity. This pattern is not seen in any of the other simulations. The level of contact forming is 
somewhat lower than the level of contact breaking overall.  More rapid transitions in the level of 
contact making are apparent in the second half of the simulation, while no such pattern is 
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observed in the contact breaking activity. The distinct alteration in the event pattern may in 
some way be contributing to P2's ability to inhibit TcdB. While P2 is bound, it appears to disrupt 
the native pattern of conformational searching, but in an entirely different way than P1. No 
similarity is evident between the P2 bound and UPG bound simulations, suggesting that P2 is 
not acting as a UPG mimic.  
3.5 Computational functionalization of peptide leads 
 Functionalization of HQSPWHH was considered necessary, while the peptides were 
inhibitory in vitro they did not provide cell protection in cell assays. The etiology of the toxin is 
such that we propose that the peptide inhibitors were becoming dislodged during the course of 
endosomal escape. To determine whether or not an irreversibly linked peptide could provide cell 
protection, initial studies with a photo-activatable crosslinker were performed, and cell protection 
was observed. However, as photo-activation of an inhibitor is at the very least inconvenient in a 
clinical setting, we chose to pursue other methods of irreversible binding. Inclusion of an 
epoxide in the structure was selected, as nucleophilic attack would result in a covalently linked 
inhibitor.The studies described in Section 3.4 indicated that of the two peptides chosen for study 
HQSWPHH was a better choice for functionalization. EGWHAHT mimics UDP-Glucose in our 
studies, and we considered the risk of off-target effects problematic, however initial 
functionalization studies were still performed. Alanine scanning was performed to locate sites 
where modification was possible, followed by epoxide scanning. As in vitro work included 
assays on TcdA, docking was carried out against both TcdA and TcdB structures. Once a lead 
molecule was selected, synthesis and testing were carried out.  
3.5.4 Alanine and epoxide scanning 
 In silico scanning was performed to determine the optimal site for modification based on 
docking energies to TcdB (PDB: 2BVL) (387) and reiterated in light of recent high resolution 
crystal structure for C. difficile TcdA (PDB: 3SS1) (436). This optimization was done in several 
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steps. The first step involved incorporation of an alanine at each position to determine the 
relative contribution of the parent side chain at each site. It was determined that positions 1 and 
5 of EGWHAHT and positions 1, 5 and 7 of HQSPWHH were not detrimental to either binding 
conformation or docking score. Modifications at positions 2 and 3 of EGWHAHT or 2 and 4 of 
HQSPWHH perturbed binding, dramatically altered docking score or both. All other positions 
had intermediate effects. These positions were then assessed for both the ability to sterically 
accomodate an epoxide moiety, and availability of nearby nucleophiles.  
Table 0-7 Docking scores of parent and derivatized peptides and number of surrounding nucleophiles  
The two positions chosen for functionalization are highlighted in gray. Selection was made based on docking 
score and number of nearby nucleophiles 
 WT H-1-X Q-2-X S-3-X P-4-X W-5-X H-6-X H-7-X 
Alanine -36.01 -38.84 -31.93 -29.86 -35.18 -34.74 -35.47 -39.12 
Epoxide R -35.58 -32.53 -15.74 -24.94 -40.76 -32.04 -37.50 -43.38 
Epoxide S -36.04 -29.04 -2.06 -35.34 -20.89 -52.85 -33.01 -24.26 
Nucleophiles 
surrounding nucleophiles  
     -     2     1      2      2       4      2     6 
WT: Parent peptide HQSPWHH 
X-substitue t, either alanin  or R/S epoxides 
 
 Due to the nature of the docking algorithm, slight fluctuations in scores occur as a 
consequence of sub-angstrom variations in the docked conformation, predominantly through 
rotation around bonds in the flexible side chains. While not on an absolute energy scale, this 
procedure provides reliable relative binding affinities to assess positions where the epoxide 
might be accepted. A docking score of greater magnitude than the parent peptide was 
considered an advantageous modification, while a docking score lower than the parent peptide 
was considered disadvantageous.  
 Peptides were selected for derivatization based on two criteria: a) epoxy modified 
peptides with tighter binding affinity but relatively few reactive nucleophiles nearby or b) with 
moderate binding affinity but with larger number of surrounding nucleophiles. Two peptides 
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derivatized at different residues were subsequently selected for synthesis shown in Figure 0-10, 
both with docking scores more favorable than the parent peptide (parent docking score, -35.58): 
HQSPGepoxyHH (H-epoxy-5) (Figure 0-10 Epoxidated peptide structures and conformationsA 
and C) and HQSPWHGepoxy (H-epoxy-7) (Figure 0-10 B and D). One reason for selecting H-
epoxy-5 was that it displayed the overall tightest docking score, while the rationale for selecting 
H-epoxy-7, despite a more modest docking score, was due to the higher number of potential 
nucleophiles in its vicinity that might facilitate rapid cross-linking. In all cases the structures 
interact both with the active site catalytic Manganese and residues on the highly conserved 
mobile loop within the active site critical in glucosylation (456, 457). The parent peptide 
HQSPWHH adopts a curled conformation (407) as seen in Figure 0-4. The N-terminal histidine 
contacts a active site region comprised of  an Asn 270 -Asp 273 pair, while the C-terminal 
histidines interacts with the charged loop region comprised of residues 513-526 (456, 457). The 
epoxide of H-epoxy-5 has close contact with Lys142, Leu 265 and Asn 139. The epoxide of H-
epoxy-7 is within reach of Lys 452, Asp 523, Asp 461 and Ser 518. Even though the structural 
(436) and functional similarity between the GTD of TcdB and TcdA makes TcdB a suitable 
substitute for the purpose of docking, we revalidated the binding modes and surrounding 
nucleophiles in terms of GTD of TcdA  
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Figure 0-10 Epoxidated peptide structures and conformations.  
Structures of selected epoxy-peptides and close-up view of ribbon structure of the TcdB active site, showing 
binding modes of peptides H-epoxy-5 and H-epoxy-7. Panels A and B show the structure of the epoxidated 
peptides. Panels C and D show the binding conformations of H-epoxy-5 and H-epoxy-7 respectively.The 
epoxide residue of H-epoxy-7 is in close proximity to more polar amino acids when compared to H-epoxy-5. 
The catalytic Manganese ion is indicated as a green sphere in both images 
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3.4.6 Comparison to TcdA  
 To verify that the active sites of TcdA and B were similar enough to be confident that our 
epoxidated peptide would react with both toxins, we compared the structures with respect to the 
bound peptide conformations. The docked structure of the TcdB-peptide complexes were 
structurally aligned with the TcdA crystal structure and spatial compatibility and active site 
similarity were assessed.  
 
Figure 0-11 Overlay of TcdA on peptide bound TcdB structures.  
Panel A shows H-epoxy-5 and panel B shows H-epoxy-7. TcdA is shown in green and TcdB in yellow. The 
aligned structures are similar in their overall active site organization, with a backbone RMSD of 0.85Å. No 
steric clashes were observed between TcdA and the epoxy-peptides.   
 No steric clashes were observed, so we continued to comparison of the sequence of 
TcdA and TcdB in the active site. o determine the extent of similarity between contacts in the 
bound conformations, the structural alignment was used to determine which residues are 
conserved in the putative binding orientation. All residues within 5Å of the peptides in the TcdB 
conformation were considered "contacts", the structurally cognate residues in TcdA were 
determined and compared for both the H-epoxy-5 and H-epoxy-7 structures.  
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Table 0-8 Comparison of residues in contact with H-epoxy-5.  
Structurally cognate residues within 5Å of H-epoxy-5 in both TcdB and TcdA are compared. Residues 
highlighted in green are identical, those in blue are conservative substitutions, and those in red have non-
conservative substitutions 
H-epoxy-5  H-epoxy-7 
TcdA TcdB  TcdA TcdB 
ASN 138 ASN 139  ASP 288 ASP 287 
LYS 141 LYS 142  MET 289 MET 288 
LEU 264 LEU 265  ILE 382 VAL 381 
SER 268 SER 269  ILE 383 ILE 382 
ARG 272 ARG 273  ASN 384 ASN 383 
TYR 283 TYR 284  GLN 385 GLN 384 
ASP 285 ASP 286  MET 448 THR 447 
ILE 382 ASN 384  GLU 449 LYS 448 
ASN 383 GLN 385  LEU 450 ILE 449 
GLN 384 GLU 515  PRO 460 GLU 460 
ASN 516 ALA 517  GLU 515 GLU 514 
SER 517 SER 518  MET 516 ASN 516 
LEU 518 LEU 519  SER 518 SER 517 
     LEU 519 LEU 518 
     TRP 520 TRP 519 
     SER 521 SER 520 
     PHE 522 PHE 521 
     ASP 523 ASP 522 
     ASP 524 GLN 523 
 
 The conclusions from these comparisons were that the epoxidated peptides would likely 
have activity in both TcdA and TcdB. There were enough conserved residues in the proposed 
binding site, including conserved nucleophiles to move forward with synthesis.  
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3.6 Experimental validation of proposed inhibitors 
3.6.1 Synthesis and in cellulo testing of epoxidated peptides 
 
 Dr. Sanofar Abdeen synthesized the epoxidated peptides by oxidizing allyl-glycine 
substituted peptides with mCPBA. Details of the synthesis and purification are described in 
Abdeen et al. (JBC submitted) As the parent peptides were capable of inhibiting TcdA and TcdB 
in vitro, but were unable to protect cells, the epoxidated peptides were tested in cellulo. Vero 
cells were challenged with 600µm TcdA and observed over a 48hr period. Cell viability was 
quantitated using an ATP-sensitive luminescent assay. All cell viability assays and imaging was 
performed by Dr. Stephanie Kern.  
 It was determined that the H-epoxy-5 was capable of providing 95% cell protection in 
cellulo and had no cellular toxicity. No cell protection was detected with H-epoxy-7. We propose 
that either the dissimilarity in the active site of TcdB and TcdA affected a critical contact in the 
H-epoxy-7 binding site, or that the overall binding geometry for this complex is more unfavorable 
than predicted.  
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Figure 0-12 Cell protection and viability quantitation.  
Panel A shows the morphological assessment of cells under various treatments. Sub-panel (a) shows 
healthy cells in PBS buffer, cells are elongated and adherent. Following treatment with TcdA, cells exhibit 
rounding and detach from the surface of the plate (b). Sub-panel (c) shows healthy cells in the presence of 
the parent peptide. No toxicity is observed. Upon challenge with TcdA, the parent peptide provides no 
protection and apoptosis is detected (d). Cells imaged in sub-panel (e) were treated with the H-epoxy-5, 
indicating that the epoxidated peptide is not inherently toxic. Lastly, treatment with both TcdA and H-epoxy-5 
in (f) shows a dramatic reduction in observed apoptosis. Cell adherence and elongation are both preserved. 
Panel B describes the quantitation of these results. Cell protection as a percentage is plotted vs. increasing 
inhibitor concentration.   
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3.6.3 Validation of crosslinking site by mass spectrometry 
 To determine whether or not the epoxidated peptides were acting as designed, or if they 
were nonspecifically inhibiting TcdA by some other mechanism, mass spectrometry was used to 
determine the site of crosslinking.  Recombinant TcdA was allowed to react with H-epoxy-5, 
then subjected to tryptic digestion and analyzed via FT-ICR mass spectrometry. Full details are 
available in Abdeen et al. (JBC in submission). Sequence coverage of roughly 70% was 
obtained, and the site of crosslinking was structurally mapped.  
 
Figure 0-13 Stereoimage of TcdA/B crosslinking site.  
The ribbon structure of TcdB in complex with H-epoxy-5 (in blue)  is shown as a stereoimage. Shown in red 
is the TcdA sequence where crosslinking was detected by FT-ICR mass spectrometry. It is clear that the 
docking and epoxidation studies correctly predicted the bound conformation and crosslink region 
 From these studies it is apparent that the inhibitory activity was not due to random 
crosslinking, but that the predicted binding conformation was accurate. The epoxide is 
positioned directly facing the detected site of crosslinking.  
3.7 Conclusions  
 In this study, we rationally designed an epoxide-containing peptide that acts as an 
irreversible inhibitor of the clostridial-glucosylating toxins sufficiently potent to protect cultured 
cells from intoxication. Previously described peptide inhibitors of TcdA and TcdB were found to 
employ differential mechanisms of inhibition in vitro. Upon docking, the peptides were found to 
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bind tightly to different regions of the active site. Long timescale simulations were applied to 
investigate possible mechanisms. Application of GMD analysis indicated that the peptides 
induced significantly different event patterns over the course of the simulations. Application of 
PCA analysis determined that flexibility in the active site is restricted when UPG and EGWHAHT 
are bound relative to the Apo structure. Binding of HQSPWHH, which proved to be the best 
inhibitor of glucosyltransferase activity, greatly deformed the protein-protein recognition face of 
TcdB. Evidence suggests that EGWHAHT acts as a UDP-Glucose mimic, while HQSPWHH 
interferes in the conformational selection mechanism.  HQSPWHH was selected for further 
functionalization; computational alanine and epoxide scanning was used to determine which 
residues would perform best upon epoxidation. Following synthesis, H-epoxy-5 was able to 
provide 95% cell protection during in cellulo assays, and mass spectrometric analysis showed 
that the peptide covalently crosslinked exactly where the parent peptides were computationally 
predicted to bind.  
 
3.8 Methods  
 All simulations were carried out using NAMD (428) with the CHARMM27 (439) force 
field. It is well known that this force field has a tendency to prefer helical structures (458, 459). 
Previous long timescale simulations did not show significant formation of helical structures in 
crystallographically unstructured regions (449), based on these results we decided to continue 
our studies with the CHARMM27 force field. The apo simulation was prepared by removal of the 
crystallographic UDP and Glucose as previously described. Bound conformations for UPG, 
HQSPWHH and EGWHAHT were generated using the LeadIT (338, 460-463) suite for docking. 
Docking parameters were tested using the crystallographic UDP conformation as proof of 
method, as published previously (407). All substrates were initially built and minimized at the 
AM1 level of theory using Spartan '03 (464) and docked into a sphere encompassing all 
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residues within 20 Å of the catalytic manganese. All crystallographic waters were retained and 
utilized as both fully rotatable and displaceable.  Triangle matching was used for base fragment 
placement, and dockings were performed with two thousand solutions per each iteration and 
fragmentation. The standard scoring scale based on Bӧhm's scoring algorithm (465-467) was 
employed. Docking was carried out against dynamically relaxed structures following simulation 
of the apo toxin from a previous work (449) as well as the crystal structure. Following docking to 
the crystal, 60 ns and 80 ns structures, clustering was carried out.  
 Force field parameters for UDP glucose were created both de novo from single point 
calculations and by generalization. UDP-Glucose was built in Spartan and initially optimized at 
the AM1 level of theory. Restricted Hartree-Fock optimization at the 6-31G* level of theory was 
performed using Gaussian '03 (463). The optimized geometry was utilized for frequency 
calculation, NPA and ESP charge fitting. Paratool (431) was used to convert the Gaussian 
output into CHARMM format parameters for comparison with the manually determined 
parameters.  Parameterization by generalization was performed using the parameters from UTP 
for the UDP after removal of the terminal phosphate. CHARMM parameters for glucose were 
readily available and parameters for the sugar-UDP linkage were obtained from those 
determined for phosphoserine. Comparison of parameters derived from these two methods 
indicated that they were identical within the decimal places utilized by the standard CHARMM 
force field.  
 MD simulations were run on the WSU rocks cluster. The canonical ensemble was 
maintained via periodic boundaries, with Langevin dynamics and thermostat (430). Simulation 
stability was verified by use of the trajectory analysis tools available with the VMD software 
(431). Stability was monitored by energy and RMSD. The systems were solvated with TIP3P 
water, neutralized with counter ions and subjected to 1000 steps of conjugate gradient 
minimization and temperature ramped to 300K. Frames from the trajectories were written every 
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1 ps. The solvation box includes a 15Å pad on each face of the box. Long-range electrostatic 
effects were taken into account using the smooth particle mesh Ewald method (441), and van 
der Waals interactions were calculated with a non-bonded cutoff of 8Å and a switching function 
between 7-8 Å.  Results were analyzed by use of GMD graphs, via TimeScapes (442), and by 
PCA using the bio3d package for R.  Hydrogen bond and salt-bridge analysis was performed 
using VMD. All hydrogen bonds and salt bridges occurring for more than 90% of the simulation 
time were noted. RMSDs were calculated using VMD.  
 Clustering was carried out on both MD and docked peptide conformations. Standard 
clustering in Chimera was performed (468). Cross comparison of the docked and MD 
conformations was carried out by superposing all conformers from the docking clusters onto 
representative structures from the MD clustering. RMSDs between best matching pairs were 
calculated, and the docking cluster to which they belonged was identified for rank comparison. 
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Chapter 4 Investigation of an allosteric circuit in the cysteine protease 
                 domain of Clostridium difficile Toxin B 
 
 
4.1 Background 
 The cysteine protease domain (CPD) of the C. difficile toxins A and B is responsible for 
cytosolic release of the glucosyltransferase domains, and was recently crystallized 
(PDBID:3PEE) (402) Once the toxin undergoes receptor mediated endocytosis, CPD and GT 
domains undergo translocation through a pore created by the translocation domain. Cleavage of 
the CPD releases the GT domain into the cytosol at this point. Cellular damage occurs when an 
endocytosed toxin transfers a glucose moiety from UDP-Glucose to any number of Rho-family 
GTPases. The CPD domain is a possible drug target since targeting virulence factors may be a 
way to abrogate the cellular damage that occurs during an active infection,. The CPD domain 
could be targeted at two points during cellular intoxication due to the etiology of the toxin,. 
Endosomal escape may be prevented if the CPD domain is bound irreversibly to a small 
molecule and tight folding prevents translocation,. The GT domain would potentially remain 
endosomal, no interaction with Rho-GTPases would be possible. If cleavage and release of the 
GT domain occurs before cell contact and endocytosis, there will be no GT domain translocated 
to damage the cells. Induction of CPD domain cleavage in the lumen of the intestine would 
preclude cell death. 
4.2 Cysteine protease domain of TcdB 
 CPD cleavage is allosterically activated by the binding of inositol hexakisphosphate 
(IP6). Binding of IP6 triggers the organization of the CPD catalytic triad into an active 
conformation. Figure 0-1 shows the structure of the CPD from Clostridium difficile TcdB. 
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Residues comprising the catalytic triad are shown in red, residues experimentally determined to 
participate in IP6 binding are shown in purple, and the β-hairpin shown in blue has been 
determined experimentally to have an effect on rate of cleavage (402). We have introduced the 
mutations shown in Panel B in green, also experimentally explored (402), to determine their 
possible structural consequences both apo and IP6 bound. K764N is predicted to affect 
interactions with IP6,E764N potentially perturbs folding of the β-hairpin responsible for active 
site organization and R751Q is predicted to communicate IP6 binding allosterically to induce 
hairpin formation. The objective of studying these mutations is to determine which activities, IP6 
binding, hairpin formation or communication, is most critical to folding and function. Further use 
of this work might include design of inhibitors based on IP6 with the purpose of manipulating 
one or more of these functions.  
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Figure 0-1 Structure of the CPD domain and investigated mutations. 
 Structure of the CPD domain is shown in panel A. IP6 binding residues are shown in purple, The β-hairpin 
mutagenically shown to contain an allosteric communication circuit are shown in blue. Shown in red are the 
catalytic triad responsible for protease activity. Panel B shows the three mutations studied in this work, and 
Panel C indicates their putative roles. E753N participates in a salt bridge responsible for organizing the β-
hairpin structure. K764N is directly involved in IP6 binding, and R751Q is a putative allosteric communicator. 
 
4.3 Investigation of allosteric circuit through molecular dynamics 
 Previous work by Shen et al. determined the in vitro effects of introducing several 
mutations of the CPD domain. MD simulations of both the wild type and three mutant CPD 
structures both apo and IP6 bound were performed. Analysis of these simulations by PCA and 
GMD indicates differential behavior and may provide context for the development of targeted 
inhibitors or activators of function. Puri et al have designed cleavage inhibitors, however, these 
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molecules are active intracellularly (446). While some work has been done by Puri et al towards 
designing inhibitors of cleavage, however these molecules are active intracellularly. We hope 
that these studies may lead to the development of molecules that would induce CPD cleavage 
extracellularly, or prevent GT domain escape, as this would preclude issues of cellular transport. 
Cell protection by either of these avenues would allow for more efficient treatment of infection 
and alleviate many of the symptoms of CDAD.  
 A total of eight MD simulations were performed as listed in Table 0-1; Apo and IP6 
bound structures of the wild type and each of the three mutants described above. Unbiased MD 
was performed as described in the Methods section, the Apo-WT simulation was run for 130ns, 
while all other trajectories were run for 25ns. The Apo-WT simulation was allowed to run for a 
longer time to provide better data density for analysis. Following preliminary analysis, the Apo-
E753N simulation was extended to 90ns to determine if additional information on the mutant 
simulations was forthcoming with longer simulation times. Correlation analysis as well as PCA 
and GMD analyses were applied.  
Table 0-1 Simulations performed on Apo and IP6 bound CPD domain.  
A total of eight simulations were performed. The wild type and three mutant structures in both Apo and IP6 
bound conformations were studied. The wild type was simulated longest to give more structural context for 
the molecular motions. E753N was extended following initial analyses. 
Total simulation time 
Structure Apo IP6 
Wild Type 130 ns 25ns 
E753N 90 ns 25ns 
R751Q 25ns 25ns 
K764N 25ns 25ns 
 
 From visual inspection of the trajectories, it was clear that the apo structure exhibits a 
high degree of flexibility throughout the simulation. This is to be expected as IP6 binding is 
responsible in vitro for the organization of the active site. An overall loose fold was expected as 
Apo-CPD must be able to thread through a pore during endosomal escape. All IP6 bound 
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simulations are far less mobile relative to the Apo simulations and tight contacts with the IP6 
phosphate groups are maintained throughout. All simulations were stable through their time-
courses as was monitored by RMSD and total energy. Backbone RMSDs for all simulations 
were below 1.5Å.  
4.3.1 Principal Component analysis of MD simulations 
 The PCA of both the IP6 bound and Apo simulations is very revealing. Figure 0-1 Panel 
A, shows the cross-plots of PC1 and PC2 for both the Apo and IP6 bound simulations. PC1 is 
on the x-axis and PC2 is on the y-axis. For each set (Apo vs IP6) the trajectories were projected 
onto the same core residues and may be directly compared. While Apo-IP6 cross-plot 
comparisons are not quantitatively reasonable, the breadth, localization, and transition patterns 
can be used to discern qualitative relationships. Panel B shows a broadened ribbon diagram for 
all first principal components, colored as in Figure 2. The longest timescale simulation Apo-WT 
shows a wide range of conformational freedom, which is to be expected. In both the Apo and 
IP6 bound sets of simulations, viewed horizontally across panels, the mutants all behave 
similarly to one another. One point of interest is the range of the axes on the IP6 bound plots 
relative to the Apo plots; there is considerable restriction in the conformational space explored in 
all IP6 containing simulations. 
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Figure 0-2 PCA analysis of Apo and IP6 bound CPD simulations. 
 Panel A: All apo simulations were projected onto the same invariant core for PC analysis, as were all IP6 
simulations. Quantitative comparisons can be made left to right, and qualitative comparisons top to bottom. 
The greatest amount of flexibility was observed in the Apo-WT simulation. All Apo simulations seem to 
occupy the same general conformational space to varying degrees and in slightly more punctate or diffuse 
manners. The same is seen in the IP6 bound simulations. Again, the wild type has the highest degree of 
flexibility, and the mutant simulations are somewhat comparable. Panel B: Broadened ribbon diagrams of the 
first principal component projected onto the structures. All have been oriented similarly for comparison. 
 In the Apo simulations, while all mutants seem to exhibit similar behavior, Apo-K764N 
shows a bit more diffuse conformational exploration, while Apo-R751Q shows more clearly 
defined paths between conformational regions. Apo-E753N shows both consistent grouping and 
smooth transitioning. 
 In the IP6 bound mutant simulations, again all three behave similarly, though the IP6-
E753N shows diffuse conformational space relative to IP6-K764N and IP6-R751Q. R751Q 
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shows transitioning between regions by clearly defined paths, showing some similarity to the 
Apo simulation.  
 Between the Apo and IP6 bound WT simulations, there is both restriction of 
conformational space, and alteration in the mode of transition. In all other simulations there is 
transitioning between conformational regions, while in the Apo-WT simulation there are a few 
isolated regions of localization. This may be due to the longer timescale of the simulation, 
possibly exploring several local minima that the other simulations do not investigate. 
4.3.2 Interaction analysis of Apo and IP6 bound simulations  
 We performed hydrogen bond analysis, salt-bridge analysis, and assessed water-protein 
hydrogen bonds to quantitate the effects of IP6 binding on the simulations,. Tables 2-4 describe 
these metrics. With respect to intra-protein hydrogen bonds, the stabilizing effect of the IP6 
dramatically increases organization.  
 Table 0-2 lists the total number of intra-protein hydrogen bonds for each simulation. In all 
cases the inositol bound simulations exhibit over twice the number of detected hydrogen bonds. 
This is physiologically sensible, as IP6 binding is predicted to stabilize the fold, theoretically 
allowing time for the optimization of the local hydrogen bonding network. This conclusion is 
supported by the data presented in Table 0-3 .  
 In all simulations, the apo structures exhibit greater hydrogen bonding to water 
throughout the simulation. As we observed considerable structural flexibility in the apo 
simulations, it would be logical that charged amino acids would be available to form more 
solvent-protein hydrogen bonds. Lastly, Table 0-4 presents the total number of salt bridge 
interactions detected in each simulation. This echoes the result of the intra-protein hydrogen 
bond analysis, where over twice as many self-interactions were detected. We again attribute 
this to the IP6 binding-induced stability allowing the protein structure to optimize it's self 
interactions.  
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Table 0-2 Intra-protein hydrogen bonds observed for both Apo and IP6 bound simulations.  
In all IP6 bound simulations, we observe nearly double the total number of stable hydrogen bonds, we 
attribute this behavior to the additional backbone stability afforded by IP6 binding. 
Intra-protein hydrogen bonds 
Structure Apo IP6 
Wild Type 56 129 
E753N 50 137 
K764N 57 128 
R751Q 57 131 
 
Table 0-3 Solvent-protein hydrogen bonds observed in both Apo and IP6 bound simulations.  
In agreement with the information in Table 4-2, without the stabilizing presence of IP6 the apo simulations 
fulfill their desired hydrogen bonding networks with solvent-protein hydrogen bonds. In the IP6 bound 
simulations, there are consistently fewer protein-solvent hydrogen bonding interactions.  
Solvent-protein hydrogen bonds 
Structure Apo IP6 
Wild Type 189 129 
E753N 193 129 
K764N 204 144 
R751Q 166 143 
 
Table 0-4 Intra-molecular salt bridges observed in both Apo and IP6 bound simulations.  
Stable salt bridges were assessed for all trajectories. IP6 bound simulations show over twice as many salt 
bridged residues as the Apo simulations do in all cases. Again, we attribute this to the overall stability 
increase due to IP6 binding that allows to sidechains to find intra-protein interaction partners, rather than 
interacting with solvent during large scale conformational changes.  
Salt bridges 
Structure Apo IP6 
Wild Type 8 20 
E753N 7 19 
K764N 8 19 
R751Q 7 17 
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4.3.3 Correlation analysis on Apo and IP6 bound simulations 
 Correlation analysis was applied to determine the effects of the mutations on the overall 
motions of the simulations. Difference plots are shown in Figure 0-3, where the correlation 
matrices of the mutant simulations have been subtracted from the correlation plot of the wild 
type. When plotted, this data indicates which residues show altered correlated motion relative to 
the wild type. Anti-correlation is shown as blue, correlated motions are shown as orange, and x 
and y axes are residue numbers. What is immediately apparent in these plots is that correlation 
is dramatically perturbed in the Apo-E753N simulation. Upon examination of the structure 
however, this is very logical. The mutation removes a salt bridge pair, replacing an Arg-Glu 
interaction with an Arg-Asn. This substitution causes the β-hairpin critical in forming the active 
site to partially unfold during the simulations, presumably damaging overall correlation as well 
as active site organization. The K764N position is involved in IP6 binding, and R751Q in 
communication of that binding, so it is not surprising that we see no effects on correlated motion 
in the Apo simulations.  
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Figure 0-3 Difference correlation plots .  
Correlation matrices of the mutant simulations have been subtracted from the wild type simulations to 
determine how the introduction of the mutation affects overall concerted motion. It is readily apparent that 
E753N dramatically perturbs how the CPD domain explores its conformational space. In all IP6 bound 
simulation, a low degree of motility is observed, and this low correlation overall is to be expected. 
 
 Once IP6 is bound we see little overall motion in all simulations, and consequently there 
can be a limited amount of correlated motion. As we see in the three mutant IP6 bound 
simulations, there is no discernible difference between the three other than a few slight point 
correlations. While IP6 binding precludes differentiating between these mutations by correlation, 
GMD was applied to determine the effects on the activity of the simulations. 
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4.3.4 Generalized Masked Delaunay analysis of simulations  
 Generalized masked Delaunay plots for all simulations are shown in Figure 0-4. Total 
activity is indicated in blue, contact forming is in green and contact breaking is in red. This 
analysis provides a number of events per frame, by monitoring the space explored by a residue 
during a window of the trajectory, and then determining whether or not motions that occur are 
significant or trivial. Please refer to the original manuscript for further information (442).  
 
Figure 0-4 : GMD plots of all Apo and IP6 bound simulations.  
Total activity is indicated in blue, contact breaking is in red, and contact forming is in green. This analysis 
provides events per frame and was used to monitor overall activity as well as investigate specific activity 
peaks, such as those seen in the IP6-K764N simulation. 
 
 The Apo-WT shows a high level of activity overall, two phases of bond breaking and 
forming are observed around 70ns and 115ns, these alternating contact forming and breaking 
periods indicate an open-close behavior when the trajectory is observed at these points and is 
likely a normal part of the conformational exploration of this protein. While the Apo-E753N 
behaves dissimilarly from the other simulations, we interpret this as associated with the 
breaking of the concerted motions of the β-flap that were previously described. The Apo-R751Q 
simulation shows slightly higher activity overall, between 0.2 and 0.5 events per frame, slightly 
higher than the Apo-E753N and K764N simulations.  
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 The IP6-bound simulations all show a low level of activity relative to the Apo-WT 
simulation, which is partly due to simulation length, but is expected due to the low motion 
observed in the PCA analysis. The IP6-WT simulation shows the lowest level of activity overall, 
with some periodic fluctuations. The mutant IP6 bound simulations all share a common feature, 
a high activity peak somewhere between 7 and 20ns. As this peak occurs at different times in 
the simulations we believe it is not an artifact, but rather a consequence of forcing IP6 binding to 
these mutants. When the trajectory is observed, these time points correlate to rearrangement 
near the IP6 binding site.  
 The IP6-E753N simulation shows the lowest of these peaks, presumably because this 
mutation does not directly contact the IP6 molecule. The mutation, while removing an Arg-Glu 
interaction as discussed above, does not result in a repulsive pairing and the β-hairpin remains 
largely stable through the simulation. The IP6-K764N simulation shows the most pronounced 
peak, and when observed this also includes some rearrangement of the β-hairpin as well. The 
K764N mutation is directly interacting with the IP6 molecule, and therefore this would likely have 
the most dramatic effect on an IP6 bound conformation. The R751Q mutation does not directly 
interact with the IP6, but interacts with the K764 position to communicate IP6 binding. The GMD 
of this simulation shows a moderate peak, occurring later in the simulation than in either the 
E753N or K764N. Interestingly, the Apo-K764N simulation also shows this peak, and may be 
indicative of the K764N position having structural importance beyond IP6 binding.  
4.3.5 Quantitation of active site organization 
 Organization of the active site was quantitated in two ways, by RMSF, and by calculating 
the area of the triangle defined by the alpha carbon of the Asp 44, Lys 112 and Cys 155, the 
residues of the catalytic triad.  
 Figure 0-5 plots RMSF of the three residues over the simulation time, normalized to wild 
type. The first four columns are the Apo simulations, while the last four are the IP6 bound 
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simulations. Interestingly, even in the highly flexible apo simulations, the active site remains 
fairly stable. What is more interesting is that on a per-residue basis, the mobility of the active 
site triad is not evenly distributed. In all simulations the Cys155 residue has the highest RMSF. 
This residue is positioned adjacent to the β-flap that gets organized upon IP6 binding, and we 
theorize that this residue may be an extension of the allosteric circuit, critical in organizing the 
active site.  
 
Figure 0-5 Rmsf vs. simulation for three catalytic residues normalized to wild type.  
Cys 155 shows much higher flexibility than either Lys 112 or Asp 44, and as this residue is proximal to the β-
flap critical for activity, this is to be expected. While overall the activities are fairly consistent, IP6-K764N 
shows a somewhat increased level of activity 
 To determine the extent of organization of the active site, a triangular distance metric 
was created, using the area as a measure of "openness" Measured at the C-alpha position, the 
average distance for each of the three active site triad residues was observed for all 
simulations. The area of the triangle defined by these distances was calculated by Heron's 
formula and is included in Table 0-5. A visualization of this metric is shown in Figure 0-6.  
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Figure 0-6 Visualization of the distance metric used to describe active site stability.  
 Distance between the alpha carbon of Asp 44, Cys 155 and Lys 112 were averaged through all trajectories. 
The triangle described by this region was used as a metric of active site stability. 
 
Table 0-5 Distance between C-alpha of catalytic triad and area of triangle representing active site 
organization. 
Apo 
Simulation 44 to 155(Å) 155 to 112(Å) 44 to 112(Å) Area(Å2) 
Wild Type 14.7 9.6 9.8 46.5 
E753N 13.7 9 13.8 58.4 
K764N 14.84 6.99 14.3 49.28 
R751Q 16.15 11.32 10.76 60.75 
IP6 bound 
Simulation 44 to 155(Å) 155 to 112(Å) 44 to 112(Å) Area(Å2) 
Wild Type 14.17 7.33 13.29 48.14 
E753N 14.16 7.15 13.07 48.56 
K764N 14.11 7.67 13.18 49.84 
R751Q 15.21 6.17 14.1 43.47 
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 The overall results are similar to that of the RMSF calculation, but there are some slight 
differences, in both the apo and IP6 bound simulations, the active site seems relatively stable. 
There are a few notable exceptions, which support the evidence for an allosteric pathway. 
 Residue R751Q has been previously described as being critical in the communication of 
IP6 binding to the active site. As previously shown in our RMSF calculations, we theorize that 
the active site residue with the largest amount of flexibility, and therefore the highest effect on 
active site organization is Cys 155. In the Apo-R751Q simulation, there is a dramatic increase in 
the Cys155 to Lys 112 distance. This causes an increase in the area of the catalytic triad from 
roughly 46-48 Å2 to 60.75 Å2, a phenomenon not observed in any of the other simulations. 
Again, in the IP6 bound simulations, we observe a relatively stable active site area, with the 
exception of IP6-R751Q. In this case the active site area is actually decreased relative to the 
other IP6 bound simulations. We propose that perturbing the allosteric circuit even in the 
absence of IP6 has effects on the organization of the active site. It is possible that an inhibitor 
that alters the distance between the catalytic triad may be effective in preventing protease 
activity, or an activator that stabilizes this section of the allosteric pathway might be able to 
induce cleavage extracellularly.  
4.4 Conclusions  
 This work assesses the effects of three mutations of the CPD domain of TcdB on IP6 
binding, overall conformational mobility, correlation and activity. Comparison of the effects of 
these mutations illustrates in greater depth the interactions required for the formation of the 
CPD active site. This information will be useful in the future design of inhibitors or activators of 
cleavage for this protein.  
 Previous experiments indicated that the selected mutations perturbed catalytic activity as 
well as IP6 binding. It was shown that positions E753, K764 and R751 were critical for activity in 
various capacities, and their roles were determined as β-hairpin folding, IP6-binding and 
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allosteric communication respectively. While some work has been done towards development of 
inhibitors of the pre-organized active site, these require cell penetration as their active site target 
does not exist until late in the process of cellular intoxication. Currently there are no inhibitors 
exploiting the allosteric site of this protease.  
 MD simulation, PCA, correlation and GMD analyses were used to determine the where, 
what and when of these structurally important mutations. PCA allowed us to determine the 
similarities and dissimilarities in the overall structure through the simulation timecourses. 
Correlation analyses were used to indicate which mutations altered the method of movement, 
and GMD was applied to determine how the introduced mutations affect event pattern.  
MD simulations and PCA analysis indicate that in the IP6 unbound form the E753N mutation 
dramatically perturbs the conformational space of the protease, which may explain some of the 
in vitro findings with respect to IP6 binding and protease activity.  
 The correlation analysis dramatically illustrates that the E753N mutation in the apo 
conformation has strong effects on overall correlated motion. Strong correlation was observed in 
the Apo-WT simulation, and this is completely destroyed by the introduction of the E753N 
mutation. While later studies showed that the overall arrangement of the active site may not 
have been perturbed, our findings agree with the conclusions of Shen et al. that this mutation 
most dramatically interferes with protease activity. In the IP6 bound simulations, we observe a 
low level of activity and correlation as the simulations are quite stable. The difference correlation 
plots reflect this beautifully, as once IP6 is bound the protease should remain in a stable fold 
until proteolysis occurs.  
 GMD analysis was used to determine the effects of these mutations on overall activity 
and to discern critical events in simulation. While all three mutant IP6 bound simulations 
indicated an "event" during the course of the simulation, K764N was observed to have the 
greatest level of mid-simulation activity. This activity was determined to be a reorganization near 
the base of the β-flap. We propose that the alteration in IP6 interaction due to this mutation 
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partially destabilizes this region as the simulation progresses while the protein attempts to 
somewhat ameliorate the unfavorable contacts included by this mutation.  
 In observation of the RMSF and active site triad area, we determined that even through 
the highly flexible apo simulations, the active site remains fairly stable. On a per-residue basis, it 
was determined that Cys 155 appears to be an extension of the allosteric circuit defined by 
Shen et al.. As Cys 155 is proximal to the β-flap responsible for active site organization, this is 
logical. Both the K764N and R751Q mutations affect the behavior of this residue, albeit in 
different ways. During the IP6-K764N simulation, the RMSF of increases relative to wild type, 
and is in fact higher than all other simulations. The R751Q mutation affects the distances 
between the residues of the catalytic triad, directly affecting the shape of the active site pocket.  
We consider the pre-organization of the active site to be in agreement with current in vitro work 
As there has been evidence for small molecule inhibition of the CPD domain. As some of these 
studies have been performed in the absence of IP6, we consider the active site stable enough 
to be considered a target for inhibition. However, as this work has been done at pH 7, it is 
possible that the range of pH found in the gut may affect organization or flexibility of the CPD 
domain, making active site targeting difficult. Additionally, as altered pH has been observed in 
individuals with severe bowel disturbances, pH sensitive studies would be advised in the future.  
We suggest that small molecules targeting the IP6 binding region which stabilize the fold and 
allosteric circuit may potentially trigger extracellular cleavage. However, as we have determined 
that there is some extant pre-organization of the active site, targeting of the active site pocket is 
not an unreasonable goal, provided the inhibitors are not dislodged during endosomal escape. 
We propose that Cys 155 is the direct target of allosteric control in the CPD domain, and 
molecules perturbing the flexibility or position of Cys 155 would be capable of inhibiting protease 
activity. Furthermore, molecules capable of causing conformational alterations similar to those 
induced by the R751Q mutation may be able to prevent organization of the active site. 
120 
 
Investigation into allosteric activation as a potential mechanism to prevent cellular intoxication 
may prove fruitful.  
 It is clear that alteration of any step in the allosteric circuit has consequences. 
Introduction of the K764N mutation affects activity while IP6 is bound, introduction of the E753N 
mutation appears to perturb conformation, and introduction of the R751Q mutation alters 
organization of the active site. Small molecules exploiting these activities would potentially be 
powerful tools against Clostridium difficile infection.  
 
4.5 Methods 
 The wild type crystal structure of CPD (PDBID:3PEE) was used as a scaffold for the 
creation of three mutants E753N, R751Q and K764N. Mutations were introduced using the 
structure editor in Chimera (469). Conformations were selected from the Dunbrack rotamer 
library (470), and taking into account the first two atoms of the wild type side chain 
conformation. All four structures were generated with and without the crystallographic inositol for 
a total of eight simulations. Structures were solvated and ionized using the MeadIonize plugin 
for highly charged systems using VMD (431). Simulations were carried out using NAMD (428) 
with the CHARMM force field (437, 438, 471).  
 Parameterization for IP6 was performed as previously described (449) using both ab 
initio and analogy methods. Parameters from both methods agree to within the decimal places 
used by the CHARMM force fields.  
 Correlation analysis was carried out using the ptraj module of AmberTools (472). All 
atom correlation of the protein structure was performed and results were plotted using 
Mathematica (473). Solvent, ions and IP6 were excluded. Difference plots were generated for 
ease of comparison. Unsubtracted plots are available in SI.  
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 Generalized Masked Delaunay analysis was performed using TimeScapes (442). 
Simulations were strided to 1/10 of total simulation time, water, counterions and substrate was 
removed. The calculation was performed using a 5% frame window. Contact breaking, forming 
and total activity were plotted. Activity based trajectories were generated and used to examine 
the events detected in the IP6 bound simulations.  
 PCA was done using the bio3d package under R (474). Trajectories were reduced to C-
alpha atoms only, each set of four trajectories was used to determine the spatially invariant 
residues. All trajectory frames were aligned onto the "core" residues and PCA was performed. 
Crossplots of PC1 vs. PC2, PC2 vs. PC3, and PC1 vs PC3 were generated as well as a plot of 
proportion of total variance captured vs. Eigenvalue rank. Broadened ribbon diagrams were 
generated using Chimera where the degree and direction of broadening indicates degree and 
direction of eigenvalue for each PC.  
 Hydrogen bond and salt bridge analyses were carried out using VMD (431). Active site 
distance metrics were calculated using python and the Chimera visualization suite (469). Area 
of active site was calculated using Heron's theorem. Rmsf of selected residues was performed 
using R (475).  
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Chapter 5 Comparative analysis of Clostridium difficile Toxins A and 
                 B 
 
5.1 Background 
 Clostridium difficile  (C. diff) is a well known hospital-acquired infection that costs 
the American healthcare system millions of dollars and thousands of lives per year (374, 
376). Infection occurs following treatment with broad-spectrum antibiotics during an 
inpatient stay.(370). While the broad-spectrum antibiotics perturb the natural colonic 
microflora, hospitalization provides exposure to C.diff bacteria and spores; creating the 
perfect opportunity for C. diff infection. Preventing patient-to-patient transmission would 
preclude the spread of C. diff infection, however complete control by this method is 
difficult in a real world setting. C. diff is a gram-positive, spore forming anaerobe, and 
the spores are notoriously resistant to antimicrobial agents, up to and including bleach 
(476). Once exposed to live cultures or spores, C. diff quickly takes over a compromised 
patients intestinal tract. The presence of the bacillus itself does not always result in 
disease and can be observed in a sub-clinical state in some individuals (477). However 
this is contingent on other gut bacteria keeping the local C. diff population in check. The 
more virulent strains involved in disease onset produce two large glucosylating toxins 
(GT's) which cause large scale tissue damage(370). Infection with C. diff causes a 
range of symptoms, ranging from diarrhea to  pseudomembranous colitis, and toxic 
megacolon(370).  
 C. diff is not the only bacillus known to cause tissue damage by the action of 
glucosylating toxins. There are currently five known Large Clostridial Toxins (LCT's), 
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TcdA and B of C. diff, alpha toxin (Tcn) from C. novyi, and hemorrhagic (TcsH) and 
lethal toxins (TcsL) from C. sordellii. In all cases these LCTs cause massive tissue 
damage, associated with the disregulation of cell signaling(478). The phenotypes 
associated with infection are typically edema, myonecrosis, and sepsis, usually in the 
form of gas gangrene, Toxic Shock Syndrome (TSS) or clostridium difficile associated 
diseases (CDAD). The glucosyltransfer step of these toxins places a glucose moiety 
from a nucleotide sugar onto a variety of Rho GTP-ases. This leads to disruption of cell 
signaling, followed by cell death. The propensity for massive tissue damage coupled 
with the fact that clostridial infections are difficult to treat with antibiotics has recently led 
to a novel approach. Treatment with anti-toxin therapies during an active infection may 
preclude the severe tissue damage that these toxins cause and improve clinical 
outcomes.  Toxin binding polymers, monoclonal antibodies, and epoxide inhibitors are 
all currently being pursued for this purpose, with some success(383, 407, 446, 479-
483).  
 To better design anti-toxin agents however, a thorough understanding of the 
causative agents is essential. An excellent comparison of the genetic structure and 
cellular targets of these toxins was performed by Busch and Aktories(478) in 2009, but 
a considerable amount of structural information has become available since those 
studies. Drug design based on structural and dynamic studies of the GT domain of 
TcdB have proved particularly productive (484). By incorporating information obtained 
through molecular dynamics studies, a potent and irreversible anti-toxin molecule was 
developed. It is with these studies in mind that we undertook a structural comparative 
analysis of the two glucosylating toxins of  C. diff, TcdA and TcdB.  
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 While the structure of TcdB was solved several years ago(408), TcdA has only recently 
been structurally characterized (436) provided a unique opportunity for study. While the 
toxins have a similar domain structure (Figure 1 Panel A), they have some common and 
some unique intracellular targets, and differing levels of toxicity. The overlay in Panel B 
is a superposition of the GT domains of TcdA and TcdB with relevant regions for 
analysis indicated. For the purposes of these studies, the toxins will always be 
presented in this orientation. The protein-protein recognition face, and active site flap 
are in the center, the four-helix bundle responsible for membrane localization is on the 
lower right, and the promontories unique to these toxins are shown at the top. Panel C 
shows a cutaway of the active site, with the glucose donor UDP-Glucose complexed to 
the catalytic manganese ion. In the TcdB crystal structure hydrolysis of this substrate 
occurred, producing a UDP and Glucose, it remains complete in the TcdA structure. 
While the simple structural overlay appears highly homologous, these proteins have 
dramatically different properties on a per-residue level. The initial TcdA structural 
analysis by Pruitt et al included some electrostatics images which seemed to disagree 
with my initial examination of the structure. Upon further examination, it became 
apparent that their "electrostatics" was simply coloring by residue type. This prompted a 
quick coloumbic surface calculation, which revealed a dramatically different surface for 
TcdA than what had been observed for TcdB. This fascinating result led to a deep 
comparative analysis of the two proteins investigating electrostatics, hydrophobicity, pH 
sensitivity and dynamic motion between TcdA and TcdB.  
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0-1 Comparison of TcdA and TcdB.  
(A) Schematic diagram of the domain organization of TcdA/B. Both proteins have conserved 
glucosyltransferase, cysteine protease and translocation domains. The most significant difference is in the 
C-terminal repetitive oligopeptide receptor binding region. (B) Structural superposition of the toxins. (C) 
Structural overlay of the GT-domain active site. Both structures were crystallized with UDP-glucose in the 
active site, however hydrolysis occurred in the TcdB structure, resulting in separate UDP and Glucose 
moieties in the crystal. 
5.2 Comparison of surface properties 
 Full electrostatic surfaces were calculated for TcdA and TcdB using the 
Accelerated Poisson-Boltzmann Solver (APBS) (485). Hydrophobicity, sequence 
similarity, crystal structure RMSD, and charge differentials at pH 7 were all compared. 
Straightforward investigation of electrostatics as well as novel mapping techniques were 
used to determine regions on the structures where pH sensitivity may play a role in their 
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differential activity. Multi-Conformer Continuum Electrostatics (MCCE) calculations were 
carried out along with a computational pH titration to determine residues in both 
structures which show shifted pKa's.  
5.2.1 Surface electrostatics, hydrophobicity and structural similarity at pH 7 
 Figure 2 shows the full electrostatic APBS results of TcdA and TcdB at pH 7 
projected onto an MSMS (Maximal Speed Molecular Surface) surface representation. 
Clockwise from top left, each progressive panel represents at 90° rotation from the 
previous panel. It is notable that on all faces, it appears that TcdB has significantly more 
charged residues on the surface compared to TcdA leading to more electrostatically charged 
surface on the former  
 
0-2 APBS electrostatics at pH 7 projected onto the surfaces of TcdA and TcdB.  
Panel A presents the active site and protein-binding face, with TcdA on the right and TcdB on the left. The 
four-helix membrane localization domain is positioned at the bottom right on this panel. TcdB shows 
considerably more electrostatic character than TcdA in all orientations, Panels B-D represent 90° rotations 
around the y-axis from each previous panel 
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 Panel A orients the active site and protein-protein interface towards the viewer. It 
is notable that there is a prominent negatively charged patch directly on the active site 
interface. Also, between the two upper promontories there is a considerably greater 
amount of negative charge. The four-helix bundle in shows greater positive charge on 
the TcdB structure in all orientations. Panels C and D are striking in that there is a 
dramatic increase in negative character for TcdB relative to TcdA.  
 
 
0-3 Charged residues on TcdA and TcdB 
Charged residues of all types are colored on TcdA and TcdB. Those from TcdA are colored orange,a nd those from 
TcdB are colored blue. It is noticeable that there is a distinct lack of charged residues on the TcdA structure in and 
near the active site, while many of the surface charge has been maintained.  
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 Structural superposition followed by sequence alignment indicates that overall, 
TcdA has far fewer charged amino acids than TcdB does. A full sequence alignment is 
available as Supplementary Figure S1. It was determined that TcdA has 49.54% identity 
with TcdB, increasing to 50.66% if gaps are omitted. Nearly all active site mutations 
(those occurring within 20Å of the crystallographic UDP-Glucose) replace charged 
amino acids with nonpolar residues as shown in Abdeen et al. in press. It is interesting 
to note that although TcdB has many more charged residues in its sequence, the 
tertiary structure for both proteins results in the arrangement of many charged residues 
on the surface for TcdA as well as TcdB. Additionally this results in a lack of charged 
residues in the active site of TcdA.  
 The overall charge distribution at pH 7 indicates that the two proteins, while 
structurally similar, have different surface properties. Figure 4 plots the Kyte-Doolittle 
hydrophobicity on an MSMS surface. Kyte-Doolittle hydrophobicity is based on a 
hydropathy scale derived from experimental observations, applied to a protein structure 
by using a moving-segment approach to determine average hydropathy within a 
segment. Panels A-D are each rotated 90° from the previous frame. Hydrophobic 
regions are shown in orange while hydrophilic regions are shown in blue. Neutral 
residues are shown in white. Panel A orients the toxins with both the protein recognition 
face and active site facing forward.  
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0-4 Kyte-Doolittle hydrophobicity surfaces of TcdA and TcdB 
Toxins are in the same orientation as Figure 2 with the active site and protein-interface located in the center 
of the image. TcdA is on the right and TcdB is on the left. Panels B-D represent 90° rotations around the y-
axis from each previous panel. There is a notable increase in hydrophilicity on the TcdA active site and 
protein interface regions, with an overall slight increase in hydrophilicity on the sides and rear of the protein. 
 More hydrophilic character is observed in the center of the TcdA structure, as 
seen in the center of the top left panel, and the amphipathicity of the membrane 
association bundle is greater than that of TcdB. The hydrophobic areas shown in Panel 
B are nearly identical, while an increase in hydrophilic residues in TcdB is observed in 
panel C. Panel D shows slightly greater hydrophilicity for TcdA on this face. The 
differential distribution of hydrophobic residues on various critical regions, notably the 
protein-protein interface and active site may be relevant for function. TcdA and TcdB 
have different preferential cellular targets(388), and this variability may correlate with 
the electronic or hydrophobic contacts on those proteins. TcdB targets Rac1, 
Rho(A/B/C), RhoG, TC10, and Cdc42 while TcdA targets Rac1, Rho(A/B/C) and Cdc42, 
so while there is some overlap in the targets, there are some unique targets as well.   
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0-5 Similarity metrics applied to TcdA and TcdB.  
Panel A shows the sequence similarity projected onto the structure. Identical residues are colored blue, 
strongly similar residues are colored pink, and dissimilar residues are colored gold. Panel B describes the 
RMSD of the crystal structures for TcdA and TcdB. High RMSD is colored magenta, while low RMSD is 
colored cyan. Panel C projects the sequence-predicted charge differences. Residues with no change in 
charge are colored white, a change of +/- 1 is indicated by purple and a change of +/- 2 is indicated by red. 
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 To better represent the differences in these two structures, we have done a direct 
comparison for several properties and overlaid them on the superimposed structures. 
We have depicted the properties of conservation, crystal structure RMSD and charge 
difference on a per-residue basis as shown in Figure 4 panels A-C.  
 Panel A indicates a measure of conservation between the two structures. 
Identical residues are colored blue, similar residues are colored pink, and dissimilar 
residues are colored gold. Similar and dissimilar residues are defined by the Al2CO 
method using the BLOSUM-62 matrix. The highest region of conservation is in the 
active site center, while high dissimilarity is seen near the protein-protein interface and 
four-helix bundle.  
 RMSD between the two crystal structures was measured and the ribbon 
structures are colored on a gradient from rose to cyan. Structurally, the two proteins are 
highly similar, with the major differences being near the active site flap. This flap is 
mobile during UDP-Glucose binding (Swett et al, Biophys J. in press) and presumably 
this difference is due to the fact that the UDP-Glucose observed in the TcdB structure 
underwent hydrolysis in the crystal and thus represents a EP complex rather than the 
ES state. Other regions with higher RMSDs are the edges of the promontories and the 
four helix bundle, presumably due to the inherent mobility in these regions or  crystal 
contacts. Both the upper promontories and the four helix bundle of TcdB were observed 
to have high mobility in both normal mode and dynamics simulations(449).   
 Absolute value of charge difference is shown in Panel C. Residues with no 
charge difference are colored white, residues with a change of + 1 are colored purple, 
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and + 2 are colored red. Again, charge consistency is conserved in and near the active 
site, with high difference in charge on the upper promontories and on the four-helix 
bundle. There are some residues showing charge alteration near the active site flap, 
slightly more distant from the catalytic center. 
5.2.2 Mapping of electrostatics for TcdA and TcdB 
 To better compare the internal electrostatics of TcdA and TcdB, a novel mapping 
method was applied to allow visualization of the sensitivity of electrostatics to pH 
changes. A pseudo-Voronoi approach was used to assign electrostatic potential as a 
property of each atom closest in space to the center of that Voronoi cell. The atom 
properties were summed per residue, allowing the accurate projection of electrostatic 
potential onto a ribbon structure as opposed to an isolevel volume projection or 
projection onto an MSMS surface. This was done from pH 5.5-8 in half pH unit intervals. 
Once assigned, subtracting the maps at a per-residue level allows us to point residues 
that are sensitive in a given pH range. Figure 5 shows the results of applying this 
mapping method to TcdA and TcdB. TcdA is shown on the top row and TcdB is shown 
on the bottom. Each map was subtracted from its nearest neighbor point, producing a 
spectrum representing pH sensitive residues at each point.  
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0-6 Mapping of pH sensitivity to the structures of TcdA and TcdB 
The change in electrostatic potential across half pH unit ranges was mapped to the ribbon representations of 
the structures. Regions that show altered electrostatics in the given pH range are colored red, with color 
intensity indicating degree of change. 
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 In both structures the region around the active site and protein-protein 
recognition face show the highest pH sensitivity, but interestingly, not in the same pH 
ranges. TcdA shows nearly no pH sensitivity between ph 5.5-6. In the pH ranges 
between 6-6.5, 6.5-7-7.5 and 7.5-8, we see pH response concentrated around the 
protein-protein interface and at higher pH's, near the active site. TcdB behaves radically 
differently, between pH 5.5-6 there is considerable response in the upper promontories 
and protein-protein interface. Between 6-6.5, this sensitivity almost completely 
disappears and a region near the c-terminus of the four-helix bundle becomes pH 
sensitive. Between pH 6.5-7, this sensitivity remains, and some pH response is seen 
proximal to the protein-protein recognition face. As the pH rises to 7-7.5 a number of 
residues in the active site and on the protein-protein interface are strongly pH 
responsive, and this sensitivity is concentrated within the active site at pH 7.5-8. We 
postulate that the differential pH sensitivity may be a factor in some of the functional 
variability between TcdA and TcdB. TcdB is far more lethal to cells and causes cell 
death far more quickly than TcdA. An increased rate of endosomal escape and refolding 
due to its higher pH sensitivity would be one plausible explanation. The pH sensitivity in 
the TcdB four-helix bundle that is not observed in TcdA may be of interest as well. If the 
unfolding and refolding of this helix is a bottleneck in the etiology of intoxication, the 
inclusion of pH sensitive residues might be helpful as TcdB transitions from the 
endosome to the cytosol.  
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5.2.3 Multi-conformer continuum electrostatics applied to pKa shift prediction 
 To further investigate the pH sensitivity of these two proteins, we applied multi-
conformer continuum electrostatics (MCCE) to identify pKa-shifted residues in both 
structures. In TcdB, 13 residues with pKa shifts of more than 2 pH units were found, and 
11 were found in TcdA. Tables with the sequence numbers and quantitative pKa shifts 
are in supplementary information Table 1. For our purposes we wanted to determine 
whether pKa shifted residues were in the regions we had determined as being sensitive 
to pH.  Figure 6 shows side by side the comparison of TcdA and TcdB at pH 7, with pKa 
shifted residues colored in blue. There are a higher overall number of pKa shifted 
residues in TcdA and TcdB, but in both cases, the presence of pKa shifted residues 
corresponds with our predicted pH sensitive regions.  
Table 0-1 MCCE determined pKa shifted residues in TcdA and TcdB 
TcdB TcdA  
Residue  Number 
Calculated 
pKa  
Standard 
pKa  Difference Residue  Number 
Calculated 
pKa  
Standard 
pKa Difference 
ARG 194 0.098 12.48 12.382 ARG 215 0.334 12.48 12.146 
ARG 6 1.284 12.48 11.196 LYS 346 0.459 10.53 10.071 
ARG 158 5.063 12.48 7.417 ARG 302 4.071 12.48 8.409 
LYS 303 4.045 10.53 6.485 ARG 405 4.318 12.48 8.162 
ARG 165 7.379 12.48 5.101 ARG 224 4.563 12.48 7.917 
ARG 16 7.898 12.48 4.582 ARG 67 8.161 12.48 4.319 
HIS 492 2.581 6.1 3.519 LYS 428 6.267 10.53 4.263 
ASP 270 0.592 3.86 3.268 ARG 535 9.07 12.48 3.41 
ASP 310 1.345 3.86 2.515 GLU 22 1.721 4.07 2.349 
ARG 445 10.101 12.48 2.379 GLU 20 1.874 4.07 2.196 
LYS 64 8.317 10.53 2.213 ASP 31 1.731 3.86 2.129 
ARG 455 10.374 12.48 2.106      
LYS 50 8.454 10.53 2.076      
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0-7 Comparison of MCCE predicted pKa shifted residues and electrostatically mapped structures of TcdA 
and TcdB.  
Regions with ph sensitivity are colored red, and residues with predicted pKa shifts are colored in blue 
 As both TcdA and TcdB transit from the lumen of the intestine, through 
endosomal acidification and into the cytosol, they are exposed to a range of pH's. We 
applied the Adaptive Poisson Boltzmann Solver to calculate the continuum 
electrostatics of both toxins across the pH range of 5.5-8. By applying a novel mapping 
method, we were able to highlight the regions that show pH sensitivity in half pH unit 
ranges. Multi-conformer continuum electrostatics calculations were performed to 
determine the positions of pKa-shifted residues. These results were in agreement with 
the pH sensitivity mapping method. TcdB shows higher pH sensitivity than TcdA, likely 
due to the increase in total number of charged residues. Additionally, the regions that 
are pH sensitive differ in the two toxins, with a region near the active site broadly pH 
sensitive on TcdA, and a section in both the protein-protein binding face and four-helix 
bundle showing sensitivity on TcdB. This sensitivity in the four-helix bundle is 
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particularly interesting. If this pH sensitive region assists in the folding or unfolding of 
the membrane localization domain, this may enhance the ability of this toxin to exit the 
endosome or localize to the cell membrane. Further work needs to be done to valdiate 
the prediction that these specific residues affect the differential function of TcdA and 
TcdB during internalization and glucose acceptor binding/specificity.  
5.3 Molecular dynamics applied to TcdA 
 All-atom molecular dynamics simulations of TcdA in the presence and absence 
of UDP-glucose were performed to determine whether there were any dynamic 
differences between TcdA and the dynamic analyses of TcdB present in the literature. 
PCA and GMD were applied to determine both the overall structural motions and event 
patterns in simulation. Solvent analysis, hydrogen bonding and salt bridge analyses 
were performed to determine whether or not the increased hydrophobicity of TcdA 
affects solvent dynamics relative to TcdB.  
 As computational studies on the dynamics of TcdB have already been discussed 
in chapter 2 and 3, we performed molecular dynamics simulations to assess the 
behavior of TcdA in comparison to TcdB. We simulated TcdA in the presence and 
absence of UDP-Glucose for 40 and 20ns respectively. We performed generalized 
masked Delaunay analysis (GMD), as well as PCA and hydrogen bond analysis. These 
experiments were undertaken to determine the extent of similarity in dynamic motion 
relative to the previously published data(449). It was previously shown that the Apo-
TcdB structure had an increased range of motion, higher overall activity in GMD 
analysis, and increased active site solvation relative to the UDP-glucose-bound 
138 
 
conformer. The results of the TcdA simulations echo these results , and are discussed 
below. 
5.3.1 Simulation of TcdA assessed with GMD, PCA and interaction analysis 
 Binding of UDP-glucose decreases the overall activity and flexibility of TcdA, in 
agreement with previous results for TcdB. Figure 7 shows the data from conformational 
analysis of this protein. Panels A and B are generalized masked Delaunay plots, which 
indicate the number of significant and persistent "events" per frame. This can be used 
as a rough gauge of the overall activity of a simulation. Panel A indicates that for the 
Apo simulation, the overall level of activity remains higher than the UDP-glucose-bound 
simulation shown in panel B. The PCA analysis shown in panels C and D largely agrees 
with these results. Crossplots of the eigenvalues for each simulation frame from 
principal component vectors 1, 2 and 3 are shown, along with a breakdown of the 
contribution to total variance expressed as a percentage of total. Overall Panel C 
indicates a lower amount of conformational space explored by the UDP-glucose bound 
simulation than that seen in panel D.  This finding goes hand in hand with the data in 
panels A and B, we observe both lower overall activity, and a decreased amount of 
conformational space explored in the UDP-glucose-bound state. During visual 
inspection of the trajectories, we observed no large scale reorganization in either the 
Apo or bound form. RMSD's were calculated at 1.8Å and 1.6Å for the Apo and UDP-
glucose-bound simulations respectively.  
139 
 
 
Table 0-2 GMD and PCA analysis of TcdA simulated both Apo and in the presence of UDP-glucose.  
Panels A and B plot the number of significant events over the course of the trajectory. Panels C and D show 
the crossplots from the first three eigenvectors of the simulation, along with the proportion of variance that 
each contributes to the total. 
 Hydrogen bonding, solvent-interaction and salt bridge analyses suggest that the 
introduction of the UDP-Glucose increases the stability of the structure. Table 1 
describes these interactions. Interaction type is broken down into intramolecular 
hydrogen bonds, solvent hydrogen bonds, and salt bridges. TcdA and TcdB simulations 
both in the presence and absence of UDP-glucose are presented for comparison. In the 
TcdA simulations, we see an increase in hydrogen bonds upon UDP-glucose-binding. 
This is largely due to the additional backbone stability contributed by ligand binding. 
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 With UDP-glucose bound, the structure is more able to optimize intramolecular 
interactions. We also see a decrease in active site hydrogen bonds, as these are 
physically precluded by the presence of UDP-glucose. With respect to solvent 
interactions, we observe overall increased solvation in the active site and surface 
relative to TcdB, and again, several active site interactions are disturbed by the 
presence of UDP-glucose. During the TcdA simulations, there is an increase in salt-
bridge formation upon UDP-glucose binding. This is in contrast to the TcdB simulations, 
however, several of the salt bridges disrupted in TcdB were in the active site, and are 
physically disrupted by the presence of UDP-glucose. Overall, we have determined that 
TcdA is stabilized by the presence of UDP-glucose, and we see a higher level of 
solvation, relative to TcdB. Differential behavior with respect to salt bridges is due to the 
location of interactions within the structures.  
Table 0-3 Interaction analysis for the simulation of TcdA in the presence and absence of UDP-glucose.  
Interaction type 
TcdA TcdB† 
Apo UPG bound Apo UPG bound 
Intramolecular h-bond 28 39 - - 
Intra-active site h-bond 13 9 - - 
Intra-binding face h-bond 5 5 - - 
Solvent h-bond 68 62 81 77 
solvent-active site h-bond 7 4 1 0 
solvent-binding face h-bond 6 6 1 1 
Salt-bridges 67 74 77 58 
† Reproduced from Swett et al. (In press) 
 Molecular dynamics was applied to determine whether or not TcdA and TcdB 
behave similarly in solution. TcdA was simulated in the presence and absence of UDP-
glucose, and analyzed with GMD, PCA and several interaction analyses. In comparison 
141 
 
to previous simulations of TcdB, the results are largely similar. We observe higher 
activity in the GMD analysis when TcdA is in the Apo form, as well as an increased 
range of conformational motion as shown by PCA. The interaction analysis indicates 
that TcdA has a higher level of stationary water molecules, some of which are 
displaceable upon UDP-glucose binding. As observed in the GMD and PCA, TcdA is 
more conformationally stable when bound to UDP-glucose and this results in a higher 
level of intramolecular interactions. We suggest that the additional backbone stability 
allows the sidechains to optimize their hydrogen bonding networks and salt bridges 
more readily than the Apo form. A decrease in the overall number of salt bridges 
observed on TcdB upon UDP-glucose binding was previously described, and is due to 
the interruption of active site salt-bridges by the substrate.  
5.4 Conclusions 
 We have performed a full electrostatic and dynamic comparison of the clostridial 
toxins TcdA and TcdB. While the proteins have a highly similar overall fold, there are 
significant sequence changes that result in radically different electrostatic properties. 
These were compared across multiple pH's to determine the location, if any of pH 
sensitive residues. A novel mapping method was applied to allow clear visualization of 
these regions. Multi-conformer continuum electrostatics was used to probe pKa shifted 
residues and determine their locations relative to pH sensitive regions. Molecular 
dynamics simulations of TcdA in the presence and absence of TcdB were performed to 
determine whether or not there were significant differences in the mobility of TcdA, as 
compared to literature information on TcdB.  
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In conclusion, we have delineated the effects of the limited sequence similarity between 
TcdA and TcdB on the surface properties of these two toxins. We suggest that while the 
toxins have similar dynamic properties, the alterations in pH sensitivity and 
electrostatics may play a role in both their differential targets, and catalytic efficiency. A 
novel mapping method was developed and applied to indicate regions of pH sensitivity 
across pH ranges. This has discovered a pH sensitive region in the four helix bundle of 
the toxins which may aid in the translocation step, by assisting in the unfolding or 
refolding of the toxins following endosomal acidification and escape. As it has already 
been shown that the cytotoxicity of these proteins can be alleviated by perturbing the 
protein-protein binding face (ref), we suggest that the design of an inhibitor based on 
surface properties of the toxins may be useful as well. Also, as the dynamic comparison 
of TcdA and TcdB indicated very similar behavior in response to UDP-glucose, and it 
has been previously shown that inhibitors targeting TcdA also affect TcdB, we suggest 
that active site binders will likely have cross-toxin activity.  
5.5 Methods 
 Structural superposition was performed using the Needleman-Wunsch algorithm 
in conjunction with the BLOSUM-62 matrix. A gap extension penalty of 1 was selected. 
Secondary structure score was included as 30% of the total superposition score. 
Secondary structure assignments were calculated using ksdssp(Kabsch and Sander 
Define Secondary Structure of Proteins) with an energy cutoff of -0.5, a minimum helix 
length of 3, and a minimum strand length of 3. Within the secondary structure score, 
structural gap-opening penalties were applied as follows. In predicted helices, an intra-
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helix or intra-strand gap required a penalty of 18, and any other gap was a penalty of 6. 
After superposition, a structure-based sequence alignment was generated. The total 
alignment score was 1775.8. The percent identity was calculated based on simple 
alignment (49.54%), and with non-gap columns only (50.66%)  
 Conservation was calculated using AL2CO methods(486). The Independent 
counts method was used for frequency estimation, and conservation was calculated by 
the sum of pairs method. The averaging window was set to 1 and the gap fraction was 
set to 0.5. The Sum-of-pairs matrix again was set to BLOSUM-62, with no matrix 
transformations applied. .   
 Sequence alignment is colored by the ClustalX standard. Conservation is 
represented by bar height. Full height indicates identical residues, 2/3 indicate strong 
similarity, 1/3 height indicate weak similarity. as per AL2CO standards. Charge variation 
is relative to TcdA. Blue bars indicate more positive charge, red bars indicate more 
negative charge. Full height bars indicate a change of +2 charge units, and half height 
bars indicate a change of +1 charge units. RMSD is represented as a gray bar with 
height relative to increasing RMSD per residue. Hydrophobicity coloring was projected 
onto an MSMS surface(487), using the KD method(488).  
 APBS was used for the initial electrostatic calculations(489). The AMBER force 
field was used for the calculation, and output was returned using the APBS internal 
naming scheme. The hydrogen bonding network was optimized and PropKa(490) was 
used to assign protonation states between 5.5-8 in half pH unit intervals. An 
automatically configured sequential focusing multigrid calculation was performed(491, 
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492). For the TcdB structure, this used 193 grid points in all directions for grid-based 
discretization. The focusing calculation was carried out with the following coarse mesh 
domain lengths: x-direction 136.583, y-direction 143.144, z-direction 123.15. Fine mesh 
lengths were: x-direction 100.343, y-direction 104.215, z-direction 92.441. For the TcdA 
structure, this used 225 x-direction, 161 y-direction, and 193 z-direction points per 
processor for grid-based discretization. The focusing calculation was carried out with 
the following coarse mesh domain lengths: x-direction 153.095, y-direction 114.974, z-
direction 126.133. Fine mesh lengths were: x-direction 110.056, y-direction 87.632, z-
direction 94.196. 
 Both grids were centered at the center of mass of the protein structure. No 
mobile ion species were included in the calculation. The biomolecular dielectric constant 
was set at 2, and the dielectric of the solvent was set at 78.54. Point charges were 
mapped to the grid using cubic B-spline discretization(493), and 10 grid points per 
square angstroms were used in surface construction. Ion accessibility coefficients were 
defined based on a molecular surface definition, with an ion accessibility coefficient 
defined by an "inflated" van der Waals model and smoothed by a 9-point harmonic 
averaging(485). The temperature was set at 298.15K for the PBE calculation.  
 Mapping of the density to structure was performed using a pseudo-Voronoi 
approach. All electrostatic potential closest to a given atom was defined as a property of 
that atom, and atom "electrostatics" were summed per residue. This allows 
representation on a ribbon projection or surface. By subtracting the allocated density 
maps it is possible to determine which residues experience changes in the nearby 
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electrostatic field across a pH range. This was performed using the APBS generated 
electrostatic potential maps for both TcdA and TcdB across the range of 5.5-8, in 0.5 pH 
unit intervals.  
 MCCE calculations were run at the standard full level of analysis. pH titration was 
carried out between pH 0-14 at 1 pH unit intervals. Generation of rotamers was carried 
out by creating heavy atom rotamers followed by protonation at low energy positions. 
Using the Dunbrack rotamer library conformers all possible conformations for all 
sidechains were generated. The protein structure was stripped of residues and 
generated with all sidechains in “allowed conformations". Clash tolerance was set at 2Å 
and multiple protonation states were allowed for titratable residues. Structures were 
created with 5000 repacks per conformer were allowed with an occupancy cutoff of 
0.01. Delphi was used to calculate the reaction field energy and pairwise electrostatics. 
Solvent dielectric constant was set at 80, and the 65 grids per calculation were used 
with a target of 2 grid points per angstrom. The probe radius used was 1.4Å, with an ion 
radius of 2Å and a final salt concentration of 0.15 mMol. Monte Carlo sampling was 
used to determine which conformers dominate at each pH. The number of sampling 
steps was set to2000 times the number of conformers generated. Energy was traced for 
50,000 steps per round with a maximum of 1 million microstates allowed during the 
analytical solution step. A protein microstate is a combination of one conformer for each 
residue, any cofactors present, and water. pKa determination is done by determining 
which conformers dominate when we perturb all possible microstates. This was 
performed from pH 0-14, to obtain the pKa of each titrating group. 
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 Both molecular dynamics simulations were done using the CHARMM force field 
with NAMD, on the WSU rocks cluster. The canonical ensemble was used with periodic 
boundary conditions, Langevin dynamics and thermostat. Simulations were monitored 
by GMD, and simulation stability was assessed using the trajectory analysis tools under 
VMD monitoring energy and RMSD. The systems were solvated with TIP3P water, 
neutralized with counterions and minimized for 1000 steps of conjugate gradient 
minimization. A smooth ramp to 300K was used to bring the simulation to production 
temperature. A 1 fs timestep was used in the calculation and frames were written every 
1ps. Both simulations consist of approximately 57,000 atoms, with approximate box 
dimensions of 100Å x 70Å x 80Å. The solvation box includes a 10Å pad on each face of 
the box. Short range electrostatics were calculated with a non-bonded cutoff of 8Å, with 
switching between 7-8Å. Long range electrostatics were calculated with the smooth 
particle mesh Ewald method. Results were analyzed by GMD, PCA and assessed for 
hydrogen bonds, solvent interactions and salt bridges. Timescapes, bio3d for R and 
VMD were used for these calculations, respectively. For the hydrogen bond analyses, 
intramolecular hydrogen bonds were considered stable if they were present for 50% of 
the simulation or more, and solvent-protein hydrogen bonds were considered stable if 
they were present for 90% of the simulation or more. For the purpose of categorizing 
these interactions, "active site" residues are those within 10Å of the crystallographic 
UDP-Glucose, and "protein-protein interaction face" residues are those between 440 
and 497 as this region encompasses all known residues critical for protein-protein 
association(411, 413, 415).  
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Chapter 6 CoGent-Seq: Connecting genes to sequence. Relating motif  
                 sequences to annotated gene structures. 
 
6.1 Background  
 As increasing interest in protein binding motifs and regulatory elements develops, 
determining which genes contain these elements is required. Genome is a program designed to 
quickly search regions of a genome near either the 5' or 3' UTR for a pattern, and to return a 
user defined segment of genome for analysis. It can be applied to any genome, and any given 
set of annotations. It is capable of matching multiple patterns and returning a true/false match 
for each query. This program is user-friendly, requires minimal user interaction with input, and 
returns data ready for analysis via blast, structural characterization  or statistical analysis. To 
date it has been applied to searches for Dcm methylation sites, and Hfq binding sites in 5' UTRs 
of the E.Coli genome. This chapter will include a brief description of the application of CoGent-
Seq to the search for Hfq mediated regulatory sRNA's.  
 Detection of consensus sequences and recognition motifs can be performed by 
employing statistical methods to detect enrichment of various sequences in a genome. From the 
perspective of a molecular biologist however, detection of consensus sequences or motifs is 
largely informed from wet lab studies. Much of this research is focused on regulatory elements 
in either the 5' or 3' UTR, with novel sequences being reported frequently. Once found 
experimentally, exploration of these sequences within a genome may be attempted, but without 
simple, user-friendly tools, this may be a daunting prospect for a molecular biologist. It is tedious 
and time consuming to perform these searches by hand, and so here we present software 
capable of automating this task. Given a sequence such as a protein recognition motif, 
modification flag, or contextual region within a noncoding RNA, CoGent-Seq will return a list of 
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all genes containing that motif within a user specified region at either the 5' or 3' end of a gene, 
along with a segment of sequence to facilitate further analysis.  
6.2 CoGent-Seq 
 
 A user need only supply the genome for query in the form of a FASTA formatted text file, 
the positions of interest for searching nearby as a .csv formatted list, the pattern or patterns to 
match (i.e. AATTCCGG) and the region the user would like excised for further study if desired. 
The entire program was written in Java, so as to facilitate cross-platform use. It can be used 
either command line or with a GUI, both of which are distributed as executable jar files. Results 
are given as a csv formatted table returning the start site, the motif or motifs searched with a 
true/false identifier, and the segment of sequence requested by the user. For negative sense 
genes, This is ideal for RNA studies where immediate secondary structure prediction of the 
region is required.  
 
 Figure 1A shows the graphical user interface, while Figure 1B shows a typical workflow 
for this software. Upon selecting the version of a genome appropriate to a researchers work, the 
number of nucleotides to the 5' and 3' regions are declared, as is the motif of interest. Any 
number of motifs may be searched simultaneously. The list of either 5' or 3' sites appropriate to 
the organism of study is required in .csv format, which is readily available from several 
databases. Output is returned in two .csv formatted files. The “sequence hits” file returns the list 
of start sites, and reports whether each motif has been found. The “data export” file returns the 
segment of sequence requested by the user for each start site region that contains the motif 
requested. These are semicolon separated for use with either BLAST searches or Mfold 
analysis.  
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6-1 Graphical user interface and workflow for CoGent-Seq 
CoGent-Seq requires minimal user inputs. The graphical user interface in panel A, 
describes these fields. From top to bottom, length of search into 5' and 3' regions, 
sequence to match, a list of annotations for searching, a genome in fasta format, and 
then filenames for data export. A sample workflow would include selecting an 
organism of study, downloading the genome and annotations, applying the search by 
selecting a motif and local range for the search, and CoGent-Seq returns both a list 
of genes containing that motif, and the sequences queried.  
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6.3 Application to E. Coli Hfq-mediated sRNA regulation.  
 A first application of CoGent-Seq to a bacterial system involved the search for Hfq 
mediated sRNA-mRNA interactions in E. Coli. Hfq is known to assist in regulatory RNA function 
for several stress-response systems, and it has a known putative binding sequence. CoGent-
Seq was applied to find all mRNAs in E. Coli containing the sequence AAYAA, to which Hfq 
binds. It was later determined that AAYAA is a subset of the Hfq binding sequence (ARN)x, 
where x=2 or more. The purpose of these studies was to attempt to find novel regulatory sRNA-
mRNA pairs employing Hfq as a chaperone. Following the initial bioinformatics search, Martha 
Faner pursued the prospective mRNA's and performed both structural bioinformatic analysis 
and in vitro testing. 
A list of all E.Coli gene start positions and sense were obtained from the EcoGene 
database and formatted as a .csv file(494). The genes were sorted by sense, and the start 
positions for both forward and reverse sense genes were output to separate files. A search was 
performed across the E. coli K-12 genome wherein the region from -200 to +60 was searched 
for the sequence AATAA or AACAA, setting zero as each gene start position iteratively. The 260 
nucleotide range and start position were outputed into a .csv file by line for all lines containing 
either the AATAA or AACAA sequence. This process was repeated for all negative sense genes 
using the E.Coli K-12 genome complement strand sequence.  Start position was matched back 
to gene name for systems analysis and the extracted 260 nucleotide region was submitted to 
mfold for structural analysis. Annotated transcription start sites for the biocyc database were 
used to discard any mRNA that contained and AAYAA in the region -200 to +60 but within the 
start site(495).  
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Martha Faner subjected the results of this CoGent-Seq search to structure 
approximation, assessment of sRNA potential binding partners, followed by in vitro testing. 
Structural assessment of known Hfq mediated mRNAs indicates that Hfq prefers a single 
stranded ARNx motif, flanked by structure. The mRNAs returned from this search were 
subjected to the folding predictor mfold, and mRNAs without ARNx sites meeting this structural 
requirement were discarded. This leaves a pool of roughly 20% of the annotated E.Coli mRNA's 
with potential Hfq mediated sRNA regulation. These were then subjected to sRNA matching 
using IntaRNA, resulting in a list of mRNAs with potential sRNA binding partners (M. Faner 
unpublished data).  
Two mRNAs were selected for further study, nhaA and mak, both having logical 
connections to the type of stress-response typically mediated by Hfq. nhaA encodes a sodium 
antiporter used to maintain pH and sodium levels (496). mak endcoes a mano(fructo)kinase 
which participates in fructose metabolism (497). Their IntaRNA predicted partners were RhyeB 
for mak and RyfA for nhaA. Using electromobility gel shift assays it was determined that in the 
presence of Hfq, ternary complexes of the two RNA binding partners in complex with Hfq were 
stable. An in vivo GFP assay was applied to determine whether or not these interactions were 
regulatory in nature. It was determined that in the presence of RyfA, the expression of NhaA 
was downregulated. This constitutes the successful discovery of a novel sRNA-mRNA 
regulatory pair. 
6.4 Conclusions 
 The discovery of numerous novel regulatory elements in recent years, along with the 
increasing interest in  regulatory pathways is placing a demand on computational chemist to 
produce user friendly tools that can both inform and be informed by experimental data. CoGent-
Seq is a simple, yet powerful tool that facilitates broad study of regulation at the 5' or 3' UTR, by 
individuals that may have varying levels of bioinformatic experience. Basic user input 
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requirements, along with a streamlined GUI and easy to parse output allow users with little to no 
interest in computational methods to easily perform genome wide analyses. Following the 
experimental detection of a regulatory or protein binding sequence, the results from a CoGent-
Seq analysis will indicate which other systems may be involved through the same regulatory 
element. In application to E. Coli regulatory RNA systems chaperoned by Hfq, this led to the 
discovery and validation of one completely novel interaction. The purpose of CoGent-Seq was 
to provide a simple interface that provides initial motif searching  for deeper bioinformatic or in 
vitro discovery. While this is only one of many possible applications of CoGent-Seq, it is an 
excellent illustration of the potential of this tool.  
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Chapter 7 Hypothesis Driven Single Nucleotide Polymorphism Search  
                (HyDn-SNP-S)3  
7.1 Background 
 In recent years, the amount of genomic data on disease phenotypes has increased 
exponentially. The decreasing cost of genotyping, along with the future promise of personalized 
medicine has resulted in a boom in individual genomic data (498-502). Most bioinformatic 
techniques determine clusters of mutations that may be followed and used as a diagnostic tool 
in various diseases (503-506). Traditional analysis of genome wide association studies (GWAS) 
focus on a single phenotype, and aim to find SNPs that show statistically significant association 
with the phenotype in any of the measured genes. In most cases these analysis do not have an 
a priori hypothesis of the locations of the SNPs. Therefore, very stringent statistical criteria are 
needed to obtain SNPs that are predictive, resulting in only a small number of SNPs being 
identified. Few studies have leveraged the vast information generated to identify new SNPs with 
clear functional impact on disease onset (507-510). 
 Moreover, tracking a mutation resulting from these SNPs through transcription and 
translation to their ultimate effects in a cell is largely left to the scientific community at large. In 
addition, correlating a mutation to a phenotype is a daunting task for researchers who typically 
work at a cellular level. Most biochemists or molecular biologists have a biosystem of interest, 
and broad sweeping GWAS studies are typically intractable for their purposes. It was our intent 
to create a tool that would allow a user to query genome-level data for their system of interest. 
There have been examples previously where this has been done on a single GWAS study, but 
not on combined data sets(511). To this end, we developed and implemented an algorithm with 
which a researcher can directly query one or several GWAS studies for their gene region of 
                                                          
3
 Sections of Chapter 7 have been previously published (DNA Repair In Press) 
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interest. We term this method Hypothesis Driven SNP Search (HyDn-SNP-S). The software 
returns all SNP mutations within their gene region, along with regarding the phenotype 
associated with the mutation. Further statistical methods can then be applied to the GWAS data. 
Additionally, by returning a focused set of mutations, tracking the consequences of the 
mutations through transcription, RNA processing and translation becomes trivial. 
 The workflow shown in Figure 1 outlines the process used in HyDn-SNP-S. Researchers 
can select one or many studies associated with the phenotype(s) of interest, apply HyDn-SNP-S 
to search for their gene of interest, and further analysis can be performed, as desired, on the 
output. Our program returns both intronic and exonic SNPs, allowing the investigation of impact 
on RNA, processing or protein sequence. The simplicity of the software implementation makes 
this method ideal for researchers uncomfortable with large-scale bioinformatic analyses, or 
those who lack the resources to perform such studies. 
  
Figure 7-1 : Flowchart of the HyDn-SNPs method.  
Upon development of a hypothesis, researchers select GWAS studies with relevant phenotypes, and obtain 
locations of the genes of interest. Following application of the algorithm, SNPs can be separated by intronic 
or exonic. Further analysis can be performed by in vitro validation or computational studies. 
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 The database of Genotypes and Phenotypes (dbGaP, http://www.ncbi.nlm.nih.gov/gap) 
was developed to "archive and distribute the results of studies that have investigated the 
interaction of genotype and phenotype". Results are distributed in the form of either raw 
genotyping data tagged with individual specific data such as gender, race and onset of 
phenotype; or as catenated lists of SNPs. This repository provides an ideal source of GWAS 
data useful to researchers with a targeted interest. Users are able to freely download the sets of 
SNPs, in a standard format for use with our software. Any phenotype of interest that is 
represented in this database would be a possible point of study for a HyDn-SNP-S study. 
 In this chapter, we present the development of HyDn-SNP-S and its application to 
search for cancer related SNPs on DNA polymerases and Histone Deacetylases. These 
enzymes are involved in all processes related to DNA duplication. The efficiency and fidelity of 
the processes involved with duplication of DNA are critical since errors can lead to 
carcinogenesis. Numerous studies indicate that mutations in DNA polymerases affect 
characteristics ranging from fidelity, to nucleotide incorporation rate, to cell proliferation (450, 
512-522). However, a direct link has not been established between these mutations and cancer 
onset.  
 Our results uncovered a large number of cancer related SNPs on DNA polymerases. 
Statistical analysis on selected studies reveals for the first time the possibility that DNA POLL 
could be a major contributor to cancer risk. Molecular dynamics simulations were performed on 
wild-type and a SNP mutant on POLL to further investigate the functional impact of the 
mutation. 
7.2 Hy-Dn-SNP-S 
 The HyDn-SNP-S method returns results from whole genome genotyping studies 
rapidly, far faster than traditional bioinformatic methods. Pre-screening with HyDn-SNP-S 
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dramatically decreases the time required to perform statistical analysis on GWAS data, by 
excluding all mutations not relevant to a researcher’s hypothesis. As proof of concept four 
genotyping studies have been statistically analyzed following application of the HyDn-SNP-S 
method. Additionally, one mutation, determined to be both statistically significant and of 
structural interest, was subjected to molecular dynamics studies and subsequent analysis.  
7.2.1 Application to cancer phenotypes 
 Hy-Dn-SNP-S was applied to four cancer phenotype studies, melanoma, breast, lung 
and prostate cancer (523-528). A search for mutations in all polymerase genes was performed, 
resulting in a total of 708 cancer associated mutations. Of these mutations, 491 were intronic, 
and 217 were exonic. Additionally, four of the exonic mutations were found to be at splice sites. 
As per the workflow described above, all four searches were carried out simultaneously, and 
results were available within a few minutes. The four studies were subjected to traditional 
biostatistical analysis (529) following application of the HyDn-SNP-S. The focused nature of the 
search allows for relaxation of the more stringent mathematical methods, and facilitates more 
thorough analysis of the resulting mutations. Haplotype analysis on whole genome genotyping 
data is frequently not performed since the combinatorial nature of these studies across all 
mutations would be prohibitively expensive, computationally speaking. As the dataset used for 
analysis following the HyDn SNP-S method has significantly reduced complexity, these targeted 
studies can detect mutations of moderate significance that would be overlooked in traditional 
bioinformatic analyses and perform these searches more rapidly than is typically possible. 
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7.2.2 Statistical analysis 
 Logistic regression and haplotype analysis was performed on the resulting SNPs to 
determine their statistical significance. Results are presented in Table Table 7-1: 
Table 7-1 DNA polymerase SNPs correlated to four cancer studies 
 
 
 
 This data is shown in The GWAS for prostate cancer yielded 69 SNPs in the genes of 
interest. Association of 11 SNPs with prostate cancer was statistically significant for at least one 
genetic model. The melanoma cancer case/control database examined yielded 215 SNPs in the 
genes of interest. Twenty-six of them were significantly associated with disease status for at 
least one genetic model after controlling for age and gender. The breast cancer study yielded 
100 SNPs in the genes of interest. Twenty-two of them were statistically significantly associated 
with breast cancer status for at least one genetic model. The lung cancer case/control database 
examined yielded 51 SNPs in the genes of interest. Twenty of them were statistically 
significantly associated with lung cancer status for at least one genetic model. Table 7-2 reports 
the identities of the significant SNPs, their p-value and corresponding POL gene. 
 Analysis to determine the association between the derived haplotypes from each gene 
and disease status was performed. No haplotypes were predictive of disease status for the lung 
cancer study nor the melanoma study using any of the three genetic models. However, the 
haplotypes constructed from SNPs on POLL were borderline significant for the breast cancer 
study using a recessive (p-value = 0.048) or additive (p-value = 0.091) model formulation. This 
haplotype is constructed from two SNPs: rs3730477 (C>T; R438W) and rs3730463 (A>C: 
T221P). The odds ratios from individual significant and borderline significant contrasts within 
Phenotype Total SNPs  Significant 
Prostate 69 11 
Melanoma 215 26 
Breast 100 22 
Lung 51 20 
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each model type are reported below.  In the case of the additive model, for each additional C-A 
haplotype observed, the odds of breast cancer are multiplied by 1.15, (p-value =0.029). 
Similarly, for each additional C-C haplotype observed, the odds of breast cancer are multiplied 
by 0.812 (p-value =0.062), i.e., a protective genotype. For the recessive model, having 0 or 1 
copy of the C-A haplotype results in the odds of breast cancer being multiplied by 0.829 relative 
to having 2 copies of the C-A haplotype (p=0.026). Having 0 or 1 copy of the C-C haplotype 
results in the odds of breast cancer being multiplied by 3.01 relative to having two copies of the 
C-C haplotype (p=0.099).  The haplotypes constructed from SNPs on the PolG genes were 
significant for prostate cancer.  This haplotype is constructed from three SNPs: rs3087374, 
rs2351000 and rs2247233. The odds ratios from individual significant contrasts within each 
model type are reported below.  For the recessive model, having 0 or 1 copy of the G-T-G 
haplotype results in the odds of prostate cancer being multiplied by 1.33 relative to having 2 
copies of the G-T-G haplotype (p=0.005). Having 2 copies of the G-C-A haplotype results in 
9.64 of the odds of prostate cancer as compared to having 0 or 1 copy of the G-C-A haplotype 
(p=0.008).  
  A literature search indicates that only one of these statistically evaluated mutations has 
been explored in vitro (530). Experimental analysis of the mutations we report here is outside 
the scope of this work. However, the mutations arising from these SNPs present interesting 
targets for further experimental studies.  
7.2.3 Edge-Node Analysis 
 The data resulting from a HyDn-SNP-S search can be discussed at the molecular level, 
and in the context of predictive power, but due to the nature of these studies, it also allows a 
much broader basis of understanding. Relating many phenotypes to many polymerases 
generates a network of data best represented by an edge-node interactive diagram. Using the 
number of SNPs as a weighting property, it is possible to broadly examine the complete network 
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of phenotype-polymerase interactions. Figure 2 shows a flattened version of this data, limited to 
statistically explored phenotype data, which is available in interactive form online at 
http://chem.wayne.edu/cisnerosgroup/gexf-js2/index2.html 
 
Figure 7-2 Edge-node network of the HyDn-SNPs results.  
Phenotypes  and polymerases are shown as nodes, edges are weighted by total number of SNPs connecting 
each phenotype to each polymerase. Statistically validated connections are shown in red. 
 The complete dataset is also available in this form. Both polymerases and phenotypic 
studies are represented as nodes, sized according to SNP density. By clicking on a node, all 
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connections to that node will be listed. Clicking on any of those connections will return all 
connections to that selected node.  
 The interactive map allows investigation of the network associations of various 
phenotypes and polymerases and the complete list of connections is available for download 
from the top of the page. This file also includes the translated mutations. Many diseases are not 
caused by a single point mutation, but rather by a collection of factors. As the formatting for the 
results of HyDn-SNP-S is well suited to network analysis, and additional data can be garnered 
as desired from the genotyping studies, this approach may have critical importance in searching 
for combinations of factors that may be predictive for disease. Due to the targeted nature of the 
search, there is a significant reduction in the analytic space and thus, more thorough analysis 
can be performed. The haplotype described above is one example; individually the two 
mutations would have been overlooked by traditional analysis, but in combination they are 
strongly predictive. 
7.2.4 Molecular Dynamics investigations of DNA Polymerase λ mutant R438W 
 
 To further validate that hypothesis driven analysis of whole genome genotyping data is 
valuable to researchers, we sought to study a mutation with statistical significance that would 
have been overlooked by traditional methods. Of the two mutations that comprise the haplotype 
linking POLL to breast cancer, only the mutation R438W is in the polymerase domain. This 
position is not close to the active site, but it is within 14 Å of Loop 1, which has been shown to 
be critical for fidelity (531). The R438W SNP mutation has been previously shown to contribute 
to decreased fidelity in vitro, increased mutation frequency, and generation of chromosomal 
abnormalities (532). An 8-fold increase in inaccurate substitutions was observed in base 
substitution assays and karyotypic analysis of several cell lines carrying this mutation also 
reported a high level of spontaneous or IR-induced chromosomal aberrations. With ample 
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evidence to suggest a molecular basis for these results, we selected DNA polymerase lambda 
R438W for further study.   
 Four MD simulations were performed using crystal structures 1RZT and 2PFQ. These 
structures were selected as they represent the binary and ternary complexes of Pol Lambda, 
respectively. The change in Loop 1 conformation between the two structures is shown in  Figure 
7-3 panel A. Panel B shows a closer view of the loop conformations, indicating both binary and 
ternary conformations. Panels C and D illustrate the relative proximity to the R438W mutation. 
As the structure transits between the two loop conformations, the mutation ranges from roughly 
12.6 Å to 14.3 Å away. Mutations in this loop have been shown to have no effect on catalytic 
rate while simultaneously increasing the number of misincorporations, thus Loop 1 is critical for 
polymerase fidelity (531). Following a 14 ns simulation, correlation analysis was carried out to 
determine whether the residues in Loop 1 were affected by the mutation.  
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Figure 7-3 Structure and relevant regions of PolL  
 binary and ternary conformations. DNA is shown in light blue, and the Loop 1 is 
shown in purple. (B) Differences in loop 1 orientation between the two conformations. Distance between 
position 438 and loop 1 following an interpolation between the two structures at its furthest (Panel D) and 
closest (Panel C) approaches. 
 
7.2.5 Correlation and GMD analysis of PolL R438W 
 
 These simulations were analyzed by both GMD and correlation analysis. Details of GMD 
analysis were described in Chapter 2.7.4. Briefly, it calculates the number of significant and 
persistent motions experienced by a structure, and plots them against frame number. This gives 
an approximation of the overall level of activity and can be used for event detection. Correlation 
analysis can determine whether residues are moving in the same direction in space 
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(correlation), or opposite directions at the same time (anti-correlation) through the course of a 
trajectory. Specific residues or regions on a protein that show correlation frequently have 
structural implications for function(533). This is plotted on an orange to blue scale with color 
intensity depicting high correlation or anti-correlation. Residues whose motion is unrelated are 
presented in white.  
 As shown in Figure 7-4, the binary complex shows little change in correlation between 
the wild-type and mutant structures. Conversely, the ternary complex shows high correlation 
and anti-correlation in two regions. The highest points of correlation are between residues at 
position 438 and 569, as well as between 438 and 420. Residues showing the greatest change 
in correlation in the ternary complex were mapped to the structure and colored orange as shown 
in Figure 4C. It is notable that a majority of these residues are on Loop1. To further understand 
the impact of the SNP mutation on Loop 1, the correlation data between position 438 and all 
residues in Loop 1 was extracted and plotted. Figure 4D shows that although there is higher 
correlation in the ternary complex between the wild-type and mutant, both complexes show 
altered correlation between the wild-type and mutant. The sum of these analyses suggests that 
the introduction of the R438W mutation alters the overall correlation pattern in the ternary 
complex, but more importantly, directly affects the motions of Loop 1 in both complexes. Since 
loop 1 regulates fidelity, and transit between the two conformations shown in Figure 3 is 
required for catalysis, the SNP leading to the R438W mutation likely has direct effects on 
polymerase activity in vitro and in vivo.  
 In addition to the correlation analysis, generalized masked Delaunay (GMD) analysis 
was performed to determine the impact, if any, on the overall dynamics of the protein (during the 
simulation time). The results are shown in Figure 5, events are plotted on the Y-axis, and frame 
number is plotted on the X-axis. GMD defines events as persistent motions across the masked 
Delaunay reduced representation of the protein structure. Panels A and B show the wild type 
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activity for both the binary and ternary complexes, with average activity levels of roughly 0.2 
events per frame. These patterns are typical of stable simulations, where no major 
rearrangement is occurring. The alteration in the correlation plots combined with the stability of 
the GMD indicates that the mutation induces only local alterations in activity.  
 The sum of the correlation and GMD analysis indicates that the R438W mutation 
appears to modify only the movement of Loop 1, while the overall dynamics are not significantly 
altered. This provides context for the experimental work by Terrados et al (532). Their 
experiments indicated that the R438W mutation increases the error rate of Pol lambda, but does 
not alter the overall rate of polymerization. Our results indicate that the R438W mutation alters 
only the behavior of Loop 1, while leaving the overall conformational motions of Pol lambda 
unperturbed. This would agree with the behavior observed experimentally. The R438W mutation 
alters the behavior of Loop 1, thus decreasing fidelity, while the overall behavior of the 
polymerase is unaffected, allowing it to maintain a normal rate of polymerization.  
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Figure 7-4 Correlation difference plots for the binary (A) and ternary (B) conformations relative to the wild 
type. Highly correlated residues are shown in orange (C) and total correlation for residues in Loop 1 is 
shown in (D) 
 Increases in correlation are shown in orange, while increases in anti-correlated motions are shown in blue. 
In both cases, alterations in the correlation plots are visible, more notably in the ternary complex. The 
highest values from the ternary complex correlation plots were mapped back to the residues affected, and 
are colored orange in Panel C. Notably many of these residues are on Loop 1. Panel D shows the individual 
correlation values for each of the residues in Loop 1. While the binary complex shows moderate alteration on 
several , the ternary complex shows considerable differences for several residues, particularly between 
residues 469 and 472. 
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Figure 7-5 : GMD plots for the binary and ternary complex simulations in both wild type and mutant form. 
 No drastic differences are apparent between the four simulations indicating that all four are showing the 
same general level of physical activity. This result indicates that the overall motions of the polymerase are 
not perturbed by the presence of the mutations. In light of the data presented in Figure 4, this indicates that 
the significant alterations in conformational space are restricted to the Loop 1 region. 
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7.2.6 Associated Studies 
 During the development of this project, HyDn-SNP-S was also applied to Histone 
Deacetylases (HDACs). Further analysis of many of these projects is pending, but the work on 
HDACs has proved interesting. HDACs are responsible for the modification of histone tails 
during the process of chromatin repacking, and several have been known to be implicated 
cancer, including breast and colon (534-540). Following application of HyDn SNPs to HDACs 
1,3, and 6, several mutations were both detected and pursued in various manners. Mutations 
found in HDAC 3 correlated to breast cancer were determined to be near the active site, and 
thus docking studies were performed to determine whether or not substrate binding was 
affected. Figure 7-6 shows the locations of the two mutations.   
 
Figure 7-6 Two mutations on correlated to cancer mapped to HDAC3. 
The Arg 265 mutation was determined to be in proximity to the typical SAHA binding site. Comparative 
dockings were performed to determine the possibility of altered substrate binding. Shown in blue is the 
inhibitor SK-691.  
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 The R265W was determined to be adjacent to the natural substrate binding site, and a 
library of known HDAC3 inhibitors were docked to the structure (PDBID:4A69) to determine 
whether or not this mutation might have implications in the treatment of breast cancer. Following 
docking to both the wild type and mutant HDAC3, the docking scores were calculated. As 
shown in Table 7-2, several of the inhibitors show preference for either the mutant or wild type. 
Negative scores indicate preferred binding to the wild type, while positive scores indicate 
preferred binding to the mutant.  
Table 7-2 Table of inhibitors showing preferential binding to wild type or mutant HDAC 3
†
 
Inhibitor WT R265P Δbinding 
SK-691 -33.01 -36.86 3.85 
SK-692 -31.36 -33.64 2.28 
SK-683 -30.89 -30.73 -0.16 
SK-658 -27.57 -30.8 3.23 
TSA -25.25 -22.96 -2.29 
APHA-1 -22.47 -24.06 1.59 
APHA-8 -20.63 -24.67 4.04 
SAHA -18.83 -21.55 2.72 
CG1521 -16.18 -15.3 -0.88 
† Inhibitor structures were retrieved from Wang et al (541). Docking scores of Wild type and the R265P 
mutants are shown, Δbinding is the difference in LeadIT docking scores.  
 
 These studies indicate that a breast cancer-associated SNP in HDAC3 may have 
implications for treatment based on differential substrate binding. Isoform specificity is a 
problem for drug design with respect to HDACs as their high degree of similarity leads to off-
target inhibition. It may be possible in the future to determine if a specific drug may be 
preferable for treatment depending on the gene sequence of the individual patient.  
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7.3 Conclusions 
 We have developed a powerful method that allows researchers to interact with whole 
genome genotyping data in a focused, hypothesis driven way. By allowing researchers to find 
data on their own systems of interest, we will expedite the study of any mutations that may 
logically be connected to a phenotype. Also, the focused nature of these searches will allow 
more thorough statistical analysis, and appropriate recognition to combinations of factors that 
would be difficult to fully assess in an extremely broad GWAS analysis. By applying this 
methodology to our system of interest we were able make the first direct statistical link between 
DNA polymerases and cancer, define two haplotypes with strong predictive power, and trace a 
cancer-associated mutation to a structural effect in the translated protein and investigate its 
functional impact by computational simulations. Furthermore we were able to extend these 
studies to several other systems, one of which has shown promise in the development of 
isoform specific histone deacetylase inhibitors.  
 
7.4 Methods 
 In this section we describe the algorithm to search for disease related SNPs based on a 
given hypothesis and its implementation in an easy to use software package. Subsequently we 
describe the statistical methods to determine the association of the SNPs with the phenotype. 
This is followed by a description of the graph analysis of the resulting data from HyDn-SNP-S 
for the present studies. Finally, the details of molecular dynamics (MD) simulations on DNA 
polymerase lambda structures are described. 
 HyDn-SNP-S:  SNP collections deposited through studies on the database of genotypes 
and phenotypes are obtained. A header is appended to the data declaring the phenotype 
associated with each individual mutation. Mutations listed relative to the HuRef and Celera 
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genomes are removed, as we are working within the frame of reference of the GrCh37 human 
genome reference build. The SNP collections are then catenated into a searchable resource 
file. Following generation of this resource file, the program HyDn SNPs was used to search for 
mutations within the gene region of interest. Users enter the chromosome, and gene range for 
searching, and point the program to the resource file. Sample resource files are available with 
the HyDn SNPS download. Further information and instructions are available in the 
documentation for this program. Any SNPs found that match the chromosome and gene 
location range are deposited into a results file. This file lists all the SNP associated information, 
such as ss and rs number, allele, chromosome, chromosomal location, contig number, and 
contig location, and type of chip used in the original genotyping experiment. These can then be 
categorized by location; intronic, exonic, or at a splice site. For our purposes, exonic SNPs were 
then compared to reference SNPs to ascertain the extent of prior investigation, as well as 
relative allele frequency in the natural population. The consequence of any given SNP was 
determined either by use of the reference SNP database, or in the case of previously 
unreported SNPs, translated by use of a DNA codon table in conjunction with the gene 
sequence and protein sequence. HyDnSNPs is available for download at the link provided in the 
abstract. 
 Statistical Analysis: We utilized four publically available case/control genome wide 
association studies (GWAS) from dbGAP (access request # 1961) across multiple cancer types 
(including breast, melanoma. lung and prostate cancers)(14, 523, 524, 526-528) to determine if 
SNPs or haplotypes constructed from SNPs in our genes of interest are associated with a 
disease phenotype. Additionally, we determined if any synergistic results across multiple 
databases exist that may imply a common cancer genesis. Multiple genetic modes of 
inheritance were examined: additive, dominant, recessive and genotypic in a covariate-adjusted 
logistic regression analysis associating each SNP with the disease phenotype. The maximum 
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likelihood estimate of the posterior probabilities of haplotypes for each observation was 
produced using the EM algorithm. Score statistics for the association of the haplotypes with the 
cancer phenotype were constructed using these posterior probabilities. We use the R package 
“haplo.stats“ to implement these haplotype functions (529). Logistic regression is also used to 
estimate the association of a haplotype with the disease phenotype, given the genetic context. 
As we focus on the SNPs in only a few genes, we avoid issues with multiple testing, which are 
burdensome when trying to evaluate the association between genetic markers and a disease 
phenotype when measuring thousands or millions of genetic variants.  
 Graph analysis: For ease of visual analysis, the data resulting from the HyDn-SNP-S 
search has been transformed into edge-node format to allow visual interpretation of the 
networks of phenotypes and polymerases involved in tumorigenesis. Frequently more than one 
polymerase was found to have single point mutations within a cohort of cancer patients; network 
analysis allows for easy visual interpretation. Edge-node tables were csv formatted for use in 
Gephi (542), visualization was performed with a Fruchterman-Reingold (543) algorithm using an 
area of 15,000 and a gravity of 7.0. Nodes and edges were weighted by degree; for these 
analyses, weight was the number of mutations occurring between each phenotype and 
polymerase.  
 MD simulations: MD was performed on wild-type and the R438W mutant of POLλ in the 
binary and ternary conformations (PDBID: 1RZT, 2PFQ) using NAMD. The simulations were 
performed using a parallel build of NAMD(428) employing the CHARMM(429) force field on the 
XSEDE Teragrid. The structures were solvated, and appropriate counterions were added to 
reach 0.5mM NaCl. A timestep of one femtosecond was used, a Langevin thermostat was used 
to maintain temperature at 300K, and a Nose-Hoover Langevin combination method was used 
to control pressure. The systems were solvated with TIP3P water, neutralized with counter ions 
and subjected to 1000 steps of conjugate gradient minimization and temperature ramped to 
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300K. After equilibration, the systems were run for at least 14 ns of production time. Frames 
from the trajectories were written every 1 ps. The solvation boxes included a 15 Å pad on each 
face of the box. Long range electrostatics were calculated using particle mesh Ewald (441), and 
van der Waals were calculated with a nonbonded cutoff of 8 Å and a switching function between 
7-8 Å. 
 Correlation analysis: Correlation analysis by residue was carried out for each system 
using the ptraj module of Amber11, across the entire simulation. An all residue correlation was 
performed and difference plots were calculated using Mathematica (544).  Correlation between 
the mutated residue and the residues in Loop 1 were also calculated and plotted.  Generalized 
Masked Delaunay analysis was carried out using the TimeScapes software from the D.E. Shaw 
group (442). Trajectories were prepared using VMD (431), and all solvent and nucleic acids 
were excluded from analysis. A sliding window of 5% of the total number of frames was used, 
and total events per frame were calculated and plotted against frame number.  
 HDAC 3 Dockings: The R265W mutation was introduced to HDAC3 (PDBID:4A69)  via 
the structure editor under Chimera. Substitution was made using the Dunbrack Rotamer library, 
and 1000 steps of conjugate gradient minimization were applied to relieve unfavorable 
interactions. All HDAC inhibitors built and minimized at the AM1 level of theory using Spartan 
'03 (464) and docked into a sphere encompassing all residues within 20 Å of the center of the 
SAHA binding pocket. All crystallographic waters were retained and utilized as both fully 
rotatable and displaceable.  Triangle matching was used for base fragment placement, and 
dockings were performed with two thousand solutions per each iteration and fragmentation. The 
standard scoring scale based on Bӧhm's scoring algorithm (465-467) was employed. 
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ABSTRACT 
 
COMPUTATIONAL APPROACHES TO ANTI-TOXIN THERAPIES AND BIOMARKER 
IDENTIFICATION 
by 
REBECCA JANE SWETT 
December 2013 
Advisor:  Dr. Andrew Lee Feig 
Co-Advisor: Dr. Gerardo Andrés Cisneros 
Major: Chemistry 
Degree: Doctor of Philosophy 
 This work describes the fundamental study of two bacterial toxins with computational methods, 
the rational design of a potent inhibitor using molecular dynamics, as well as the development of two 
bioinformatic methods for mining genomic data.  
 Clostridium difficile is an opportunistic bacillus which produces two large glucosylating toxins. 
These toxins, TcdA and TcdB cause severe intestinal damage. As Clostridium difficile harbors 
considerable antibiotic resistance, one treatment strategy is to prevent the tissue damage that the 
toxins cause. The catalytic glucosyltransferase domain of TcdA and TcdB was studied using molecular 
dynamics in the presence of both a protein-protein binding partner and several substrates. These 
experiments were combined with lead optimization techniques to create a potent irreversible inhibitor 
which protects 95% of cells in vitro. Dynamics studies on a TcdB cysteine protease domain were 
237 
 
performed to an allosteric communication pathway. Comparative analysis of the static and dynamic 
properties of the TcdA and TcdB glucosyltransferase domains were carried out to determine the basis 
for the differential lethality of these toxins.  
 Large scale biological data is readily available in the post-genomic era, but it can be difficult to 
effectively use that data. Two bioinformatics methods were developed to process whole-genome data. 
Software was developed to return all genes containing a motif in single genome. This provides a list of 
genes which may be within the same regulatory network or targeted by a specific DNA binding factor. A 
second bioinformatic method was created to link the data from genome-wide association studies 
(GWAS) to specific genes. GWAS studies are frequently subjected to statistical analysis, but mutations 
are rarely investigated structurally. HyDn-SNP-S allows a researcher to find mutations in a gene that 
correlate to a GWAS studied phenotype. Across human DNA polymerases, this resulted in strongly 
predictive haplotypes for breast and prostate cancer. Molecular dynamics applied to DNA Polymerase 
Lambda suggested a structural explanation for the decrease in polymerase fidelity with that mutant. 
When applied to Histone Deacetylases, mutations were found that alter substrate binding, and post-
translational modification.  
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